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One of the main goal of modern organic chemistry is to develop efficient methods for the 
synthesis of complex molecules with high chemo-, regio- and stereoselectivity. In addition, 
the development of new drugs is a great challenge for organic chemists1. For example, it is 
important to develop new antibiotics, due to the increasing problem of resistance of many 
bacteria against various antibiotics. 
 
In the search for new active ingredients, natural substances often are important lead 
structures for drug discovery. Thus, it is obvious to construct synthetic compounds or 
substances which are derived from nature, following the example of nature. The usual 
procedure for the synthesis of organic compounds is the stepwise formation of individual 
bonds. However, it would be much more efficient if one could form several bonds in one step 
without isolating the intermediates, changing the reaction conditions, or adding reagents.1 It is 
obvious that this type of reaction would allow to reduce the waste compared to sequential 
reactions. In addition, the amount of solvents, reagents, adsorbents, and energy would be 
dramatically decreased. Furthermore the amount of labor would go down. Thus, these 
reactions would allow an ecologically and economically favourable production. We call this 
type of transformation a domino reaction1.  
 
The value of domino and cyclization reaction with masked dianion lies in the heart of 
organic synthesis and has immense applications. The reactions are often carried out as a one-
pot method and can provide an easy access to a large number of natural product analogues. 
The pharmacological efficiency of these analogues may be better than that of the natural 
products themselves. 
My studies are focussed on the development of new and reliable synthetic strategies and 
their application for the preparation of natural product analogues and of pharmacologically 
active carba- and heterocycles. The target structures include pyridyl salicylates, 
phenanthridinones, chlorinated biaryls, chlorinated dibenzo[b,d]pyran-6-ones, chlorinated 
flourenones, bis(benzophenones) and 7,8-benzo-9-azabicyclo[3.3.1]nonan-3-ones 
(isobenzomorphanones). Computational studies for the synthesis of 7,8-benzo-9-
azabicyclo[3.3.1]nonan-3-ones have been carried out in cooperation with Dr. Haijun Jiao, 




A significant part of this dissertation has recently been published (see list of publications at the end). 
The work embodied in this dissertation is concerned with the synthesis of functionalized arenes based 
on [3+3] cyclocondesations of 1,3-bis(silyloxy)-1,3-butadienes and related transformations and 
cyclocondensations of aryl-1,3-bis(silyloxy)-1,3-butadienes with isoquinolines and 3-
formylchromones.  
 
Synthesis of Functionalized 6-(Pyridyl)salicylates, Bis(benzophenones), 
Chlorinated 6H-Benzo[c]chromen-6-ones, 9H-Fluoren-9-ones, 
Isobenzomorphans and Dibenzo[b,d]pyrid-6-ones based on  
New Cyclocondensations of 1,3-Bis(silyloxy)-1,3-butadienes  
 
1. This chapter deals with the formal [3+3] cyclizations of 1,3-bis(silyl enol ethers) with 3-
pyridyl-3-silyloxy-2-en-1-ones which afforded regioselective 6-(pyridyl)salicylates 9, 12 and 15 are 
reported. Further more 3-(pyridyl)-1,3-diones 7, 10 and 13 were prepared by LDA and NaH-mediated 
reaction of ketones 5 with ethyl (pyridyl)carboxylates 6 are also reported.  
2. Chapter two includes the synthesis of functionalized 6(5H)-phenanthridinones 
(dibenzo[b,d]pyrid-6-ones) 20a-h based on formal TiCl4 mediated [3+3] cyclocondensation of masked 
dianions, methodology developed by Chan and coworkers, And subsequent reduction by H2, Pd/C, 
lactamization strategy. Synthesis of amino biaryls 21a-b were also carried out by the reduction of nitro 
biaryls are presented. 
3. In this chapter, I have described the synthesis of functionalized chlorinated biaryls 26a-r 
which were prepared by formal 3+3 cyclocondensation of 2-chloro-3-(silyloxy)alk-2-en-1-ones 25a-f 
and bis(silylenol ethers) 4a-c. Furthermore the lactonization of 26m-r have done in the presence of 
BBr3, KOtBu to get biaryl lactones 27a-f. In addition some of baryls are converted onto respective 
flourenones 31a-f. The methodology described here provides an easy and direct route for the synthesis 
chlorinated biaryls lactones and flourenones. 
4. In chapter 4, I have reported the synthesis of bis(benzophenones) 34 by condensation of aryl-
1,3-bis(trimethylsilyloxy)-1,3-butadienes 32a-l with 3-formyl-benzopyrylium triflates by ′Michael-
retro-Michael-Mukaiyama-aldol′ reaction. This synthesis is carried out under mild conditions and the 
reactions proceed in acceptable yields with very good regio- and chemoselectivity. 
5. This chapter deals with the synthesis of functionalized 7,8-benzo-9-azabicyclo[3.3.1]nonan-3-
ones (isobenzomorphanones) by the condensation of aryl-1,3-bis(trimethylsilyloxy)-1,3-butadienes 
with isoquinolines fallowed by TFA mediate cyclization and subsequent reduction with H2, Pd/C. In 
addition a simple rout to synthesis of natural product analogues in excellent yields. 
7. This chapter includes the experimental, spectroscopic data and full characterization of 
all new products has been described. 
 3
1. One-pot synthesis of 6-(pyridyl)salicylates based on [3+3] cyclocondensations of  
1,3-bis(silyl enol ethers) with 3-pyridyl-3-silyloxy-2-en-1-ones  
 




Dianions represent important building blocks for the regioselective formation of carbon-
carbon bonds. Ambident dianions are organic substrates containing two delocalized negative 
charges. Dianions can be generated by reaction of 1,3-dicarbonyl compounds in the presence 
of strong base, such as LDA or n-BuLi1. The functionalization of the terminal carbon atom of 
1,3-dicarbonyl compounds by reaction of the corresponding dianions with electrophiles 
represents an important synthetic method which has been used in the synthesis of natural 
products. The terminal carbon atom of the dianion can be regioselectively coupled with one 
equivalent of an electrophile E+ to give a monoanion which can be subsequently trapped by 
addition of a second electrophile. Two general mechanistic pathways for cyclization reactions 
































Scheme 1-1: Possible mechanistic pathways for cyclization reactions of 1,3-dicarbonyl 
dianions. Nu = nucleophile center, E = electrophile center. 
 
Mechanism type A: the dianion can react with monofunctional electrophiles with 
transposition of a negative charge from the dianion to the electrophile. This carbanion attacks 
an E+ centre of the former dianion moiety (e.g. the ester group) to give a cyclic monoanion 
which is subsequently quenched with water. 
 4
Mechanism type B: the dianion can react as a dinucleophile with a dielectrophile. A 
monoanion is formed, followed by attack of the latter onto a second E+ center. 
 
Cyclization reactions of dianions with dielectrophiles are synthetically useful. However, 
problems can arise since both starting materials are highly reactive compounds which have 
low reactivity matching. In addition, 1,2-dielectrophiles are often rather labile, and reactions 
with nucleophiles can result in polymerization, decomposition, formation of open-chained 
products, elimination or SET-process. These intrinsic limitations can be overcome by two 
ways: a) a proper tuning of the reactivity of dianion and dieletrophile and b) the use of 
eletroneutral dianion equivalents (masked dianions) in Lewis acid catalyzed reactions.1  
 
Many studies proved that 1,3-bis(enol silyl ethers) can be considered as equivalents of the 
corresponding 1,3-dicarbonyl dianions.2 The chemistry of bis(silyl enol ethers) has been 
developed during the last two decades.[2d] It is, for example, known that silyl enol ethers can 
condense with various carbonyl compounds in the presence of Lewis acids.3 These Lewis-
acid-mediated reactions4(e. g. alkylation and aldol condensation) provide useful alternatives 
to classical enolate chemistry. In cyclization reactions, 1,3-bis(silyl enol ethers) can react as 
1,3-dinucleophiles or, similar to the well-known Danishefsky diene5, as functionalized 
butadienes. 1,3-Bis(silyl enol ethers) undergo reactions with electrophiles at the terminal 
carbon atom followed by reaction of the central carbon or the oxygen atom. Silyl enol ethers 
can be cleaved with nucleophiles such as MeLi, LiNH2 or R4N+F- to give enolates. These can 
be reacted with halides (Br2, Cl2, I2) or pseudohalides (PhSCl, PhSeCl, Cl-N=O).6 Whereas 
enolates can be alkylated only by primary or secondary halides, silyl enol ethers can be 
alkylated by tertiary halides.7  
 
The preparation of silyl enol ethers mainly follows the procedures reported by Chan and 
Molander. These syntheses rely on the preparation of mono(silyl enol ethers), Which are 
subsequently transformed into bis(silyl enol ethers) by deprotonation with LDA and 
subsequent silylation.8,9 
 
In this chapter, I present the synthesis of novel 4-alkyl-1,3-bis(trimethylsilyoxy)-1,3-




1.1.2 Results and discussion 
 
Following the procedures of Chan and Molander, 1,3-bis(trimethylsilyloxy)-1,3-butadiene 
4a-c,f can be prepared from the respective 1,3-dicarbonyl compounds 2a-c,f in two steps. 
Treatment of the β-ketoesters with NEt3, Me3SiCl afforded silyl enol ethers 3a-c,f 
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Scheme 1-2: Synthesis of 1,3-bis(silyl enol ethers) 4a-c,f; i: 1) NEt3 (1.5 equiv.); 2) 
Me3SiCl (1.5 equiv.), C6H6, 20 °C, 12 – 48 h; ii: 1) LDA (1.5 equiv.), THF, 0 °C, 2 h; 2) 
Me3SiCl (1.5 equiv.), –78 → 20 °C, 6 – 12 h. 
 
The synthesis of alkyl-substituted-1,3-bis(silyl enol ether) derivatives require the synthesis 
of the respective β-ketoesters 2d-e which was carried out in collaboration with I. Hussain. It is 
known that the regioselectivities of the reactions of monoanions and dianions generally differ 
greatly. 1,3-Dicarbonyl monoanions are generally alkylated at the central carbon or at the 
oxygen atom, whereas the formation of dianions allows the functionalization of the terminal 
carbon atom. Based on this, the 4-alkyl-3-oxobutanoates 2d-e were prepared by reactions of 
the dianion of methyl acetoacetate with the respective alkylhalides 1a-b (RI). These 
compounds were transformed, according to a known procedure,2 into the desired 1,3-bis(silyl 





































Scheme1-3: Synthesis of alkyl-substituted 1,3-bis(silyl enol ether) derivatives; i: 1) 2.5 
LDA, THF, 0 °C, 1 h; 2) methyl acetoacetate, 1a-b, –78 → 20 °C; ii: Me3SiCl (1.5 equiv.), 
NEt3 (1.5 equiv.), C6H6, 20 °C, 48 h; iii: 1) LDA (1.5 equiv.), THF, –78 °C, 1 h; 2) Me3SiCl 
(1.5 equiv.), 20 °C, –78 → 20 °C. 
 
All 4-alkyl-1,3-bis(silyl enol ethers) prepared could be stored at suitable conditions (-20 oC, 
dry, inert gas atmosphere) for several months without decomposition. The 1,3-bis(silyl enol 






























The application of a the known procedure allows the synthesis of novel 4-alkyl-1,3-bis(silyl 
enol ethers). These masked dianions are used in the cyclization reactions for synthesis 
heterocycles and aromatic rings - important building blocks of natural products analogue. 
 




Pyridines are of considerable pharmacological relevance and occur in a variety of natural 
products.10 (Pyrid-2-yl)arenes are present in natural 4-azafluorenones (e. g. kinabaline, 
darienine, and onychine) which exhibit a strong antimicrobial activity.11 In addition, these are 
present in 1,6-diazabenzo[de]anthracen-7-one natural products, such as sampangin or  
eupomatidine.12 The latter were shown to induce apoptosis and are active against human 
leukemia HL-60 cells.12 Some years ago, Faizi et al. have isolated penduline, isourisoline and 
pendulamine A, B alkaloids from the Roots of Polyalthia longifolia var pendula, which 







a H OMe 
b Me OMe 
c Et OEt 
d nHex OMe 
e nOct OMe 























Figure 1.1: Pendulamine A Figure 1.2:Pendulamine B
Figure 1.3: Penduline  
 
Hetaryl-substituted arenes are available, for example, by palladium(0)-catalyzed cross-
coupling reactions.13 Despite their great synthetic utility, the scope of all these methods is 
limited by the availability of the starting materials. In fact, the synthesis of more complex aryl 
halides or triflates by regioselective functionalization of arenes is often rather difficult. In 
addition, transition metal catalyzed reactions of sterically encumbered substrates often 
proceed in low yield or not at all. Some years ago, Chan and coworkers reported2 an elegant 
approach to salicylates by cyclization of 1,3-bis(silyl enol ethers)1 with 3-(silyloxy)alk-2-en-
1-ones. In recent years, Langer et al. reported the application of this method to the synthesis 
of a variety of functionalized arenes.14  
 
Herein, I report a new synthesis of functionalized 3-(pyrid-2-yl)phenols based on formal 
[3+3] cyclizations of 1,3-bis(silyl enol ethers). These reactions represent what are, to the best 
of my knowledge, the first [3+3] cyclizations of heterocyclic substrates. From a preparative 
viewpoint, they offer a convenient and regioselective approach to functionalized and sterically 





1.2.2 Results and discussion 
 
The 3-(pyrid-2-yl)-1,3-diones 7a-d were prepared by LDA-mediated reaction of ketones 
5a-d with ethyl (pyrid-2-yl)carboxylate (6a). The silylation of 7a-d afforded the silyl enol 
ethers 8a-d. The TiCl4-mediated formal [3+3] cyclization of 8a-d with 1,3-bis(silyl enol 
ethers) 4a-f prepared from the corresponding 1,3-dicarbonyl compounds in two steps17 – 
afforded the 6-(pyrid-2-yl)salicylates 9a-l (Scheme 1-4, Table 1-2). All products were formed 
with very good regioselectivity. During the optimization of this reaction, the (high) 
concentration and the temperature played an important role. The cyclization of 7 with 4 
proceeds by TiCl4-mediated isomerization of 8 by shift of the silyl group (intermediate A), 
TiCl4-mediated attack of the terminal carbon atom of 4 onto the carbon located next to 
substituent R1 to give intermediate B (conjugate addition), cyclization (intermediate C), and 
subsequent aromatization.2, 15 It is noteworthy, that the lone pairs of the nitrogen atom of the 

















































































Scheme 1-4: Synthesis of 9a-l; i: LDA (1.5 equiv.), THF; ii: 1) NEt3 (1.6 equiv.), Me3SiCl 
(3.6 equiv.), C6H6, 20 °C, 3 d; iii: TiCl4, CH2Cl2, –78 → 20 °C. 
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Table 1-2: Synthesis of 9a-l 
 
a Yields of isolated products 
 
The NaH-mediated reaction of acetone (5a) with ethyl nicotinate (6b) afforded 3-(pyrid-3-
yl)-1,3-dione 10. The silylation of 10 afforded silyl enol ether 11. The TiCl4-mediated formal 
[3+3] cyclization of 11 with 1,3-bis(silyl enol ethers) 4a-c afforded the 6-(pyrid-3-














8 4 9 R1 R2 R3 % (9)a 
a a a Me H Me 31 
a d b Me nHex Me 30 
a e c Me nOct Me 30 
a f d Me Cl Et 33 
b a e Et H Me 40 
b b f Et Me Me 44 
b c g Et Et Et 38 
b d h Et nHex Me 30 
b e i Et nOct Me 30 
c a j nPr H Me 33 
c b k nPr Et Et 31 






























Scheme 1-5: Synthesis of 12a-c; i: NaH (4.0 equiv.), ethyl nicotinate (1 equiv), acetone 
(2.0 equiv), Et2O, reflux, 2 h; ii: 1) NEt3 (1.6 equiv.), Me3SiCl (3.6 equiv.), C6H6, 20 °C, 3 d; 
iii: TiCl4, CH2Cl2, –78 → 20 °C. 
 
Table 1-3: Synthesis of 12a-c 
 
a Yields of isolated products 
 
The 3-(pyrid-4-yl)-1,3-dione 13 was prepared by LDA-mediated reaction of pentan-2-one 
(5c) with ethyl (pyrid-4-yl)carboxylate (6c). The silylation of 13 gave silyl enol ether 14. The 
TiCl4-mediated cyclization of 14 with 1,3- bis(silyl enol ethers) 4a,b afforded the 6-(pyrid-4-




4 12  R1 R2  % (12)a 
a a H Me 44 
b b Me Me 38 

























15a (R = H): 44%







Scheme 1-6: Synthesis of 15a-b; i: LDA (1.5 equiv.), THF; ii: 1) NEt3 (1.6 equiv.), 




In conclusion, a variety of 6-(pyridyl)salicylates were regioselectively prepared by formal 
[3+3] cyclizations of 1,3-bis(silyl enol ethers) with 3-pyridyl-3-silyloxy-2-en-1-ones. These 
reactions represent what are, to the best of our knowledge, the first [3+3] cyclizations of 1,3-












2. Synthesis of functionalized 6(5H)-phenanthridinones based on a [3+3]-




6(5H)-Phenanthridinones (dibenzo[b,d]pyrid-6-ones) are pharmacologically important 
molecules which occur in a variety of natural products. This includes, for example, 
sanguinarinone which shows antiparasitic activity against the dog roundworm, anticoagulant 
activity, and anti-proliferative activity against leukemia HL-60 cells (Scheme 1).16 Benzo [c] 
phenanthridine alkaloids including, nitidine (Figure 2.1) and sanguinarine (Figure 2.2) , have 
been attractive to synthetic organic chemists and biochemist over last two decades since such 
compounds have shownintresting biological properties16d-g Oxotoddaline has been reported to 
possess anti-proliferative activity against P-388 and human colon carcinoma HT-29 cells.17 A 
number of other pharmacologically active natural products, e. g. cytotoxic oxynitidine,18 have 
been reported.19,20 Recently Cho et al.21j reported the total synthesis of oxysanguinarine, 

















































6(5H)-Phenanthridinones have been prepared by reductive cyclization of 2-nitro-2’-
alkoxycarbonyl-biphenyls under various conditions (including Fe/AcOH, Fe/THF, Zn/HOAc, 
Raney-Ni, and H2-Pd/C).21b The corresponding biaryls have been prepared by Ullmann-type 
reactions and by nucleophilic aromatic substitutions.22 An alternative approach relies on the 
nitration of appropriate biphenyls.23 The scope of these reactions is limited by the harsh 
reaction conditions and by steric effects. In fact, sterically encumbered and highly 
functionalized derivatives are not readily available by this approach. In addition, the synthesis 
of the starting materials, highly functionalized arenes, is often not an easy task. These 
problems can be circumvented by application of a ‘building block approach’. To the best of 
my knowledge, only a single application of this strategy has been reported to date. Ashburn 
and coworkers reported the synthesis of 2-nitro-2’-alkoxycarbonyl-biphenyls based on [4+2] 
cycloadditions.24  
 
Chan and coworkers were the first to report a convenient synthesis of functionalized 
phenols by TiCl4-mediated [3+3] cyclization14 of 1,3-bis(trimethylsilyloxy)-1,3-butadienes1 
with 3-silyloxy-2-en-1-ones. In recent years, Langer et al. studied the application of this 
reaction to the synthesis of various functionalized arenes. Recently, Langer et al.25 reported 
the synthesis of dibenzo[b,d]pyran-6-ones based on a [3+3] cyclization / lactonization 
strategy.  
 
Herein, I wish to report what is, to the best of my knowledge, the first synthesis of 6(5H)-
phenanthridinones by application of a [3+3]-cyclocondensation / lactamization strategy. 
Although recently Cho et al.21j reported the synthesis oxyphenanthridinones, which they 
synthesised in fourteen steps, and I like to present an efficient methodology to prepare the 
same skeleton in two steps. Noteworthy, the products are formed with very good 
regioselectivity and are not readily available by other methods.  
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2.2 Results and discussion 
 
The LDA-mediated condensation of acetone (5a) and pentan-2-one (5c) with benzoyl 
chlorides 16a-c afforded the nitro-substituted benzoylacetones 17a-d which were transformed 
into the 1-aryl-1-silyloxy-1-en-3-ones 18a-d (Scheme 2-1, Table 2-1). The TiCl4-mediated 
cyclization of 18a-d with 1,3-bis(trimethylsilyloxy)-1,3-butadienes 4a-e, readily available in 
two steps from the corresponding β-ketoesters,2 afforded the novel nitro-substituted biaryls 
19a-n (Scheme 2-2, Table 2-2). All cyclizations proceeded with very good regioselectivity. 
During the optimization, it proved to be important to carry out the reactions in a highly 
concentrated solution. The structures of all products were established by spectroscopic 
methods. The structure of 19m was independently confirmed by X-ray crystal structure 


























Scheme 2-1: Synthesis of 19a-n; i: LDA (1.5 equiv.), THF; ii: 1) NEt3 (1.6 equiv.), 
Me3SiCl (1.8 equiv.), C6H6, 20 °C, 3 d. 
 
The regioselective formation of products 19a-n can be explained, following a mechanism 
first suggested by Chan,2 by TiCl4-mediated isomerization of 18 into intermediate type A, 
TiCl4-mediated attack of the terminal carbon atom of 1,3-bis(silyl enol ether) 4 onto the 
carbon located next to substituent R1 to give intermediate type B (conjugate addition), 
cyclization (intermediate type C), and subsequent aromatization (Scheme 2-2, Table 2-2). 
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Table 2-1: Synthesis of 17, 18a-d 
5 16 17 18 R2 R3 R4 R5  % (17)a  % (18)a 
a a a a Me NO2 H H 54 91 
b a b b nPr NO2 H H 45 88 
a b c c Me H NO2 H 34 90 
a c d d Me H H NO2 43 92 
a Yields of isolated products 
 
Table 2-2: Synthesis of 19a-n 
4 18 19 R R1 R2 R3 R4 R5  % (19)a 
a a a Me  H Me NO2 H H 36 
b a b Me Me Me NO2 H H 41 
c a c Et Et Me NO2 H H 35 
e a d Me nOct Me NO2 H H 40 
a b e Me H nPr NO2 H H 48 
b b f Me Me nPr NO2 H H 38 
c b g Et Et nPr NO2 H  H 37 
d b h Me nHex nPr NO2 H H 25 
a c i Me H Me H NO2 H 32 
b c j Me Me Me H NO2 H 50 
c c k Et Et Me H NO2 H 37 
a d l Me H Me H H  NO2  36 
b d m Me Me Me H H  NO2  46 
c d n Me Et Me H H  NO2 33 























Figure 2.7: Ortep plot of 19m 
 
The Pd/C-catalyzed hydrogenation of 19a-h directly afforded the 6(5H)-phenanthridinones 
20a-h (Scheme 2-3, Table 2-3). The products are formed by transformation of the nitro into 


























Table 2-3: Synthesis of 20a-h 
a Yields of isolated products 
 
The hydrogenation of 3-nitro-3′-hydroxy-biphenyls 19j and 19k afforded the 3-amino-3′-
hydroxy-biphenyls 21a and 21b (Scheme 2-4). Noteworthy, 3-amino- and 3-nitro-3′-hydroxy-
biphenyls are of considerable current interest, due to their wide range of pharmacological 
properties. This includes, for example, antimalarial activity, binding affinity to C5a receptor 
(human monocyte cell line U937), inhibition of cyclic nucleotide phosphorodiesterases 

















21a (R = Me, R1=Me,81%)
21b (R = Et, R1 = Et,78%)  
 




19 20 R R1 R2  % (20)a 
a a Me  Me H 64 
b b Me Me Me 52 
c c Et Me Et 70 
d d Me Me n-Octyl 69 
e e Me n-Propyl H 56 
f f Me n-Propyl Me 50 
g g Et n-Propyl Et 63 




In conclusion, I have reported a regioselective approach to functionalized nitro and amino 
substituted biaryls and 6(5H)-phenanthridinones by application of a [3+3] cyclization / 































3. Synthesis of chlorinated biaryls, biaryl Lactones and fluorenones based on 




4-Chlorophenols are of considerable pharmacological relevance and occur in a variety of 
natural products. This includes dibenzo[b,e][1,4]dioxepin-11-ones,27 spirocycles (e. g. 
aspirochlorins, grisandions, griseofulvins),28 xanthones (austocystin A),29 tetracyclins,30 
isochromanones (ochratoxin A), (Figure 3.1),31 terpenes (ascofuranol, ascochlorin),32 
macrocycles (radicicol, bazzanin K),33 dibenzo[b,d]pyran-6-one (graphislactone G),34 
oligosaccharides (flambamycin),35 benzophenones,36 polycyles,37 arenes,38 and biaryls 
(ambigol A).39 They have found many technical and medicinal applications and represent 
important synthetic building blocks. 2-acyl-4-chlorophenols are found, for example, in the 
natural product chloratranorin (Figure 3.2).27 Chloroarenes also represent useful starting 























Figure 3.1: Ochratoxin A                                Figure 3.2: Chloratranorin 
 
Classic syntheses of functionalized chlorophenols, based on chlorination of phenols, often 
suffer from low regioselectivities and yields. Syntheses of 4-chlorophenols based on [4+2] 
cycloadditions of chloro-substituted buta-1,3-dienes have been reported. For example, 
Brassard and coworkers reported the synthesis of a chlorinated anthraquinone by [4+2] 
cycloaddition of 2-chloro-1-methoxy-1,3-bis(trimethylsilyloxy)buta-1,3-diene with a 2-
chloronaphthoquinone.41a 4-Chlorophenol was also prepared by [4+2] cycloaddition of a 
chlorinated thiophene with dimethyl acetylenedicarboxylate.42b Recently, Langer et al. 42 have 
reported an efficient method for the synthesis of functionalized 4-chlorophenols based on 
[3+3] cyclizations of 1,3-bis(silyl enol ethers), which can be regarded as electroneutral 
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equivalents of 1,3-dicarbonyl dianions and novel 2-chloro-3-(silyloxy)alk-2-en-1-ones. 
Traditional methodologies rely on the functional group manipulations at aromatic rings, 
which in many cases was quite difficult to handle and yields were also not satisfactory. In 
addition, combination of that approach with Suzuki cross-coupling strategy and subsequent 
BBr3 mediated lactonization offered access to the synthesis of chloro substituted biaryl 
lactones.  
 
 Herein, I present full details of these studies. With regard to previous work of Langer et 
al.42a the preparative scope was considerably extended and a variety of novel chlorinated 
biaryls were regioselectively prepared. In addition, the synthesis of novel chlorinated biaryl 
lactones (dibenzo[b,d]pyran-6-ones) and chlorinated fluorenones, based on regioselective 
[3+3] cyclizations, is reported. Notably, the functionalized chlorinated arenes reported herein 
are not readily available by other methods. 
 




Functionalized biaryls containing a 3-arylsalicylate substructure occur in a variety of 
pharmacologically relevant natural products. The simple biaryls cynandione A-C (Figure 3.3) 
have been isolated from many plant sources and show a considerable in vitro activity against 
hepatocytes, human bladder carcinoma T-24 cells, epidermoid carcinoma KB cells, and 
human hepatoma PLC/PRF/5 cells.43 Number of natural products, such as knipholone, 6'-O-
methylknipholone or (+)-asphodelin, contain an anthraquinone moiety.44 Other compounds, e. 
g. secalonic acid A or globulixanthone E, contain a bixanthenyl substructure.45 3-
arylsalicylates are also present in many flavones (e. g. 2,3-dihydroamentoflavone,45c 
bartramiaflavone,46b robustaflavone,45d dichamanetin).46d,e For some derivatives, inhibition of 
the human liver cathepsin B and K has been reported.46f,g The natural product anastatin A 

















The most important synthetic approach to biaryls relies on palladium(0)-catalyzed cross-
coupling reactions.13 Although these reactions are broadly applicable, the synthesis of 
sterically encumbered products can be difficult or not possible at all. In addition, the 
regioselective synthesis of the required aryl halides or triflates can be a very difficult task. 
Some years ago, Chan et al. developed14b a convenient approach to salicylates by formal 
[3+3] cyclizations14b of 1,3-bis(trimethylsilyloxy)-1,3-dienes14a with 3-trimethylsilyloxy-2-en-
1-ones. Recently, Langer et al. developed a catalytic variant of this transformation.48 In my 
thesis I studied, for the first time, the synthesis of 2-Chloro-3-(silyloxy)alk-2-en-1-ones and 
their application to the synthesis of functionalized 4-chloro biaryls. The sterically encumbered 
and functionalized biaryls reported herein are not readily available by other methods. 
 
3.2.2 Results and discussion  
 
2-Chloro-3-(silyloxy)alk-2-en-1-ones 25a-f were prepared as follows. The LDA mediated 
reaction of ketones 5a,b with benzoyl chlorides 22a-f afforded the 1,3-diketones 23a-f. The 
chlorination of the latter with NCS afforded products 24a-f which were transformed into 25a-
f by silylation (Scheme 3-1, Table 3-1). The TiCl4 mediated cyclization of 1,3-bis(silyl enol 
ethers) 4a-c,g with 2-chloro-3-(silyloxy)alk-2-en-1-ones 25a-f afforded the chlorinated biaryls 
26a-r (Scheme 3-2, Table 3-2). The structures of products 26a and 26c were independently 



























Scheme 3-1: Synthesis of 25a-f; i: LDA (1.5 equiv.), THF; ii: NCS (1 equiv.), CCl4, 75-80 
oC; iii: NEt3 (1.6 equiv.), Me3SiCl (1.8 equiv.), C6H6, 20 °C. 
 
Table 3-1: Synthesis of 2-chloro-3-silyloxy-2-en-1-ones 25a-f 
23,24,25 R1 R2 R3 % (23) a % (24) a % (25) a 
a Me H H -  b 95 90 
b Me H F 36 66 80 
c Me H Cl 38 52 73 
d Me Me H 33 44 72 
e Me OMe H 37 47 76 
f nPr OMe H 72 81 84 































Scheme 3-2: Synthesis of 26a-r; i: TiCl4, CH2Cl2, –78 → 20 °C, 20 h. 
 
Table 3-2: Synthesis of chlorinated biaryls 26a-r 
4 25 26 R1 R2 R3 R4 R5 % (26)a 
a a a Me H H H OMe 49 
b a b Me H H Me OMe 31 
g a c Me H H H Me 51 
c a d Me H H Et OEt 43 
a b e Me H F H OMe 30 
b b f Me H F Me OMe 48 
c b g Me H F Et OEt 44 
a c h Me H Cl H OMe 44 
b c i Me H Cl Me OMe 34 
c c j Me H Cl Et OEt 47 
a d k Me Me H H OMe 26 
b d l Me Me H Me OMe 40 
a e m Me OMe H H OMe 47 
b e n Me OMe H Me OMe 50 
c e o Me OMe H Et OEt 42 
a f p nPr OMe H H OMe 34 
b f q nPr OMe H Me OMe 46 
c f r nPr OMe H Et OEt 51 






Figure 3.5: Ortep plot of 26a 
 
 
Figure 3.6: Ortep plot of 26c 
 
3.2.3 Conclusions  
 
In conclusion, a general method for the regioselective synthesis of chlorinated, sterically 
encumbered and biaryls by formal [3+3] cyclizations of 1,3-bis(silyl enol ethers) with 2-
chloro-3-(silyloxy)alk-2-en-1-ones was reported. Chlorinated biaryls 26a-r are isolated in 
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moderate to good yields. The yields mainly depend on the individual quality of the starting 
materials and on the handling of each individual experiment. 
 




Functionalized dibenzo[b,d]pyran-6-ones (‘biaryl lactones’) occur in a number of natural 
products such as alternariol, autumnariol, autumnariniol and altenuisol; 44c-e 
dibenzo[b,d]pyran-6-ones containing an additional lactone bridge are present in ellagic and 
coruleoellagic acid.45e,f benzo[d]naphthopyran-6-ones occur in antibiotics and antitumor 
compounds isolated from Streptomyces; this includes, for example, defucogilvocarcin V, 
gilvocarcins, chrysomycins and ravidomycins.46h Some structures, which were isolated from 
the culture broth of a streptomycete as antitumor substances, were determined as 6H-
benzo[d]naphtho[1,2-b]pyran-6-one.47b Ravidomycin was extracted from Streptomyces 
ravidus and is mainly active against Gram-positive bacteria including mycobacteria. 
Ravidomycin also exhibits potent antitumor activity against lymphocytic leukemia, tumor and 
mammary tumor.47c The 6H-dibenzo[b,d]-pyran-6-one moiety is also present in compounds 
extracted from Pteropi faeces (the species of Trogopterus xanthipes Milne-Edwards). These 


















Recently, Langer et al. reported the synthesis of 6H-benzo[c]chromen-6-ones by reaction of 
1,3-bis(silyl enol ethers) with benzopyrylium triflates. As recently Langer et al. reported the a 
new approach to 6H-benzo[c]chromen-6-ones relies on the [3+3] cyclizations of 1,3-bis(silyl 
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enol ethers) with 1-(2-methoxyphenyl)-1-(trimethylsilyloxy)alk-1-en-3-ones and subsequent 
lactonization.25b. 
 
Herein, I wish to report the scope of this methodology to the synthesis of 10-chloro-6H-
benzo[c]chromen-6-ones. The synthesis of this type of chlorinated structure has, to the best of 
our knowledge, not yet been reported.  
 
3.3.2 Results and discussion  
 
The chlorinated biaryls 26m-r contain an ortho-methoxy group located at one of the aryl 
groups. Treatment of 26m-r with borontribromide and subsequent addition of an aqueous 
solution of potassium tert-butanolate, following a protocol recently reported by Langer et 
al.,25b afforded the novel chloro-substituted dibenzo[b,d]pyran-6-ones 27a-f (Scheme 3-3, 
Table 3-3). The structure of 27d was independently confirmed by X-ray crystal structure 

















Scheme 3-3: Synthesis of dibenzo[b,d]pyran-6-ones 27a-f.; i: 1) BBr3 (4 equiv.), CH2Cl2, 










Table 3-3: Synthesis of dibenzo[b,d]pyran-6-ones 27a-f 
26 27 R1 R2 R3 % (27) a 
m a Me H Me 73 
n b Me Me Me 78 
o c Me Et Et 67 
p d nPr H Me 88 
q e nPr Me Me 54 
r f nPr Et Et 48 





Figure 3.8: Ortep plot of 27d 
 
3.3.3 Conclusions  
 
In conclusion, I have reported the synthesis of variety of chlorinated 6H-benzo[c]chromen-
6-ones based on regioselective [3+3] cyclizations of 1,3-bis(silyl enol ethers) with 2-chloro-3-
silyloxy-2-en-1-ones. This approach provides a convenient pathway to synthesis of various 
functionalized chlorinated lactones which are not readily available by other methods. 
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1-Hydroxyfluorenones are interesting lead structures in medicinal chemistry and are also 
present in nature (e. g. in the natural products dengibsin, dengibsinin, and dendroflorin ).49 
(Figures 3.8, 3.9) Fluorinated fluorenones50 are of specific interest in current medicinal 
chemistry. For example, it was shown that 4-fluorofluorenones  possess antagonistic in vitro 
activity to human progesterone receptor B (hPR-B) in cotransfected CV-1 cells (IC50 = 158 
nM).51 Fluorenones have already been prepared, for example, by intramolecular Friedel–
Crafts acylations of biaryls.53 Snieckus and co-workers reported the synthesis of fluorenones 
based on remote aromatic metalation.54 Some years ago, the synthesis of fluorenones using a 
Suzuki coupling/intramolecular Friedel–Crafts acylation sequence has been reported.55 
Recently, Reim et al reported an efficient synthetic approach to fluorenones based on a ‘[3+3] 
cyclization/Suzuki crosscoupling/Friedel–Crafts acylation’ strategy. 52 Chan et al. reported the 
synthesis of 1-hydroxy-3-methylfluorenone by reaction of methyl 6-phenylsalicylate with 
concentrated sulfuric acid.2  
 
Herein, I wish, to report an approach to synthesis of fluorenones and chlorinated 
















3.4.2 Result and discussion  
 
Aryl-4-(trimethylsilyloxy)but-3-en-2-ones 28g-h, which were prepared by reaction of 1,3-
diketiones 23g-h with Me3SiCl/NEt3. The TiCl4 mediated formal [3+3] cyclization of 28g-h 
(Scheme 3-4, Table3-4) with 4b-c 1,3-bis(silyl enol ethers), 4b-c– prepared from the 
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corresponding 1,3-dicarbonyl compounds in one or two steps14– afforded the novel biaryls 
29a-c in moderate to good yields. Treatment of the later with concentrated sulfuric acid 

































Scheme 3-4: Synthesis of 30a-c; i: NEt3 (1.6 equiv.), Me3SiCl (1.8 equiv.), C6H6, 20 °C, 72 
h; ii: TiCl4, CH2Cl2, –78 → 20 °C; iii: H2SO4, 20 °C, 1 h. 
 
Table 3-4: Synthesis of fluorenones 30a-c 
4 28 29 30 R1 R2 R3 R4 % (23)a % (24)a 
b g a a Cl Me Me OMe 32 80 
c g b b Cl Me Et OEt 35 60 
b h c c F Me Me OMe 32 51 






3.4.3 Chlorinated fluorenones 
3.4.3.1 Results and discussion 
 
The reaction of chlorinated biaryls 25a,b,e,f,h,i with concentrated sulfuric acid afforded the 
novel chlorinated fluorenones 31a-f by an intramolecular Friedel-Crafts acylation (Scheme 3-

















Scheme 3-5: Synthesis of chlorinated fluorenones 31a-f; i: concd. H2SO4, 20 °C, 1 h. 
 
Table 3-5. Synthesis of fluorenones 25a-f 
25 31 R1 R2 R3 % (31)a 
a a Me H H 70 
b b Me H Me 86 
e c Me F H 61 
f d Me F Me 55 
h e Me Cl H 84 
i f Me Cl Me 74 
.          a Isolated yields 
 
3.4.4 Conclusions 
In conclusion, I have reported the synthesis of variety of functionalized fluorenones and 
chlorinated fluorenones, which are to the best of our knowledge, are not readily available by 
other methods. 
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4. Synthesis of 2-benzoyl-4-(2-hydroxybenzoyl)phenols by catalytic domino ′Michael-
retro-Michael−Mukaiyama-aldol′ reactions of 1-aryl-1,3-bis(silyloxy)buta-1,3-dienes 
with 3-formylchromones 
 




The synthesis of relevant organic compounds such as natural products and analogues, 
drugs, diagnostics, agrochemicals, and other kinds of material is a main topic in academic and 
industrial chemistry, and it is the connecting point of interdisciplinary research in chemistry, 
biology, and medicine. The view of synthesis has altered in recent years; there is clearly a 
change in paradigm. At the beginning, organic chemistry was considered a branch of natural 
sciences dealing with a specific type of compounds, mainly isolated from living organisms. 
Even today natural products continue to play an important role in discovery and development 
of new pharmaceuticals.56 Since the discovery of penicillin, a large number of antibiotics have 
been isolated from scores of micro-organisms.57 Natural products also provide a great help in 
chemotherapy of cancer. They are an integral part of anticancer drugs e.g. bleomycin, 
doxorubicin, mitomycin, and paclitaxel.58 All this pharmacologically and biologically 
important stuff designed by Mother Nature was not available in bulk quantities which man 
demanded. Thus the development of new, highly selective methods is still being a main task, 
to get it in bulk amounts while following the foot steps of nature, but even more important is 
the search for more efficiency.59 The relationship between structural complexity and the 
number of steps in a synthesis must be improved. In addition, synthetic methodology must be 
designed in a way that it allows access to diversified substance libraries in an automatized 
way.60 A general way to improve synthetic eficciency and in addition to give access to a 
multitude of diversified molecules in solution is the development of multicompound domino 
reactions, which allow the formation of complex compounds starting from simple substrates. 
Domino reactions are defined as processes of two or more bond-forming reactions in which a 
subsequent trans-formation takes place by virtue of the functionalities introduced in a former 
transformation.59a,60d,61 The development of cyclization reaction with free62 and masked 
dianions,63 for the development of biologically relevant ring systems, and natural 
substances,64 is research priority in the working group prof. Langer.1 Despite the simplicity of 
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the idea that in the implementation dianions with 1-2 difunctional alkylhalides to cyclic 
systems, both dianions as many dielectrophiles represent highly reactive compounds, leading 
to adverse reactions, such as polymerization, reduction of dielectrophile,65 
monoalkylation,66eliminations67 or SET reactions (SET = single-electron-transfer).68 These 
problems can be achieved through : (a) optimization of proper tuning of reactivity of dianion 
and dielectrophile and (b) the use of electroneutral dianions equalivalents (masked dianion) in 
Lewis acid catalyzed reactions. Masked dianion represent important building blocks. The 
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Scheme 4-1: i: LDA (2.5 equiv.), THF, 0 °C, 1 h; ii: Br(CH2)2Cl, −78 → 20 °C, 14 h, then  
reflux, 14 h. 
 
4.1.2 Results and discussion 
 
1,3-Bis(trimethylsilyloxy)-1,3-butadienes 32a-l are available from the respective 1,3-
dicarbonyl compounds 17a-l in one or two steps. Following the procedures of Danishefsky, 
Chan and Molander, ester-derived (same for 1,3-diketone) bis(silyl enol ethers) 32a-l can be 
prepared by treatment of the respective 1,3-dicarbonyl compound with NEt3–Me3SiCl to give 
the mono(silyl enol ethers) 28a-l Deprotonation of 28a-l with LDA and subsequent addition 
of Me3SiCl afforded the dienes 32a-l (Scheme 4-2, Table 4-1).2 Simchen et al. have reported 
that 1,3-diketone derived bis(silyl enol ethers) can be prepared in one step by treatment of an 






















Scheme 4-2: Synthesis of bis(silylenol ethers) 32a-l; i: LDA,THF (1.5 equiv), acetone (1.0 
equiv), acid chloride 16a-l (1.2equiv.), -78 → 20 oC; ii: Me3SiCl, NEt3, C6H6, 20 °C, 72 h; iii: 
LDA, THF, -78 → 20 °C, Me3SiCl; iv: Me3SiOTf (2.0 equiv), NEt3, Et2O, 0→20 °C, 12 h. 
 
















Table 4-1: Products and yields 
16 17 28,32 Ar % (17) a % (28) a % (32) a 
-- b a Phenyl b 85 74 
b b b 4-FC6H5 36 80 83 
c c c 4-ClC6H5 38 80 70 
d d d 2-MeC6H5 33 88 75 
e e e 2-OMeC6H5 37 79 73 
g g g 2-ClC6H5 25 75 60 
h h h 2-FC6H5 35 80 75 
i i i 4-NO2C6H5 43 92 80 
j j j 3,4,5-OMe3C6H2  30 70 65 
k k k 1-Naph 43 71 70 
l l l 2-Naph 62 75 74 
        a Isolated yields; b Comercially available 
 
My studies in this chapter are focussed on the synthesis of functionalized carbonyl 
compounds and of pharmacologically relevant functionalized bis(benzophenones) followed 
by the synthesis of aryl-1,3-bis(trimethylsilyloxy)-1,3-butadienes. I have developed a new 
methodology for the synthesis of bis(benzophenones) by cyclization reactions of aryl-1,3-




The application of a the known procedure allows the synthesis of novel aryl-1,3-
bis(trimethylsilyloxy)-1,3-butadienes. These masked dianions are used in the cyclization 
reactions for synthesis heterocycles and aromatic rings - the important building blocks of 












Functionalized benzophenones occur in a variety of natural products and represent 
important core structures for the development of pharmaceuticals.70, 71, 72 For example, 2-
hydroxy- and 2-aminobenzophenones are promising candidates for anticancer therapy, due to 
their antitubulin activity. Functionalized benzophenones also represent important technical 
products. They are used as photosensitizers73 and as active ingredients of commercial agents 
which protect the skin or colour against UV-irradiation.74 Benzophenones are available by 
reaction of organometallic reagents with aldehydes and subsequent oxidation. A recent 
modification of this approach involves the SmI2 mediated reaction of benzaldehydes with 
benzylhalides and subsequent oxidation.75 Other benzophenone syntheses rely on Friedel-
Crafts acylations.76 However, these methods often give unsatisfactory results for the synthesis 
of functionalized benzophenones (e. g. containing a hydroxy, halide or ester group), due to 
competing side-reactions. Therefore, the development of new synthetic strategies is of 
considerable importance in organic and medicinal chemistry.  
 
3-Formylchromone represents a useful building block for the synthesis of a great variety of 
(2-hydroxybenzoyl)heteroarenes.77 These reactions generally proceed by cyclization of 3-
formylchromone with a bis(nucleophile) which involves cleavage of the chromone moiety. 
Reactions of 3-formylchromone with carbon nucleophiles are relatively rare. For example, the 
reaction of 3-formylchromones with enamines was reported to give (2-
hydroxybenzoyl)pyridines.78 The reaction of 3-formylchromone with 1,3-dicarbonyl 
compounds was reported to give open-chain products by simple attack of the central carbon 
atom of the nucleophile onto the aldehyde (aldol condensation).79 The employment of 
acetylacetone resulted in a C,C-cyclization with concurrent cleavage of the chromone moiety 
to give a benzophenone in low yield.80 Besides the low yield, the reaction proved to be not 
general. Recently, Langer et al. reported81 a new approach to 4-(2-hydroxybenzoyl)salicylates 
based on a new domino reaction of 1,3-bis(silyl enol ethers)1, 82 with 3-
(formyl)benzopyrylium triflates,83 Which are in situ generated by reaction of 3-
formylchromones with trimethylsilyl-trifluoromethanesulfonate (Me3SiOTf). Herein, I wish to 
report the synthesis of 2-benzoyl-4-(2-hydroxybenzoyl)phenols which can be regarded as 
functionalized “bis(benzophenones)”. These products are not readily available by other 
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methods. The reactions reported herein are carried out under mild conditions using catalytic 
amounts of trimethylsilyl-trifluorosulfonate (Me3SiOTf). 
 
4.2.3 Results and discussion 
 
The Me3SiOTf catalyzed reaction of 6-methyl-3-formylchromone (33a) with 1-phenyl-1,3-
bis(trimethylsilyloxy)-1,3-butadiene (32a), readily available from benzoylacetone,2 afforded 
the hydroxylated bis(benzophenone) 34a. The formation of 34a can be explained by a domino 
′Michael-retro-Michael-Mukaiyama-aldol′ reaction (Scheme 4-3). The reaction of 6-methyl-
3-formylchromone with Me3SiOTf afforded the benzopyrylium triflate A. The reaction of A 
with the terminal carbon atom of 32a gave intermediate B which underwent a retro-Michael 
reaction to give the polyketide C. An intramolecular aldol reaction gave intermediate D which 










































































Scheme 4-3: Mechanism for the formation of 34a; i: Me3SiOTf (0.3 equiv.), 20 °C, 10 min; 
ii: 1) 32a (1.3 equiv.), CH2Cl2, 0 → 20 °C, 12 h; 2) HCl (10%). 
 
The cyclization of 1,3-bis(silyl enol ether) 32a with 6-isopropyl-3-formylchromone (33b) 
and 6,8-dimethyl-3-formylchromone (32c) afforded the 2-benzoyl-4-(2-
hydroxybenzoyl)phenols 34b and 34c, respectively (Scheme 4-4, Table 4-2). The cyclization 
of 1-(4-fluorophenyl) and 1-(2-fluorophenyl)-1,3-bis(trimethylsilyloxy)buta-1,3-diene (32b,h) 
with 3-formylchromones 33b,d,e,f afforded the fluoro-substituted bis(benzophenones) 34d-g 
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and 34m-o respectively . Products 34h and 34i were prepared from 1-(2-methylphenyl)-1,3-
bis(trimethylsilyloxy)buta-1,3-diene (32d). The cyclization of 1-(2-methoxyphenyl)-1,3-
bis(trimethylsilyloxy)buta-1,3-diene (32e) with 3-formylchromones 33a, 33d, and 33e 
afforded the bis(benzophenones) 34j-l, respectively. The cyclization of 1-(1-naphthyl)-1,3-
bis(trimethylsilyloxy)buta-1,3-diene (32k) with 3-formylchromones 33a, 33b, and 33e 


























Scheme 4-4: Synthesis of 34a-r; i: 1) Me3SiOTf (0.3 equiv.) 20 °C, 10 min; ii: 32a-f (1.3 















Table 4-2: Products and yields 
32 33 34 R1  R2 R3 R4 R5 % (34) a 
a a a H H H Me H 34 
a b b H H H iPr H 37 
a c c H H H Me Me 31 
b b d H H F iPr H 30 
b d e H H F Cl H 27 
b e f H H F Br  H 35 
b f g H H F Et H 37 
d e h Me H H Br H 39 
d b i Me H H iPr H 28 
e a j OMe H H Me H 36 
e d k OMe H H Cl H 34 
e e l OMe H H Br H 38 
h e m F H H Br H 38 
h b n F H H iPr H 35 
h d o F H H Cl H 44 
k b p −(CH)4− H iPr H 32 
k a q −(CH)4− H Me H 34 
k e r −(CH)4− H Br H 36 
k d s −(CH)4− H Cl H 36 
a Isolated yields. 
 
The structure of the products was established by spectroscopic methods. The 1H NMR 
spectra showed the presence of two low field signals assigned to the intramolecular hydrogen 
bonds O–H···O. The structures of bis(benzophenones) 34f and 34m were independently 




Figure 4-1: ORTEP-Plot of 34f 
 




In conclusion, I reported the domino reaction of 1-aryl-1,3-bis(silyloxy)buta-1,3-dienes 
with 3-formylbenzopyrylium triflates which were in situ generated from 3-formylchromones. 
The products were isolated in only moderate yields. This can be explained by the fact that not 
all of the 1,3-bis(silyl enol ether) was converted into product. Noteworthy, the reactions 
reported provide a convenient access to a variety of highly functionalized 2-benzoyl-4-(2-




























5. Synthesis of fucntionalized 7,8-benzo-9-azabicyclo[3.3.1]nonan-3-one 
(isobenzomorphanone) by two-step cyclocondensation of 1,3-bis(strimethylsilyloxy)-1,3-




The isoquinoline moiety is present in a variety of pharmacologically active alkaloids.84 
Benzylisoquinoline-type alkaloids, such as papaverine I or reticuline II are isolated from 
Papaver- und Rauwolfia-plants and show spasmolytic activity.85 bis(benzyl)isoquinoline 
alkaloids include, for example, cycleanine, tetrandrine (antiinflammatory activity), 
isochondodendrin (sedative activity) and oxyacanthin (sympatholytic activity, adrenalin-
antagonist).84 Tubocurarine is the oldest muscle-relaxing agent and its dichloro derivative is 
used as a narcotic. Phthalidisoquinoline-alkaloids, isolated from Papaveraceen, are 
characterised by a tetracyclic system containing a γ-lactone moiety. Important examples are, 
for example, hydrastin and narcotin (noscapin) III. Hydrastin is used as a blood-stanching 
agent.84 Noscapin is used as an antitussivic.86 Synthetic approaches to tetrahydroisoquinoline 
alkaloids rely on asymmetric Pictet-Spengler-reactions and on Bischler-Napieralski-reactions 
and subsequent enantioselective reduction.87 Aporphine-alkaloids contain a fused tetracyclic 
system. For example, apomorphine IV is used as a strong emetic.88 Boldine represents a 
diuretic.89 Aporphine alkaloids have been prepared, for example, by application of 
photochemical methods.90 Pavine- and isopavine-alkaloids, such as dinorargemonine, 
eschscholtzine, munitagine and pavine, are isolated from Papaveraceae, Berberidaceae, 
Ranunculaceae, Lauraceae and Menispermaceae or from callus-cultures of Cryptocarya 
Chinensis and are of considerable pharmacological relevance.84,91 For example, they show 
activity against Herpes simplex virus type 192a and against tumor necrosis factor 
production.92b Pavine-type alkaloids are synthetically available.93 
Morphine-alkaloids represent the most important group of naturally occuring 
isoquinolines.84 They have been isolated from opium, a crude product mixture which is 
produced from Papaver somniferum. Important natural products include, for example, 
morphine VI, codein VII, thebaine and heroine84 which possess a wide range of 
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pharmacological activities (e. g. analgetic, sedative, hypnotic, antitussivic, miotic and 
antidiuretic activity).84 Morphine, the structure of which was elucidated by Sir Robert 
Robinson in 1925,94 is a very important drug for the treatment of pain. The synthesis of 
morphine-type alkaloids has been reported.95 
The development of simpler morphine analogues, which show no dependence-producing 
and other undesirable side-effects, has been the subject of research for many decades. Simpler 
morphine-like compounds include, for example, morphinan and benzomorphan (i. e., 
1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine).96 The first synthesis of a benzomorphan 
has been reported by Barltrop in 1947.97 The trivial name “benzomorphan” is derived from 
the trivial name “morphan” (azabicyclo[3.3.1]nonane). Positional variation of the nitrogen 































Pavine   
Figure 5-2: 
 
Isobenzomorphans (i. e., 7,8-benzo-9-azabicyclo-[3.3.1]nonanes, 1,2,3,4,5,6-hexahydro-
1,5-iminobenzo-cyclooctenes) represent interesting structural isomers of benzomorphans 
containing an imino-bridge. These compounds are, in a formal sense, simple structural 
analogues of morphine and are present, for example, in pavine-type alkaloids (Scheme 2). 
Isobenzomorphans have been prepared by Dieckmann cyclization99 and by reaction of an 
acetoneberberine-type enamine with alkyl halides.100  
 
Quinolinium- and isoquinolinium salts, generated by alkylation or acylation of quinoline 
and isoquinoline,101 are important synthetic building blocks. They have been used, for 
example, in condensations with Grignard reagents, cyanides (Reissert reaction), 
trimethylsilylacetonitrile, allylsilanes or silyl enol ethers.102 In recent years, a number of 
cyclocondensation reactions of bis(silyl enol ethers) with iminium salts have been reported.103 
Recently, Langer et al. have reported104 a convenient approach to 7,8-benzo-3-hydroxy-9-
azabicyclo[3.3.1]non-3-enes, isobenzomorphan derivatives, by condensation of 1,3-
bis(silyloxy)-1,3-butadienes1 with isoquinolinium salts and subsequent acid-mediated 
cyclization. The products are not readily available by other methods. Herein, I wish to report a 
comprehensive study of the preparative scope this methodology. In addition, I report, for the 
first time, the deprotection of the products, the synthesis of the parent 7,8-benzo-9-
azabicyclo[3.3.1]nonan-3-ones by decarboxylation. Some work from this portion will be the 
part of the Ph.D thesis of Mr. Jörg Peter Gütlein. 
 
5.2. Results and Discussion 
 
The methyl chloroformate-mediated reaction of isoquinoline (35a) with 4-(4-
fluorophenyl)-2,2,8,8-tetramethyl-6-methylene-3,7-dioxa-2,8-disilanon-4-ene (32b), available 
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from 4-flourobenzoylacetone,2 afforded the condensation product 36a (Scheme 5-1). The 
reaction proceeds by formation of the isoquinolinium salt A and subsequent regioselective 
attack of the terminal carbon of 32b. Treatment of 36a with TFA afforded the 7,8-benzo-3-
hydroxy-9-azabicyclo[3.3.1]non-3-ene 37a. The use of TFA proved to be mandatory; the 





































Scheme 5-1: Possible mechanism of the cyclization of aryl-1,3-bis(silyl enol ether) 32b 
with 35a; i: 35a (1.0 equiv.), 32b (2.0 equiv.), ClCO2Me (1.2 equiv.), CH2Cl2, 0 °C, 2 h, 20 
°C, 12 h; ii: TFA (2.0 equiv.), CH2Cl2, 20 °C, 12 h. 
 49
The formation of 37a proceeds by regioselective attack of the terminal carbon atom of 32b 
onto the iminium salt A fromed by reaction of 35a with methyl chloroformate. The TFA-
mediated cyclization proceeds by formation of the iminium salt B and attack of the enol 
carbon atom onto the latter. The regioselective cyclization can be explained by the higher 
thermodynamic stability of the iminium cation B compared to the benzylic cation formed by 
protonation of the other carbon atom of the enamine moiety (by 19.7 kcal/mol at a B3LYP/6-
31G* level). Product 37a is completely present in its enol tautomeric form (which is more 
stable by 3.3 kcal/mol than the keto form at the same level of theory). 
 
The methyl chloroformate mediated reaction of 35a-c with aryl-1,3-bis(silyl enol ethers) 
32b-l, prepared from the corresponding 1,3-dicarbonyl compounds, afforded the condensation 
products 36a-r which were transformed into the 7,8-benzo-9-azabicyclo[3.3.1]non-3-enes 
37a-r (Scheme 5-2, Table 5-1). All reactions proceeded in moderate to excellent yields. 
Regarding the cyclization step, better yields were generally obtained for substrates derived 
from 1,3-diketones compared to those derived from β-ketoesters. This can be explained by the 
higher extent of enolization of 1,3-diketones compared to β-ketoesters which is important for 
the TFA-mediated cyclization step. Noteworthy, the synthesis and reactions of pyridine- and 






































Scheme 5-2: Synthesis of 37a-r; i: 35 (1.0 equiv.), 32 (2.0 equiv.), ClCO2Me (1.2 equiv.), 


















Table 5-1: Synthesis of 37a-r 
35 32 36,37 R1 R2  % (36) a  % (37) a 
a b a 4-FC6H4 H 68 67 
a c b 4-ClC6H4 H 70 69 
a d c 2-MeC6H4 H 43 72 
a e d 2-(MeO)C6H4 H 68 69 
a g e 2-ClC6H4 H 58 78 
a h f 2-FC6H4 Et 76 81 
a i g 4-(NO2)C6H4 H 43 60 
a j h 3,4,5-(MeO)3C6H2 H 34 55 
a k i 1-Naph H 41 77 
a l j 2-Naph H 76 70 
a r k 2-Pyridyl H 68 27 
a s l 2-Thienyl H 22 34 
b c m 4-ClC6H4 NO2 54 75 
b b n 4-FC6H4 NO2 72 55 
b d o 2-MeC6H4 NO2 71 96 
b h p 2-FC6H4 NO2 41 86 
b g q 2-ClC6H4 NO2 56 60 
b l r 2-Naph NO2 56 63 
a Yields of isolated products 
All structures were proved by spectroscopic methods. Noteworthy, the 1H and 13C NMR 
spectra show a splitting of several signals, due to dynamic processes of the carbamate moiety 
which possesses a significant double bond character. The structures of 37d, and 37f were 















Figure 5-4: Ortep plot of 37f.The thermal ellipsoids of 50% probability are shown for the 
non-hydrogen atoms. 
 
The reaction of 35a-d with 1,3-bis(silyl enol ethers) 4a-c and 32b,g, in the presence of 
benzyl chloroformate, afforded the condensation products 38a-f which were transformed into 
the 7,8-benzo-9-azabicyclo[3.3.1]non-3-enes 39a-f (Scheme 5-3, Table 5-2). While all 
attempts to deprotect the methoxycarbonyl-substituted products 37a-ad proved to be 
unsuccessful, the deprotection (H2, Pd/C) of benzyloxycarbonyl-substituted derivatives 39a-e 
was possible and gave the desired products 7a-e, But the conversion of 39 f-g to 40f-g was 
unsuccessful. The hydrogenation of 39a-e resulted not only in cleavage of the protective 
group, but also in transformation of the nitro into an amino group. As expected, no splitting of 











































Scheme 5-3: Synthesis of 40a-g; i: 35 (1.0 equiv.), 4, 32 (2.0 equiv.), ClCO2Bn (1.2 
equiv.), CH2Cl2, 0°C, 2 h, 20 °C, 12 h; ii: TFA (2.0 equiv.), CH2Cl2, 20 °C, 12 h; iii;H2 Pd/C 









Table 5-2: Synthesis of 40a-g 




A great variety of functionalized 7,8-benzo-9-azabicyclo-[3.3.1]nonan-3-ones were 
prepared by methyl or benzyl chloroformate-mediated  condensation of isoquinolines with 
1,3-bis(silyloxy)-1,3-butadienes and subsequent TFA-mediated cyclization. The hydroxyl 
group could be functionalized by Suzuki reactions of the corresponding enol triflates. The N-
benzyloxycarbonyl-substituted products were successfully deprotected. The decarboxylation 
allowed the synthesis of the parent 7,8-benzo-9-azabicyclo[3.3.1]nonan-3-ones. The products 



















35 4 38,39,40 R1 R2  % (38) a  % (39) a  % (40) a 
a a a OMe H 83 37 37 
b a b OMe NO2 97 37  
b a b OMe NH2   37 
c b c Me Br 79 25  
c b c Me H   25 
a c d O(CH2)2OMe H 80 57 57 
a b e Me H 55 69 69 
a 32c f 4-ClC6H5 H 81 93 Fail 




Regioselective cyclocondensation reactions of 1,3-bis(silyl enol ethers) with different 
mono(silyl enol ethers) provide an elegant approach for the synthesis of various complex 
carba- and heterocycles from simple starting materials. 6-(Pyridyl)salicylates and biaryls are 
prepared based on [3+3] cyclocondensations of 1,3-bis(silyl enol ethers) and 1-aryl-1-
silyloxy-1-en-3-ones. Subsequently, 2-methoxy- and 2-nitro-substituted biaryls are 
transformed into biaryl lactones and 6(5H)-phenanthridinones based on a lactonization and 
lactamization strategy, respectively. Furthermore, some of the biaryls are also converted to the 
respective fluorenones by Friedel–Crafts acylations. The cyclocondensation reaction of aryl-
1,3-bis(silyl enol ethers) with 3-formylchromone yielded bis(benzophenones). In addition, 
functionalized 7,8-benzo-9-azabicyclo[3.3.1]nonan-3-ones (isobenzomorphanons) have been 
prepared by cyclocondensation of aryl-1.3-bis(silyl enol ethers) with isoquinolines. 
 
Regioselective Cyclokondensationsreaktionen von 1,3-Bis(silylenolethern) mit 
unterschiedlichen Mono(silylenolethern) bietet einen eleganten Zugang zu einer Vielzahl 
unterschiedlicher Carba- und Heterocyclen ausgehend von einfachen Startmaterialien. 6-
(Pyridyl)salicylate und Biaryle werden durch [3+3] Cyclokondensationen von 1,3-
Bis(silylenolethern) und 1-Aryl-1-silyloxy-1-en-3-onen hergestellt. Anschließend werden 2-
methoxy- und 2-nitro-substituierte Biaryle in Biaryllactone und 6(5H)-Phenanthridinone 
durch Lactonisierung bzw. Lactamisierung umgewandelt. Außerdem werden Biaryle in 
Fluorenone durch Friedel–Crafts-Acylierungen umgewandelt. Die Cyclokondensation von 
Aryl-1,3-bis(silylenolethern) mit 3-Formylchromonen lieferte Bis(benzophenone). Schließlich 
wurden funktionalisierte 7,8-Benzo-9-azabicyclo[3.3.1]nonan-3-one (Isobenzomorphanone) 





































































General Scheme: As the part of this work carried out with bis(silyl enol ethers) and types 









6. Experimental Section: 
 
6.1 General: Equipment, chemicals and work technique 
1H NMR Spectroscopy: Bruker: AM 250, Bruker ARX 300, Bruker ARX 500; δ = 0.00 ppm 
for Tetramethylsilane; δ = 2.04 ppm for Acetone d-6; δ = 7.26 ppm for (CDCl3); 2.50 ppm for 
d-6 DMSO-; Characterization of the signal fragmentations: s = singlet, d = doublet, dd = 
double of doublet, ddd = doublet of a double doublet, t = triplet, q = quartet, quint = quintet; 
sext = Sextet, sept = Septet, m = multiplet, br = broadly. Spectra were evaluated according to 
first order rule. All coupling constants are indicated as (J). 
 
13C NMR Spectroscopy: Bruker: AM 250, (62.9 MHz); Bruker: ARX 300, (75 MHz), 
Bruker: ARX 500, (125 MHz)  Ref: 29.84 ± 0.01 ppm and 206.26 ± 0.13 ppm for (CD3)2CO. 
δ = 128.00 ppm for Acetone d-6; δ = 77.00 ppm for CDCl3. The multiplicity of the carbon 
atoms was determined by the DEPT 135 and APT technique (APT = Attached Proton Test) 
and quoted as CH3, CH2, CH and C for primary, secondary, tertiary and quaternary carbon 
atoms. Characterization of the signal fragmentations: quart = quartet the multiplicity of the 
signals was determined by the DEPT recording technology and/or the APT recording 
technology. 
 
Mass Spectroscopy:AMD MS40, AMD 402 (AMD Intectra),  Varian MAT CH 7, 
MAT 731. 
 
High Resolution mass spectroscopy: Finnigan MAT 95 or Varian MAT 311; Bruker FT 
CIR, AMD 402 (AMD Intectra). 
 
Infrared spectroscopy (IR): Bruker IFS 66 (FT IR), Nicolet 205 FT IR; Nicolet Protege 
460, Nicolet 360 Smart Orbit (ATR); KBr ,KAP, Nujol, and ATR; Abbreviations for 
signal allocations: w = weak, m = medium, s = strong, br = broad. 
 
Elementary analysis: LECO CHNS-932, Thermoquest Flash EA 1112. 
 
X-ray crystal structure analysis: Bruker X8Apex Diffractometer with CCD-Kamera (Mo-
Ka und Graphit Monochromator, λ = 0.71073 Å). 
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Melting points: Micro heating table HMK 67/1825 Kuestner (Büchi apparatus); Melting 
points are uncorrected. 
 
Column chromatography: Chromatography was performed over Merck silica gel 60 (0,063 -
0,200 mm, 70 - 230 mesh) as normal and/or over mesh silica gel 60 (0,040 - 0,063 mm, 200 -
400 mesh) as Flash Chromatography. All solvent were distilled before use. 
 
TLC: Merck DC finished foils silica gel 60 F254 on aluminum foil and Macherey finished 
foils Alugram® Sil G/UV254. Detection under UV light with 254 nm and/or 366 nm without 
dipping reagent, as well as with anisaldehyde sulfuric acid reagent (1 mL anisaldehyde 
consisting in 100 mL stock solution of 85% methanol, 14% acetic acid and 1% sulfuric acid). 
 
Chemicals and work technique:All solvents for using were distilled by standard methods. 
All reactions were carried out under an inert atmosphere, oxygen and humidity exclusion. All 
of the chemicals are standard, commercially available from Merck®, Aldrich®, Arcos® and 
others. The order of the characterized connections effected numerically, but does not 
correspond to the order in the main part of dissertation. 
 
6.2. Procedures and Spectroscopic Data 
 
General procedure for the synthesis of 1,3-dicarbonyl compounds 7b-d and 13: To a 
stirred solution of LDA (75.0 mmol) in THF (1.2 mL/1.0 mmol of LDA) was added ketone 1 
(50.0 mmol) at −78 °C. After stirring of the solution for 1 h, 2 or 8 (60.0 mmol) was added. 
The temperature of the solution was allowed to rise to 20 °C during 12 h. A saturated aqueous 
solution of NH4Cl was added, the layers were separated, and the aqueous layer was extracted 
with EtOAc (3 x 50 mL). The combined organic layers were dried (Na2SO4) and filtered, and 
the solvent was removed in vacuo. The residue was purified by chromatography (silica gel, n-




Starting with LDA (1.5equiv.) in THF (62 mL), 2-butanone (4.4 
mL, 50.0 mmol), and 6a (8.0 mL, 60.0 mmol), 7b was isolated as a 




3J = 7.4 Hz, 3 H, CH2CH3), 2.41 (q, 3J = 7.3, 2 H, CH2CH3), 6.73 (s, 1 H, CH), 7.27−7.31 (m, 
1 H, CHAr), 7.68−7.74 (m, 1 H, CHAr), 7.94−7.98 (m, 1 H, CHAr), 8.54−8.56 (m, 1 H, CHAr), 
15.61 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 9.8 (CH2CH3), 33.0 (CH2CH3), 96.4 
(CH), 122.3, 126.4, 137.2, 149.5 (CHAr), 152.4 (CAr), 180.6 (COH), 199.6 (C=O). IR (neat 
cm−1): ν~  = 2976 (w), 2879 (w), 1600 (s), 1577 (s), 1563 (s), 1460 (m), 1311 (m), 1240 (m), 
1048 (m), 781 (s), 742 (s). GC-MS (EI, 70 eV): m/z (%) = 177 ([M+], 13), 162 (4), 148 (100), 
106 (69), 78 (74), 51 (14). HRMS (EI): Calcd. for C10H11NO2: 177.07843; found: 177.07890. 
 
1-Hydroxy-1-(2-pyridyl)-1-hexen-3-one (7c): 
Starting with LDA (1.5 equiv.) in THF (62 mL), 2-pentanone 
(5.3 mL, 50.0 mmol), and 6a (8.0 mL, 60.0 mmol), 7c was 
isolated as a yellow oil (5.32 g, 56%). 1H NMR (300 MHz, 
CDCl3): δ = 0.89 (t, 3J = 7.4 Hz, 3 H, CH2CH2CH3), 1.59−1.67 (m, 2 H, CH2CH2CH3), 2.35 
(t, 3J = 7.6 Hz, 2 H, CH2CH2CH3), 6.73 (s, 1 H, CH), 7.29−7.31 (m, 1 H, CHAr), 7.71−7.72 
(m, 1 H, CHAr), 7.97 (d, 3J = 8.0 Hz, 1 H, CHAr), 8.54 (m, 1 H, CHAr), 15.68 (s, 1 H, OH). 13C 
NMR (75 MHz, CDCl3): δ = 13.9 (CH2CH2CH3), 19.3 (CH2CH2CH3), 41.6 (CH2CH2CH3), 
97.0 (CH), 122.3, 126.4, 137.3, 149.5 (CHAr), 152.7 (CAr), 181.4 (COH), 198.3 (C=O). GC-
MS (EI, 70 eV): m/z (%) = 191 ([M+], 10), 163 (14), 148 (100), 121 (21), 106 (77), 93 (14), 
78.(83), 51 (15), 43 (14). HRMS (EI): Calcd. for C11H13NO2: 191.09408; found: 191.09468.  
 
1-Hydroxy-4-methyl-1-(pyrid-2-yl)pent-1-en-3-one (7d):  
 Starting with LDA (1.5 equiv.) in THF (62 mL), 3-methyl-2-
butanone (5.3 mL, 50.0 mmol), and 6a (8.0 mL, 60.0 mmol), 7d 
was isolated as a yellowish oil (5.653 g, 54%).1H NMR (300 MHz, 
CDCl3): δ = 1.09 (m, 6 H, CH(CH3)2), 2.50−2.56 (m, 1 H, 
CH(CH3)2), 6.73 (s(br), 1 H, CH), 7.23−7.25 (m, 1 H, CHAr), 7.64−7.67 (m, 1 H, CHAr), 7.92 
(m, 1 H, CHAr), 8.51 (m, 1 H, CHAr), 15.70 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 
19.5 (CH(CH3)2), 38.0 (CH(CH3)2), 95.0 (CH), 122.1, 125.9, 137.1, 149.1 (CHAr), 152.5 
(CAr), 181.5 (COH), 202.5 (C=O). GC-MS (EI, 70 eV): m/z (%) = 191 ([M+], 11), 148 (100), 
121 (22), 106 (37), 93 (4), 78.(80), 43 (40). HRMS (EI): Calcd. for C11H13NO2: 191.09408; 










Starting with LDA (1.5 equiv.) in THF (62 mL), 2-pentanone 
(5.3 mL, 50.0 mmol), 6c (5.3 mL, 35.0 mmol), 13 was isolated 
as a yellow solid (4.208 g, 63%). 1H NMR (250 MHz, CDCl3): 
δ = 0.86 (t, 3J = 7.4 Hz, 3 H, CH2CH2CH3), 1.55−1.64 (m, 2 H, 
CH2CH2CH3), 2.33 (t, 3J = 7.5 Hz, 2 H, CH2CH2CH3), 6.13 (s, 1 H, CH), 7.57 (d, 3J = 6.3 Hz, 
2 H, CHAr), 8.61 (d, 3J = 5.3 Hz, 2 H, CHAr), 15.06 (s(br), 1 H, OH). 13C NMR (75 MHz, 
CDCl3): δ = 13.3 (CH2CH2CH3), 18.4 (CH2CH2CH3), 41.3 (CH2CH2CH3), 96.8 (CH), 120.1 
(2CHAr), 141.5 (CAr), 150.7(2CHAr), 178.2 (COH), 199.6 (C=O). GC-MS (EI, 70 eV): m/z (%) 
= 191 ([M+], 18), 163 (19), 148 (100), 121 (9), 106 (27), 93 (4), 78.(20), 51 (15), 43 (10). 
HRMS (EI): Calcd. for C11H13NO2: 191.09408; found: 191.09411.  
 
General procedure for the synthesis of silyl enol ethers 8 and 14: To a stirred benzene 
solution (2.5 mL/1.0 mmol of 7) of 7 (10.0 mmol) was added triethylamine (16.0 mmol). 
After stirring of the solution for 2 h, trimethylchlorosilane (36.0 mmol) was added. After 
stirring of the solution for 72 h, the solvent was removed in vacuo and hexane (25 mL) was 
added to the residue to give a suspension. The latter was filtered under argon atmosphere. The 
filtrate was concentrated in vacuo to give silyl enol ethers 8, and 14. Due to the unstable 
nature of the silyl enol ethers, they were characterized only by NMR spectroscopy. 
 
1-(2-Pyridyl)-1-[(trimethylsilyl)oxy]-1-penten-3-one (8b): 
Starting with benzene (38.0 mL), 7b (4.73 g, 15.3 mmol), 
triethylamine (6.1 mL, 43.0 mmol) and trimethylchlorosilane 
(10.51 mL, 83.2 mmol), 8b was isolated as a reddish oil (5.10 g, 
76%). 1H NMR (300 MHz, CDCl3): δ = 0.25 (m, 9 H, OSi(CH3)3), 
1.05−1.08 (m, 3 H, CH2CH3), 2.80−2.88 (m, 2 H, CH2CH3), 7.07 (s, 1 H, CH), 7.29−7.31 (m, 
1 H, CHAr), 7.68−7.72 (m, 1 H, CHAr), 8.02−8.06 (m, 1 H, CHAr), 8.54−8.56 (m, 1 H, CHAr). 
13C NMR (75 MHz, CDCl3): δ = 0.12 (Si(CH3)3), 11.1 (CH2CH3), 27.7 (CH2CH3), 102.0 












 Starting with benzene (69.5 mL), 7c (5.31 g, 27.8 mmol), 
triethylamine (6.23 mL, 44.5 mmol) and trimethylchlorosilane 
(12.6 mL, 100.1 mmol), 8c was isolated as a reddish oil (6.20 g, 
86%). 1H NMR (300 MHz, CDCl3): δ = 0.24−0.29 (m, 9 H, 
OSi(CH3)3), 0.87−0.95 (m, 3 H, CH2CH2CH3), 1.56−1.66 (m, 2 H, CH2CH2CH3), 2.34−2.39 
(m, 2 H, CH2CH2CH3), 7.26 (s, 1 H, CH), 7.32 (m, 1 H, CHAr), 7.26−7.36 (m, 1 H, CHAr), 
7.98−8.05 (m, 1 H, CHAr), 8.54−8.58 (m, 1 H, CHAr). 13C NMR (75 MHz, CDCl3): δ = 0.09 
(OSi(CH3)3), 13.6 (CH2CH2CH3), 20.2 (CH2CH2CH3), 30.0 (CH2CH2CH3), 102.0 (CH), 
120.5, 125.8, 136.6, 148.4 (CHAr), 155.5 (CAr), 176.2(C), 188.7 (C=O). 
 
1-(2-Pyridyl)-1-[(trimethylsilyl)oxy]-1-hexen-3-one (8d):  
Starting with benzene (38.0 mL), 7d (5.65 g, 29.5 mmol), 
triethylamine (6.58 mL, 47.0 mmol) and trimethylchlorosilane 
(13.4 mL, 106.2 mmol), 8d was isolated as a reddish oil. 1H NMR 
(300 MHz, CDCl3): δ = 0.25 (OSi(CH3)3), 1.07−1.10 (m, 6 H, 
CH(CH3)2), 2.54−2.66 (m, 1 H, CH(CH3)2), 6.90 (s, 1 H, CH), 7.25−7.30 (m, 1 H, CHAr), 
7.70−7.72 (m, 1 H, CHAr), 7.97−7.98 (m, 1 H, CHAr), 8.52 (m, 1 H, CHAr). 13C NMR (75 
MHz, CDCl3): δ = 0.3 (OSi(CH3)3), 10.9 (CH(CH3)2), 32.2 (CH(CH3)2), 103.2 (CH), 127.5, 
129.2, 129.8, 133.4 (CHAr), 147.2 (CAr), 176.5 (C), 185.9 (C=O). 
 
4-Methyl-1-(2-pyridyl)-1-[(trimethylsilyl)oxy]-1-penten-3-one (14):  
Starting with benzene (65.0 mL), 13 (5.00 g, 26.1 mmol), 
triethylamine (5.8 mL, 41.8 mmol) and trimethylchlorosilane 
(11.9 mL, 94.1 mmol), 14 was isolated as a reddish oil (6.05 g, 
88%). 1H NMR (250 MHz, CDCl3): δ = 0.04 (m, 9 H, 
OSi(CH3)3), 0.70−0.73 (m, 3 H, CH2CH2CH3), 1.37−1.44 (m, 2 H, CH2CH2CH3), 2.19 (t, 3J = 
7.4 Hz, 2 H, CH2CH2CH3), 5.90 (s, 1 H, CH), 7.36−7.42 (m, 2 H, CHAr), 8.46−8.50 (m, 2 H, 
CHAr). 13C NMR (75 MHz, CDCl3): δ =0.1(Si(CH3)3) 13.0 (CH2CH2CH3), 19.5 
(CH2CH2CH3), 35.5 (CH2CH2CH3), 102.6 (CH), 120.1 (2CHAr), 127.4 (CAr), 149.5 (2CHAr), 
176.8 (COH), 187.4 (C=O). 
 
General procedure for the synthesis of salicylates 9e-l, and 15a-b: To a CH2Cl2 solution (2 











mmol) at −78 °C. The temperature of the solution was allowed to warm to 20 °C during 14 h 
with stirring. To the solution was added hydrochloric acid (10%, 20 mL) and the organic and 
the aqueous layer were separated. The latter was extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in 
vacuo. The residue was purifed by chromatography (silica gel, n-heptane / EtOAc) to give 9e-
l, and 15a-b.  
 
Methyl 4-ethyl-2-hydroxy-6-(pyrid-2-yl)benzoate (9e): 
Starting with 7b (0.425 g, 1.67 mmol), 4a (0.627 g, 1.82 mmol) and 
TiCl4 (0.20 mL, 1.67 mmol), 9e was isolated as a reddish highly 
viscous oil (0.154 g, 40%). 1H NMR(300 MHz, CDCl3): δ = 1.17 (t, 
3J = 7.6 Hz, 3 H, CH2CH3), 2.60 (q, 3J = 7.6 Hz, 2 H, CH2CH3), 
3.39 (s, 3 H, COOCH3), 6.68 (d, 4J = 1.7 Hz, 1 H, CHAr), 6.83 (d, 4J 
= 1.4 Hz, 1 H, CHAr), (ddd, 3J = 6.4 Hz, 3J = 6.0 Hz, 4J = 1.5 Hz, 1 
H, CHAr), 7.24 (d, 3J=7.8 Hz, 1 H, CHAr), 7.61−7.67 (m, 1 H, CHAr), 8.53−8.54 (m, 1 H, 
CHAr), 10.58 (s, 1 H, OHAr). 13C NMR (75 MHz, CDCl3): δ = 13.6 (CH2CH3), 27.8 
(CH2CH3), 50.7 (COOCH3), 108.4 (CAr), 115.6 (CHAr), 120.6 (CHAr), 121.9 (CHAr), 122.0, 
134.7 (CHAr), 142.4 (CAr), 147.4 (CHAr), 151.1 (CAr), 159.4 (CAr) 160.5 (COHAr), 169.8 
(C=O). IR (neat, cm−1): ν~  = 2970 (w), 2930 (w), 1603 (s), 1578 (s), 1422 (s), 1239 (s), 1214 
(s), 1158 (s), 1088 (m), 1056 (m), 818 (m). GC-MS (EI, 70 eV): m/z (%) = 257 ([M+], 32), 
225 (61), 211 (8), 197 (11), 182 (100), 154 (10), 127 (8), 84 (9). HRMS (EI): Calcd. for 
C15H15NO3: 257.10464; found: 257.10461. 
 
Methyl 4-ethyl-2-hydroxy-3-methyl-6-(pyrid-2-yl)benzoate (9f): 
Starting with 7b (0.374 g, 1.5 mmol), 4b (0.448 g, 1.65 mmol) and 
TiCl4 (0.18 mL, 1.65 mmol), 9f was isolated as a reddish highly 
viscous oil (0.180, 44%). 1H NMR (300 MHz, CDCl3): δ = 1.12 (t, 
3J = 7.7 Hz, 3 H, CH2CH3), 2.18 (s, 3 H, CH3), 2.60 (d, 3J = 7.3 Hz, 
2 H, CH2CH3), 3.39 (s, 3 H, COOCH3), 6.67 (s, 1.H, CHAr), 
7.12−7.24 (m, 2.H, CHAr), 7.59−7.65 (m, 1 H, CHAr), 8.52 (m, 1 H, 
CHAr), 10.80 (s, 1 H, OHAr). 13C NMR (75 MHz, CDCl3): δ = 11.4 (CH2CH3), 14.5 (CH3), 
27.4 (CH2CH3), 52.1 (COOCH3), 109.2 (CAr), 121.8, 122.2, 123.4 (CHAr), 124.7 (CAr) 136.1 
(CHAr), 140.7 (CAr), 148.8 (CHAr), 149.1, 160.0 (CAr), 161.1 (COHAr), 171.8 (C=O). IR (neat, 













1105 (s), 1009 (m). GC-MS (EI, 70 eV): m/z (%) = 271 ([M+], 35), 239 (100), 224 (23), 211 
(20), 196 (20), 182 (10), 167 (17), 154.(7), 84 (7), 78 (5). HRMS (EI): Calcd. for C16H17NO3: 
271.12029; found: 271.11995. 
 
Ethyl 3,4-diethyl-2-hydroxy-6-(pyrid-2-yl)benzoate (9g): 
Starting with 7b (0.498 g, 2.0 mmol), 4c (0.659 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 9g was isolated as a reddish highly 
viscous oil (0.230 g, 38%). 1H NMR (300 MHz, CDCl3): δ = 0.83 
(t, 3J = 7.3 Hz, 3 H, OCH2CH3), 1.24−1.33 (m, 6 H, CH2CH3), 
2.73−2.87 (m, 4 H, CH2CH3), 4.05 (q, 3J = 7.2 Hz, 2 H, 
COOCH2), 6.81 (s, 1 H, CHAr), 7.29−7.33 (m, 1 H, CHAr), 7.40 (d, 
3J = 7.8 Hz, 1 H, CHAr), 7.74−7.80 (m, 1 H, CHAr), 8.66−8.68 (m, 1 H, CHAr), 11.20 (s, 1 H, 
OHAr). 13C NMR (75 MHz, CDCl3): δ = 13.5 (OCH2CH3), 14.2, 15.5 (CH2CH3), 19.4, 26.5 
(CH2CH3), 61.1 (COOCH2), 109.5 (CAr), 121.8, 122.3, 123.4 (CHAr), 130.8 (CAr), 136.0 
(CHAr), 140.9 (CAr), 148.4 (CHAr), 148.8, 160.2, (CAr), 161.5 (COHAr), 171.4 (C=O). IR (KBr, 
cm−1): ν~  = 2965 (w), 2873 (w), 1655 (s), 1587 (m), 1392 (m), 1371 (s), 1273 (s), 1183 (s), 
1031 (s), 1031 (m). GC-MS (EI, 70 eV): m/z (%) = 299 ([M+], 44), 253 (100), 238 (70), 224 
(25), 210 (13), 167 (14), 117 (8), 78 (5). HRMS (EI): Calcd. for C18H21NO3: 299.15160; 
found: 299.15122. 
 
Methyl 4-ethyl-3-hexyl-2-hydroxy-6-(pyrid-2-yl)benzoate (9h):  
Starting with 4b (0.498 g, 2.0 mmol), 4d (0.751 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 9h was isolated as a reddish highly 
viscous oil (0.150 g, 30%). 1H NMR (300 MHz, CDCl3): δ = 
0.86 (t(br), 3J = 6.8 Hz, 3 H, (CH2)5CH3), 1.12 (t(br), 3J = 5.5 Hz, 3 
H, CH2CH3), 1.22−1.28 (m, 8 H, CH2), 2.64 (t, 3J = 7.6 Hz, 2 H, 
CH2(C5H11), 2.68 (q, 3J = 7.2 Hz, 2 H, CH2CH3), 3.44 (s, 3 H, 
COOCH3), 6.72 (s, 1.H, CHAr), 7.17−7.21 (m, 1.H, CHAr), 7.28−7.31 (m, 1 H, CHAr), 7.65−7-
70 (m, 1 H, CHAr), 8.56−8.58 (m, 1 H, CHAr), 10.86 (s, 1 H, OHAr). 13C NMR (75 MHz, 
CDCl3): δ = 14.4 (C5H11CH3), 15.4 (CH2CH3), 23.0, 26.3, 26.6, 29.9, 30.1((CH2)5CH3), 33.1 
(CH2CH3), 52.0 (COOCH3), 109.4 (CAr), 121.8, 122.4, 123.3 (CHAr), 129.7 (CAr) 136.1 
(CHAr), 140.7 (CAr), 148.7 (CHAr), 149.6, 160.0 (CAr), 161.1 (COHAr), 171.8 (C=O). IR (neat, 
cm−1): ν~  = 2952 (w), 2852 (w), 1663 (m), 1436 (m), 1397 (m), 1318 (m), 1271 (m), 1195 (s), 














(100), 167 (13), 117 (3), 78 (4), 57 (5), 43 (7). HRMS (EI): Calcd. for C21H27NO3: 341.19855; 
found: 341.19815. 
 
Methyl 4-ethyl-2-hydroxy-3-octyl-6-(pyrid-2-yl)benzoate (9i): 
 Starting with 7b (0.498 g, 2.0 mmol), 4e (0.812 g, 2.2 mmol) 
and TiCl4 (0.24 mL, 2.2 mmol), 9i was isolated as a dark reddish 
highly viscous oil (0.220 g, 30%). 1H NMR (300 MHz, CDCl3): 
δ = 0.80−84 (m, 6 H, CH3), 1.12−1.27 (m, 12 H, CH2), 2.59−2.65 
(m, 4 H, CH2), 3.39 (s, 3 H, COOCH3), 6.67 (s, 1.H, CHAr), 
7.13−7.17 (m, 1.H, CHAr), 7.23−7.26 (m, 1 H, CHAr), 7.61−7.66 
(m, 1 H, CHAr), 8.51−8.54 (m, 1 H, CHAr), 10.82 (s, 1 H, OHAr). 
13C NMR (75 MHz, CDCl3): δ = 14.5 (C7H13CH3), 15.5 (CH2CH3), 22.9, 23.1, 26.3, 26.6, 
29.9, 30.0, 30.1, 32.1 (CH8), 52.0 (COOCH3), 109.3 (CAr), 121.9, 122.4, 123.4 (CHAr), 129.8 
(2CAr) 136.2 (CHAr), 140.7 (CAr), 148.7 (CHAr), 160.0, (CAr), 161.1 (COHAr), 171.8 (C=O). IR 
(neat, cm−1): ν~  = 2953 (m), 2854 (w), 1663 (m), 1436 (m), 1397 (m), 1318 (m), 1270 (m), 
1195 (s), 1149 (m), 1010 (m). GC-MS (EI, 70 eV): m/z (%) = 369 ([M+], 11), 341 (30), 310 
(5), 271 (94), 252 (60), 239 (100), 177 (13), 127 (4), 78 (4). HRMS (EI): Calcd. for 
C23H31NO3: 369.22985; found: 369.22968. 
 
Methyl 2-hydroxy-4-propyl-6-(pyrid-2-yl)benzoate (9j): 
 Starting with 7c (0.527 g, 2.0 mmol), 4a (0.565 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 9j was isolated as a reddish highly 
viscous oil (0.200 g, 33%). 1H NMR (300 MHz, CDCl3): δ = 0.87 
(t, 3J = 7.2 Hz, 3 H, CH2CH2CH3), 1.55−1.63 (m, 2 H, 
CH2CH2CH3), 2.51 (t, 3J = 7.2 Hz, 2 H, CH2CH2CH3), 3.40 (s, 3 
H, COOCH3), 6.67 (s, 1 H, CHAr), 6.80 (s, 1 H, CHAr), 7.14−7.17 
(m, 1 H, CHAr), 7.24 (d, 3J = 7.9 Hz, 1 H, CHAr), 7.61−7.66 (m, 1 H, CHAr), 8.53−8.54 (m, 1 
H, CHAr), 10.55 (s, 1 H, OHAr). 13C NMR (75 MHz, CDCl3): δ = 14.1 (CH2CH2CH3), 24.1 
(CH2CH2CH338.3 (CH2CH2CH3), 52.1 (COOCH3), 109.8 (CAr), 117.7, 122.1, 123.0, 123.3, 
136.1 (CHAr), 143.6 (CAr), 148.9 (CHAr), 150.1, 160.8 (CAr), 161.1 (COHAr), 171.2 (C=O)). IR 
(KBr, cm−1): ν~  = 3012 (w), 2844 (w), 1662 (s), 1499 (m), 1459 (s), 1378 (s), 1239 (s), 1106 
(m), 1074 (m), 1025 (m). GC-MS (EI, 70 eV): m/z (%) = 277 ([M+], 39), 239 (69), 211 (73), 
182 (100), 167 (6), 154 (17), 127 (12), 78 (5). HRMS (EI): Calcd. for C16H17NO3: 271.12029; 













Ethyl 3-ethyl-2-hydroxy-4-propyl-6-(pyrid-2-yl)benzoate (9k): 
Starting with 7c (0.527 g, 2.0 mmol), 4b (0.659 g, 2.2 mmol) and 
TiCl4 (0.239 mL, 2.2 mmol), 9k was isolated as a reddish highly 
viscous oil (0.200 g, 31%). 1H NMR (300 MHz, CDCl3): δ = 0.67 
(t, 3J = 7.0 Hz, 3 H, CH2CH2CH3), 0.91 (t, 3J = 7.4 Hz, 3 H, 
CH2CH3), 1.10 (t, 3J = 8.5 Hz, 2 H, CH2CH3), 1.51−1.59 (m, 2 H, 
CH2CH2CH3), 2.53, (t, 3J = 7.8 Hz, 2 H, CH2CH2CH3), 2.67 (q, 3J 
= 7.4 Hz, 2 H, CH2CH3), 3.89 (q, 3J = 7.2 Hz, 2 H, COOCH2CH3), 6.63 (s, 1 H, CHAr), 6.63 
(s, 1 H, CHAr), 7.17−7.26 (m, 2 H, CHAr), 7.60−7.65 (m, 1 H, CHAr), 8.52 (m, 1 H, CHAr), 
11.04 (s, 1 H, OHAr). 13C NMR (75 MHz, CDCl3): δ = 12.1 (CH2CH2CH3), 12.8 (CH2CH3), 
13.2 (OCH2CH3), 18.1 (CH2CH2CH3), 23.1, (CH2CH2CH3), 34.2 (CH2CH3), 59.7 
(COOCH2CH3), 108.0 (CAr), 121.7 (CHAr), 129.7 (2CHAr), 134.7 (CAr), 145.6 (2CHAr), 158.9 
(2CAr), 160.1 (2CAr), 170.2 (C=O). IR (neat, cm−1): ν~  = 2958 (w), 2871 (w), 1658 (m), 1464 
(m), 1393 (m), 1371 (m), 1273 (m), 1183 (s), 1110 (s), 1027 (m). GC-MS (EI, 70 eV): m/z 
(%) = 313 ([M+], 33), 267 (19), 252 (100), 238 (29), 210 (6), 195 (3,), 167 (8), 154 (3) 78 (5). 
HRMS (EI): Calcd. for C19H23NO3: 313.16725; found: 313.16693. 
 
Methyl 2-hydroxy-4-isopropyl-6-(pyrid-2-yl)benzoate (9l): 
 Starting with 7d (0.527 g, 2.0 mmol), 4a (0.565 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 9l was isolated as a reddish highly 
viscous oil (0.142 g, 26%). 1H NMR (300 MHz, CDCl3): δ = 1.17 
(d, 3J = 7.1 Hz, 6 H, CH(CH3)2), 2.75−2.89 (m, 1 H, CH(CH3)2), 
3.41 (s, 3 H, COOCH3), 6.71 (d, 4J = 1.3 Hz, 1 H, CHAr), 6.86 (d, 
4J = 1.3 Hz, 1 H, CHAr), 7.17−7.18 (m, 1 H, CHAr), 7.26 (d, 3J = 
7.6 Hz, 1 H, CHAr), 7.64 (ddd, 3J = 7.8 Hz, 3J = 7.7 Hz, 4J = 1.7 
Hz, 1 H, CHAr), 8.54 (m, 1 H, CHAr),10.57 (s, 1 H, OHAr). 13C NMR (75 MHz, CDCl3): δ = 
23.7 (CH(CH3)2), 34.6 (CH(CH3)2), 52.1 (COOCH3) 109.9 (CAr), 115.6, 121.1, 122.1, 123.4, 
136.2 (CHAr),143.7 (CAr) 148.9 (CHAr), 156.2, 160.9 (CAr), 162.0 (COHAr), 177.2 (C=O). IR 
(neat, cm−1): ν~  = 3109 (w), 2868 (w), 1666 (m), 1601(m), 1423 (m), 1353 (m), 1300 (s), 
1270 (s), 1160 (s), 1058 (m), 809 (m). GC-MS (EI, 70 eV): m/z (%) = 271 ([M+], 33), 239 
(69), 224 (16), 196 (100), 167 (23), 141.(5), 78 (4). HRMS (EI): Calcd. for C16H17NO3: 














Methyl 2-hydroxy-4-propyl-6-(pyrid-4-yl)benzoate (15a): 
Starting with 14 (0.392 g, 1.5 mmol), 4a (0.429 g, 1.65 mmol) and 
TiCl4 (0.18 mL, 1.65 mmol), 15a was isolated as a reddish highly 
viscous oil (0.180 g, 44%).1H NMR (250 MHz, CDCl3): δ = 0.87 
(t, 3J = 7.2 Hz, 3 H, CH2CH2CH3), 1.54−1.63 (m, 2 H, 
CH2CH2CH3), 2.50 (t, 3J = 7.2 Hz, 2 H, CH2CH2CH3), 3.42 (s, 3 H, 
COOCH3), 6.48 (s, 1 H, CHAr), 6.82 (s, 1 H, CHAr), 7.09−7.12 (m, 
2 H, CHAr), 8.54−8.69 (m, 2 H, CHAr), 10.87 (s(br), 1 H, OHAr). 13C NMR (75 MHz, CDCl3): δ 
= 13.7 (CH2CH2CH3), 23.6 (CH2CH2CH3), 37.9 (CH2CH2CH3), 51.6 (COOCH3), 108.7 (CAr), 
117.4 (2CHAr), 122.7 (CHAr) 141.6 (CAr), 148.9 (CHAr), 150.2 (CAr), 150.7 (2CHAr), 151.3 
(CAr), 162.2 (COHAr), 170.5 (C=O). GC-MS (EI, 70 eV): IR (neat, cm−1): ν~  = 2962 (w), 2873 
(w), 1601 (m), 1577 (s), 1403 (m), 1283 (m), 1086 (m), 11042 (m), 993 (m), 742 (m). MS (EI, 
70 eV): m/z (%) = 271 ([M+], 48), 239 (100), 211 (99), 182 (30), 167 (5), 154 (4), 127 (16), 
78 (4). HRMS (EI): Calcd. for C16H17NO3: 271.12029; found: 271.11994. 
 
Methyl 2-hydroxy-3-methyl-4-propyl-6-(pyrid-4-yl)benzoate (15b): 
Starting with 14 (0.395 g, 1.5 mmol), 4b (0.429 g, 1.65 mmol) and 
TiCl4 (0.180 mL, 1.65 mmol), 15b was isolated as a reddish highly 
viscous oil (0.170 g, 40%). 1H NMR (250 MHz, CDCl3): δ = 0.90 
(t, 3J = 6.5 Hz, 3 H, CH2CH2CH3), 1.48−1.57 (m, 2 H, 
CH2CH2CH3), 2.21 (s, 3 H, CH3), 2.52 (t, 3J = 6.0 Hz, 2 H, 
CH2CH2CH3), 3.43 (s, 3 H, COOCH3), 6.40 (s, 1.H, CHAr), 7.11 
(m, 1.H, CHAr), 7.60−7.62 (m, 1.H, CHAr), 8.69 (m, 2 H, CHAr), 
10.87 (s(br), 1 H, OHAr). 13C NMR (62 MHz, CDCl3): δ = 10.2 (CH2CH2CH3), 13.0 (CH3), 
22.2 (CH2CH2CH3), 35.0 (CH2CH2CH3), 50.6 (COOCH3), 106.7 (CAr), 121.3 (3CHAr), 124.0, 
137.7 (CAr) 146.7 (2CAr), 149.6 (2CHAr), 159.3 (COHAr), 170.2 (C=O). GC-MS (EI, 70 eV): 
IR (neat, cm−1): ν~  = 2956 (w), 2871 (w), 1699 (m), 1429 (m), 1398 (m), 1300 (m), 1267 (m), 
1200 (s), 1114 (s), 753 (m). MS (EI, 70 eV): m/z (%) = 285 ([M+], 45), 238 (100), 225 (35), 
210 (11), 196 (16), 182 (8), 167 (17), 154 (6), 139 (5), 84 (4), 78 (4). HRMS (EI): Calcd. for 
C17H19NO3: 285.13594; found: 285.13545. 
 
General procedure for the synthesis of aryl-1,3-dicarbonyl compounds17a-d: To a stirred 
solution of LDA (75.0 mmol) in THF (1.2 mL/1.0 mmol of LDA) was added ketone 5 (50.0 













temperature of the solution was allowed to rise to 20 °C during 12 h. A saturated aqueous 
solution of NH4Cl was added, the layers were separated, and the aqueous layer was extracted 
with EtOAc (3 x 50 mL). The combined organic layers were dried (Na2SO4) and filtered, and 
the solvent was removed in vacuo. The residue was purified by chromatography (silica gel, n-




Starting with LDA (1.5equiv.) in THF (62 mL), 5a (2.90 mL, 50.0 
mmol), and 16a (7.93 mL, 60.0 mmol), 17b was isolated as a reddish 
yellow oil (5.405 g, 54%). 1H NMR (250 MHz, CDCl3): δ = 2.19 (s, 3 
H, CH3), 6.16 (s, 1 H, CH), 7.45 ─ 7.60 (m, 3 H, CHAr), 7.82 (m, 1 H, 
CHAr), 15.12 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 24.2 (CH3), 99.9 (CH), 124.3, 
129.3, 130.0, 133.0 (CHAr), 134.7, 147.8, (CAr), 187.1 (COH), 190.2 (C=O). MS (EI 70 eV): 
m/z (%) = 207 ([M]+, 38), 192 (100), 160 (19), 150 (36), 120 (8), 89 (9), 85 (27), 76 (18), 43 
(45). HRMS (EI): Calcd. for C10H9NO2: 207.05261; found: 207.05232.  
 
4-hydroxy-4-(4-nitrophenyl)but-3-en-2-one(17d): 
Starting with LDA (1.5equiv.) in THF (62 mL), 5a (2.90 mL, 
50.0 mmol), and 16c (11.130 g, 60.0 mmol), 17d was isolated 
as a yellow solid (4.405 g, 43%). 1H NMR (300 MHz, CDCl3): 
δ = 2.11 (s, 3 H, CH3), 5.74 (s, 1 H, CH), 7.95 (d, 3J = 8.7 Hz, 2 
H, CHAr), 8.21 (d, 3J = 9.0 Hz, 2 H, CHAr), 15.80 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ 
= 27.0 (CH3), 98.5 (CH), 124.3 (2CHAr), 128.6 (2CHAr), 140.9, 149.9 (CAr), 179.8 (COH), 
196.6 (C=O). GC_MS (EI 70 eV): m/z (%) = 207 ([M]+, 38), 192 (100), 165 (8), 160 (19), 150 
(36), 120 (8), 104 (18), 89 (9), 85 (27), 76 (18), 63 (7), 50 (12), 43 (45). HRMS (EI): Calcd. 
for C10H9NO2: 207.05261; found: 207.05232.  
 
General procedure for the synthesis of silyl enol ethers 18, 25 and 28: To a stirred benzene 
solution (2.5 mL/1.0 mmol of 17) of 17 (10.0 mmol) was added triethylamine (16.0 mmol). 
After stirring of the solution for 2 h, trimethylchlorosilane (18.0 mmol) was added. After 
stirring of the solution for 72 h, the solvent was removed in vacuo and hexane (25 mL) was 






filtrate was concentrated in vacuo to give silyl enol ethers 18, 25 and 28. Due to the unstable 
nature of the silyl enol ethers, they were characterized only by NMR spectroscopy. 
 
4-(2-nitrophenyl)-4-(trimethylsilyloxy)but-3-en-2-one1(18a): 
Starting with benzene (90.0 mL), 17a (6.121 g, 29.54 mmol), 
triethylamine (6.62 mL, 47.2 mmol) and trimethylchlorosilane (6.67 
mL, 53.2 mmol), 18a was isolated as a reddish oil (7.30 g, 91%). 1H 
NMR (300 MHz, CDCl3): δ =0.05-0.30 (m, 9 H, Si(CH3)3), 2.15 (s, 3 
H, CH3), 6.06 (s, 1 H, CH), 7.45 ─ 7.60 (m, 3 H, CHAr), 7.82 (m, 1 H, CHAr), 13C NMR (75 
MHz, CDCl3): δ = 0.2 (Si(CH3)3), 24.5 (CH3), 98.9 (CH), 124.9, 129.6, 130.5, 133.5 (CHAr), 
134.9, 148.8, (CAr), 180.1 (COTMS), 191.2 (C=O). 
 
1-(2-nitrophenyl)-1-(trimethylsilyloxy)hex-1-en-3-one(18b): 
Starting with benzene (63.0 mL), 17b (4.83 g, 20.2 mmol), 
triethylamine (4.50 mL, 43.0 mmol) and trimethylchlorosilane 
(4.64 mL, 33.1 mmol), 18b was isolated as a reddish oil(5.60 g, 
88%). 1H NMR (250 MHz, CDCl3): δ =0.21-0.43 (m, 9 H, 
Si(CH3)3), 1.06 ─ 1.14 (m, 3 H, CH3), 1.69 ─ 1.85 (m, 2 H, 
CH2), 2.43 ─ 2.53 (m, 2 H, CH2), 5.85 (s, 1 H, CH), 7.50 ─ 8.00 (m, 3 H, CHAr), 8.07 ─ 8.19 
(m, 1 H, CHAr), 13C NMR (75 MHz, CDCl3): δ = 0.2 (Si(CH3)3), 13.8 (CH3), 36.4, 39.5 




Starting with benzene (52.0 mL), 17d (4.405 g, 21.3 mmol), 
triethylamine (4.70 mL, 33.0 mmol) and trimethylchlorosilane 
(5.09 mL, 37.8 mmol), 18d was isolated as a yellow solid 
(5.350 g, 92%). 1H NMR (300 MHz, CDCl3): δ = 0.02-0.22 (m, 
9 H, Si(CH3)3), 2.10 (s, 3 H, CH3), 6.08 (s, 1 H, CH), 7.80 ─ 7.89 (m, 2 H, CHAr), 8.09 ─ 8.17 
(m, 2 H, CHAr). 13C NMR (75 MHz, CDCl3): δ = 0.6 (Si(CH3)3), 24.6 (CH3), 96.8 (CH), 121.5 
(2CHAr), 125.9 (2CHAr), 138.4, 147. (CAr), 177.2 (COTMS), 194.1 (C=O). 
 
General procedure for the synthesis of salicylates 19a-n: To a CH2Cl2 solution of silyl enol 








equiv.) at –78 oC under argon atmosphere. The solution was stirred at –78 oC for 30 min and 
then allowed to warm to 20 °C during 18 h. To the solution was added a saturated aqueous 
solution of 10 % HCl. The organic layer was separated and the aqueous layer was repeatedly 
extracted with CH2Cl2. The combined organic extracts were dried (Na2SO4) and filtered. The 
filtrate was concentrated in vacuo and the residue was purified by chromatography (silica gel, 
n-hexane/EtOAc) to give salicylates 19. 
 
3-hydroxy-5-methyl-2'-nitro[1,1'-biphenyl]-2-carboxylate (19a):  
Starting with bis silyl-enol ether 4a (1.145 g, 4.4 mmol), TiCl4 
(0.835 g, 4.4 mmol) CH2Cl2 (6 mL) and monosilyl enol ether 18a 
(1.117 g, 4.0 mmol), 19a was isolated (0.420 g, 36 %) as a 
yellowish oil. 1H NMR (CDCl3, 250 MHz): δ = 2.21 (s, 3 H, CH3), 
3.33 (s, 3 H, OCH3),  6.35 (d, 4J = 1.9 Hz, 1 H, CHAr), 6.74 (d, 4J = 
1.4 Hz, 1 H, CHAr), 7.10 − 7.13 (m, 1 H, CHAr), 7.36 (ddd, 3J = 7.4 Hz, 3J = 7.2 Hz, 4J = 1.4 
Hz, 1 H, CHAr), 7.47 (ddd, 3J = 7.5 Hz, 3J = 7.4 Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.92 (dd, 3J = 8.0 
Hz, 4J = 1.5 Hz, 1 H, Ar), 11.10 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 21.6 (CH3), 
51.9 (OCH3), 108.4 (CAr), 118.0, 122.5, 123.6, 127.8, 131.1. 132.4 (CHAr), 138.2, 140.2, 
145.6, 147.8, 162.4 (CAr), 170.4 (C=O). GC-MS (EI 70 eV): m/z (%) = 287 ([M]+, 26), 255 
(100), 227 (27), 197 (5), 181 (11), 152 (30), 115 (5), 76 (7). HRMS (EI): Calcd. for 
C15H13NO5: 287.07882; found: 287.07873.  
 
Methyl 3-hydroxy-4,5-dimethyl-2'-nitrobiphenyl-2-carboxylate(19b): 
Starting with bis silyl-enol ether 4b (1.207 g, 4.4 mmol), TiCl4 
(0.834 g, 4.4 mmol) CH2Cl2 (8 mL) and monosilyl enol ether 18a 
(1.117 g, 4.0 mmol), 19b was isolated (0.500 g, 41%) as a yellow 
oil. 1H NMR (CDCl3, 250 MHz): δ = 2.10 (s, 3 H, CH3), 2.16 (s, 3 
H, CH3), 3.32 (s, 3 H, OCH3), 6.35 (s, 1 H, CHAr), 7.11 (dd, 3J = 
7.5 Hz,  4J = 1.6 Hz, 1 H, CHAr), 7.33 (ddd, 3J = 7.7 Hz, 3J = 7.6 
Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.46 (ddd, 3J = 7.6 Hz, 3J = 7.5 Hz, 4J = 1.3 Hz, 1 H, CHAr), 7.88 
(dd, 3J = 8.3 Hz, 4J = 1.4 Hz, 1 H, CHAr), 11.47 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC 
= 11.5, 20.5 (CH3), 51.9 (OCH3), 108.0 (CAr), 122.6, 123.5, (CHAr), 125.0 (CAr), 127.6, 131.2, 
132.3 (CHAr), 136.9, 138.5, 143.6, 148.0, 160.5 (CAr), 171.4 (C=O). GC-MS (EI 70 eV): m/z 

















Starting with bis silyl-enol ether 4c (0.998 g, 3.3 mmol), TiCl4 
(0.625 g, 3.3 mmol) CH2Cl2 (6 mL) and monosilyl enol ether 18a 
(0.789 g, 3.0 mmol), 19c was isolated (0.350 g, 35 %) as a yellow 
solid. 1H NMR (CDCl3, 250 MHz): δ = 0.59 (t, 3J = 7.4 Hz, 3 H, 
CH3), 1.04 (t, 3J = 7.5 Hz, 3 H, CH3), 2.19 (s, 3 H, CH3), 2.61 (m, 
2 H, CH2), 3.82 (q, 3J = 7.5 Hz, 2 H, OCH2), 6.32 (s, 1 H, CHAr), 7.12 (dd, 3J = 7.5 Hz,  4J = 
1.5 Hz, 1 H, CHAr), 7.34 (ddd, 3J = 8.0 Hz, 3J = 7.5 Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.45 (ddd, 3J 
= 7.5 Hz, 3J = 7.5 Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.88 (dd, 3J = 7.6 Hz, 4J = 1.6 Hz, 1 H, CHAr), 
11.58 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 4.8, 14.8, 21.3 (CH3), 21.5 (CH2), 62.8 
(OCH2), 110.0 (CAr), 124.6, 125.5, 129.4 (CHAr), 132.8 (CAr), 133.1, 134.1 (CHAr), 138.8, 
140.8, 144.5, 149.9, 162.5 (CAr), 172.5 (C=O). GC-MS (EI 70 eV): m/z (%) = 329 ([M]+, 
100), 283 (80), 255 (24), 238 (32), 222 (78), 207 (40), 194 (99), 165 (64), 152 (29), 139 (13), 
115 (18), 77 (13). HRMS (EI): Calcd. for C18H19NO5: 329.12577; found: 329.12546.  
 
Methyl 3-hydroxy-5-methyl-2'-nitro-4-octylbiphenyl-2-carboxylate(19d): 
Starting with bis silyl-enol ether 4f (1.100 g, 3.3 mmol), TiCl4 
(0.625 g, 3.3 mmol) CH2Cl2 (6 mL) and monosilyl enol ether 18a 
(0.789 g, 3.0 mmol), 19d was isolated (0.476 g, 40 %) as a 
yellow viscous oil. 1H NMR (CDCl3, 250 MHz): δ = 0.73 ─ 0.79 
(m, 3 H, CH3), 1.13 ─ 1.30 (m, 12 H, CH2), 2.18 (s, 3 H, CH3), 
2.52 ─ 2.60 (m, 2 H, CH2), 3.31 (s, 3 H, OCH3), 6.32 (s, 1 H, 
CHAr), 7.11 (dd, 3J = 7.5 Hz,  4J = 1.2 Hz, 1 H, CHAr), 7.33 (ddd, 3J = 8.0 Hz, 3J = 7.7 Hz, 4J = 
1.3 Hz, 1 H, CHAr), 7.45 (ddd, 3J = 7.4 Hz, 3J = 7.1 Hz, 4J = 1.6 Hz, 1 H, CHAr), 7.88 (dd, 3J = 
7.5 Hz, 4J = 1.5 Hz, 1 H, CHAr), 11.43 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 16.0, 
21.8 (CH3), 24.6, 28.3, 30.6, 31.2, 31.4, 32.0, 33.8 (CH2), 53.8 (OCH3), 110.0 (CAr), 124.8, 
125.4, 129.5 (CHAr), 131.8 (CAr), 133.2, 134.1 (CHAr), 138.9, 140.5, 150.0, 162.5 (CAr), 172.9 
(C=O). GC-MS (EI 70 eV): m/z (%) = 399 ([M]+, 100), 353 (49), 340 (13), 306 (17), 268 
(69), 225 (84), 208 (80), 194 (58), 180 (27), 165 (65), 152 (21), 115 (10), 77 (5), 43 (18). 















Methyl 3-hydroxy-2'-nitro-5-propylbiphenyl-2-carboxylate (19e): 
Starting with bis silyl-enol ether 4a (1.145 g, 4.4 mmol), TiCl4 
(0.835 g, 4.4 mmol) CH2Cl2 (8 mL) and monosilyl enol ether 18b 
(1.229 g, 4.0 mmol), 19e was isolated (0.607 g, 48 %) as a yellow 
gummy solid. 1H NMR (CDCl3, 250 MHz): δ = 0.80 (t, 3J = 7.5 
Hz, 3 H, CH3), 1.47 ─ 1.56 (m, 2 H, CH2), 2.44 (t, 3J = 7.0 Hz, 2 H, 
CH2), 3.27 (s, 3 H, OCH3), 6.36 (d, 4J = 1.8 Hz, 1 H, CHAr), 6.74 (d, 4J = 1.8 Hz, 1 H, CHAr), 
7.12 (dd, 3J = 7.5 Hz,  4J = 1.8 Hz, 1 H, CHAr), 7.36 (ddd, 3J = 7.3 Hz, 3J = 7.0 Hz, 4J = 1.4 
Hz, 1 H, CHAr), 7.47 (ddd, 3J = 7.6 Hz, 3J = 7.3 Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.91 (dd, 3J = 7.2 
Hz, 4J = 1.2 Hz, 1 H, CHAr), 11.10 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 13.8 
(CH3), 23.4, 37.7 (CH2), 51.8 (OCH3), 108.6 (CAr), 117.3, 122.0, 123.7, 127.8, 131.1, 132.5 
(CHAr), 138.4, 140.3, 147.8, 150.2, 162.4 (CAr), 170.3 (C=O). GC-MS (EI 70 eV): m/z (%) = 
315 ([M]+, 47), 269 (100), 255 (17), 240 (11), 227 (14), 197 (10), 181 (18), 165 (16), 152 
(31), 115 (19), 77 (8). HRMS (EI): Calcd. for C17H17NO5: 315.11062; found: 315.11032.  
 
Methyl 3-hydroxy-4-methyl-2'-nitro-5-propylbiphenyl-2-carboxylate (19f): 
Starting with bis silyl-enol ether 4b (1.207 g, 4.4 mmol), TiCl4 
(0.835 g, 4.4 mmol) CH2Cl2 (8 mL) and monosilyl enol ether 4a 
(1.229 g, 4.0 mmol), 19f was isolated (0.500 g, 38 %) as a 
yellowish oil. 1H NMR (CDCl3, 250 MHz): δ = 0.82 (t, 3J = 7.6 Hz, 
3 H, CH3), 1.41 ─ 1.50 (m, 2 H, CH2), 2.12(s, 3 H, CH3), 2.47 (t, 3J 
= 7.5 Hz, 2 H, CH2), 3.32 (s, 3 H, OCH3), 6.34 (s, 1 H, CHAr), 7.11 
(dd, 3J = 8.7 Hz,  4J = 1.5 Hz, 1 H, CHAr), 7.34 (ddd, 3J = 8.0 Hz, 3J = 7.9 Hz, 4J = 1.4 Hz, 1 
H, CHAr), 7.45 (ddd, 3J = 7.5 Hz, 3J = 7.5 Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.88 (dd, 3J = 7.5 Hz, 
4J = 1.6 Hz, 1 H, CHAr), 11.49 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 10.3, 12.9 
(CH3), 22.1, 35.0 (CH2), 50.8 (OCH3), 107.0 (CAr), 121.0, 122.6 (CHAr), 127.7 (CHAr), 126.5, 
130.3, 131.2 (CHAr), 135.8, 137.6, 146.8, 147.0, 159.8 (CHAr), 170.1 (C=O). GC-MS (EI 70 
eV): m/z (%) = 329 ([M]+, 55), 297 (100), 283 (20), 238 (18), 224 (30), 208 (14), 194 (12), 


















Ethyl 4-ethyl-3-hydroxy-2'-nitro-5-propylbiphenyl-2-carboxylate (19g): 
Starting with bis silyl-enol ether 4b (1.207 g, 4.4 mmol), TiCl4 
(0.835 g, 4.4 mmol) CH2Cl2 (8 mL) and monosilyl enol ether 4a 
(1.229 g, 4.0 mmol), 19f was isolated (0.500 g, 38 %) as a 
yellowish oil. 1H NMR (CDCl3, 250 MHz): δ = 0.82 (t, 3J = 7.6 
Hz, 3 H, CH3), 1.41 ─ 1.50 (m, 2 H, CH2), 2.12(s, 3 H, CH3), 2.47 
(t, 3J = 7.5 Hz, 2 H, CH2), 3.32 (s, 3 H, OCH3), 6.34 (s, 1 H, CHAr), 7.11 (dd, 3J = 8.7 Hz,  4J 
= 1.5 Hz, 1 H, CHAr), 7.34 (ddd, 3J = 8.0 Hz, 3J = 7.9 Hz, 4J = 1.4 Hz, 1 H, CHAr), 7.45 (ddd, 
3J = 7.5 Hz, 3J = 7.5 Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.88 (dd, 3J = 7.5 Hz, 4J = 1.6 Hz, 1 H, 
CHAr), 11.49 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 10.3, 12.9 (CH3), 22.1, 35.0 
(CH2), 50.8 (OCH3), 107.0 (CAr), 121.0, 122.6 (CHAr), 127.7 (CHAr), 126.5, 130.3, 131.2 
(CHAr), 135.8, 137.6, 146.8, 147.0, 159.8 (CHAr), 170.1 (C=O). GC-MS (EI 70 eV): m/z (%) 
= 329 ([M]+, 55), 297 (100), 283 (20), 238 (18), 224 (30), 208 (14), 194 (12), 165 (25), 139 
(7), 115 (9), 77 (5). HRMS (EI): Calcd. for C18H19NO5: 329.12577; found: 329.12597.  
 
Methyl 4-hexyl-3-hydroxy-2'-nitro-5-propylbiphenyl-2-carboxylate(19h): 
Starting with bis silyl-enol ether 4c (0.9986 g, 3.2 mmol), TiCl4 
(0.625 g, 3.2 mmol) CH2Cl2 (6 mL) and monosilyl enol ether 18b 
(0.876 g, 3.0 mmol), 19h was isolated (0.315 g, 26 %) as a 
yellow oil. 1H NMR (CDCl3, 250 MHz): δ = 0.59 (t, 3J = 7.3 Hz, 
3 H, CH3), 0.83 (t, 3J = 6.5 Hz, 3 H, CH3), 1.07 (t, 3J = 7.4 Hz, 3 
H, CH3), 1.39 ─ 1.48 (m, 2 H, CH2), 2.43 ─ 2.50 (m, 2 H, CH2), 
2.57 ─ 2.66 (m, 2 H, Ch2), 3.82 (q, 3J = 6.5 Hz, 2 H, OCH2), 6.32 (s, 1 H, CHAr), 7.12 (dd, 3J 
= 7.5 Hz,  4J = 1.5 Hz, 1 H, CHAr), 7.34 (ddd, 3J = 8.0 Hz, 3J = 7.5 Hz, 4J = 1.5 Hz, 1 H, 
CHAr), 7.44 (ddd, 3J = 7.5 Hz, 3J = 7.4 Hz, 4J = 1.5 Hz, 1 H, CHAr), 7.88 (dd, 3J = 7.6 Hz, 4J = 
1.3 Hz, 1 H, CHAr), 11.58 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 8.9, 14.4, 15.2 
(CH3), 20.3, 25.1, 36.3 (CH2), 62.0 (OCH2), 109.4 (CAr), 123.1, 124.7, 128.6 (CHAr), 131.7 
(CAr), 132.4, 133.2 (CHAr), 137.9, 140.1, 148.1, 149.1, 162.0 (CAr), 171.8 (C=O). GC-MS (EI 
70 eV): m/z (%) = 357 ([M]+, 100), 311 (54), 283 (21), 266 (38), 250 (43), 235 (20), 220 (58), 
194 (20), 180 (39), 165 (39), 152 (27), 115 (15), 77 (11). HRMS (EI): Calcd. for C20H23NO5: 

















Methyl 3-hydroxy-4,5-dimethyl-3'-nitrobiphenyl-2-carboxylate (19j): 
Starting with bis silyl-enol ether 4b (0.598 g, 2.2 mmol), TiCl4 
(0.413 g, 2.2 mmol) CH2Cl2 (4 mL) and monosilyl enol ether 18c 
(0.548 g, 2.0 mmol), 19j was isolated (0.305 g, 50 %) as a 
yellowish oil. 1H NMR (CDCl3, 250 MHz): δ = 2.09 (s, 3 H, CH3), 
2.21 (s, 3 H, CH3), 3.36 (s, 3 H, OCH3), 6.46 (s, 1 H, CHAr), 7.30 ─ 
7.40 (m, 2 H, CHAr), 7.97 (m, 1 H, CHAr), 8.03 ─ 8.07 (m, 1 
H,CHAr), 11.19 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 12.0, 21.3 (CH3), 52.1 
(OCH3), 108.7 (CAr), 121.9, 123.5, 124.3 (CHAr), 125.7 (CAr), 128.6, 134.9 (CHAr), 139.0, 
144.0, 145.4, 148.1, 160.7, (CAr), 171.6 (C=O). GC-MS (EI 70 eV): m/z (%) = 301 ([M]+, 46), 
269 (100), 252 (66), 222 (40), 195 (17), 165 (33), 152 (28), 139 (7), 82 (5). HRMS (EI): 
Calcd. for C16H15NO5: 301.09444; found: 301.09431.  
 
Ethyl 4-ethyl-3-hydroxy-5-methyl-3'-nitrobiphenyl-2-carboxylate (19k): 
Starting with bis silyl-enol ether 4c (0.659 g, 2.2 mmol), TiCl4 
(0.41 g, 2.2 mmol) CH2Cl2 (4 mL) and monosilyl enol ether 18c 
(0.548 g, 2.0 mmol), 19k was isolated (0.250 g, 37 %) as a yellow 
gummy solid. 1H NMR (CDCl3, 300 MHz): δ = 0.63 (t, 3J = 7.7 
Hz, 3 H, CH3), 1.04 (t, 3J = 7.7 Hz, 3 H, CH3), 2.23 (s, 3 H, CH3), 
2.62 (q, 3J = 7.0 Hz, 2 H, CH2), 3.87 (q, 3J = 6.0 Hz, 2 H, OCH2), 
6.46 (s, 1 H, CHAr), 7.37 ─ 7.45 (m, 2 H, CHAr), 7.99 (m, 1 H, CHAr), 8.03 ─ 8.07 (m, 1 H, 
CHAr), 11.32 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 11.9, 12.0, 18.4 (CH3), 18.6 
(CH2), 60.0 (OCH2), 107.6 (CAr), 120.3, 122.2, 123.1, 127.2, 130.3 (CHAr), 133.5, 137.8, 
141.6, 144.1, 146.6, 159.3 (CAr), 169.7 (C=O). GC-MS (EI 70 eV): m/z (%) = 329 ([M]+, 58), 
283 (92), 266 (100), 236 (23), 209 (30), 194 (8), 178 (11), 165 (41), 152 (16), 139 (7), 115 
(6). HRMS (EI): Calcd. for C18H19NO5: 329.12577; found: 329.12659.  
 
Methyl 3-hydroxy-5-methyl-4'-nitrobiphenyl-2-carboxylate (19l): 
Starting with bis silyl-enol ether 4a (0.568 g, 2.2 mmol), TiCl4 
(0.413 g, 2.2 mmol) CH2Cl2 (4 mL) and monosilyl enol ether 
18d (0.558 g, 4.0 mmol), 19l was isolated (0.210 g, 36 %) as a 
colourless solid. 1H NMR (CDCl3, 250 MHz): δ = 2.23 (s, 3 
H, CH3), 3.36 (s, 3 H, OCH3), 6.44 (d, 4J=1.6 Hz, 1 H, CHAr), 



















CHAr), 10.81 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 21.6 (CH3), 51.7 (OCH3), 108.6 
(CAr), 118.2 (CHAr), 122.8 (2CHAr), 123.5 (CHAr), 129.0 (2CHAr), 142.1, 145.4, 146.9, 149.9, 
162.2 (CAr), 170.0 (C=O). GC-MS (EI 70 eV): m/z (%) = 287 ([M]+, 27), 255 (100), 197 (9), 
181 (30), 152 (20), 115 (5), 76 (7). HRMS (EI): Calcd. for C15H13NO5: 287.07882; found: 
287.07879.  
 
Methyl 3-hydroxy-4,5-dimethyl-4'-nitrobiphenyl-2-carboxylate (19m): 
Starting with bis silyl-enol ether 4b (0.598 g, 2.2 mmol), 
TiCl4 (0.413 g, 2.2 mmol) CH2Cl2 (4 mL) and monosilyl 
enol ether 18d (0.558 g, 2.0 mmol), 19m was isolated 
(0.420 g, 33 %) as a colourless solid. 1H NMR (CDCl3, 250 
MHz): δ = 2.16 (s, 3 H, CH3), 2.25 (s, 3 H, CH3) 3.40 (s, 3 
H, OCH3), 6.49 (s, 1 H, CHAr), 7.29 (d, 3J=8.8 Hz, 2 H, CHAr), 8.14 (d, 3J=8.8 Hz, 2 H, 
CHAr), 11.18 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 11.5, 20.4 (CH3), 51.7 (OCH3), 
108.2 (CAr), 122.7 (2CHAr), 123.6 (CHAr), 125.4 (CHAr), 129.0 (2CHAr), 138.9, 143.5, 146.6, 
150.2, 160.2 (CAr), 171.1 (C=O). GC-MS (EI 70 eV): m/z (%) = 301 ([M]+, 40), 269 (100), 
254 (19), 223 (42), 195 (17), 180 (6), 165 (32), 152 (29), 139 (7), 115 (7), 76 (5). HRMS (EI): 
Calcd. for C16H15NO5: 301.09447; found: 301.09477.  
 
Ethyl 4-ethyl-3-hydroxy-5-methyl-4'-nitrobiphenyl-2-carboxylate (19n): 
Starting with bis silyl-enol ether 4c (0.659 g, 2.2 mmol), 
TiCl4 (0.413 g, 2.2 mmol) CH2Cl2 (4 mL) and monosilyl 
enol ether 18d (0.558 g, 2.0 mmol), 19n was isolated 
(0.420 g, 33 %) as a colourless solid. 1H NMR (CDCl3, 250 
MHz): δ =  0.65 (t, 3J=7.4 Hz, 3 H, CH3), 1.09 (t, 3J=7.5 
Hz, 3 H, CH3), 2.27 (s, 3 H, CH3), 2.67 (q, 3J=7.5 Hz, 2 H, CH2), 3.92 (q, 3J=7.4 Hz, 2 H, 
OCH2), 6.46 (s, 1 H, CHAr), 7.30 (d, 3J=8.8 Hz, 2 H, CHAr), 8.14 (d, 3J=8.8 Hz, 2 H, CHAr), 
11.27 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 12.9, 13.1, 19.4 (CH3), 19.6 (CH2), 61.1 
(OCH2), 108.5 (CAr), 122.7 (2CHAr), 123.7 (CHAr), 129.1 (2CHAr), 131.3, 139.1, 142.5, 146.5, 
150.5, 160.2 (CAr), 170.7 (C=O). GC-MS (EI 70 eV): m/z (%) = 329 ([M]+, 58), 283 (100), 
266 (50), 240 (46), 222 (9), 209 (13), 178 (10), 165 (56), 152 (19), 139 (8), 115 (7), 77 (4). 















General procedure for the synthesis of 6(5H)-phenanthridinones 19a-h: To a stirred 
methanol suspension (25 mL) of Pd/C (10 mol-%) was added 19a-h (1.0 equiv.). The mixture 
was set under a hydrogen atmosphere. After stirring for 48 h at 20 °C, the reaction mixture 
was filtered (celite) and the filtrate was concentrated in vacuo. The residue was purified by 
chromatography (silica gel, heptanes heptanes/EtOAc = 2:1). 
 
7-Hydroxy-9-methyl-6(5H)-phenanthridinone (20a). 
Starting with 19a (0.429 g, 1.65 mmol), 20a was isolated (0.200 g, 
61%) by column chromatography (silica gel, heptanes/EtOAc = 30:1 
→ 20:1) as a colorless solid.. 1H NMR (DMSO, 250 MHz): δ = 2.45 
(s, 3 H, CH3),  6.82 (s, 1 H, CHAr), 7.27 − 7.30 (m, 1 H, CHAr), 7.33 − 
7.41 (m, 1 H, CHAr), 7.49 − 7.55 (m, 1 H, CHAr), 7.76 (m, 1 H, 
CHAr), 8.34 (d, 3J = 7.9 Hz, 1 H, CHAr), 12.02 (s(br), 1 H, NH), 13.25 (s, 1 H, OH). 13C NMR 
(DMSO, 62 MHz): δC = 21.8 (CH3), 107.9 (CAr), 113.1 115.0, 116.6 (CHAr), 118.0 (CAr), 
123.2, 123.6, 128.4 (CHAr), 129.8, 135.6, 146.0, 159.4 (CAr), 165.7 (C=O). MS (EI 70 eV): 
m/z (%) = 225 ([M]+, 100), 206 (10), 196 (16), 99 (14), 73 (16), 57 (27), 43 (52). HRMS (EI): 
Calcd. for C14H11NO2: 225.07853; found: 225.07843.  
 
7-Hydroxy-8,9-dimethylphenanthridin-6(5H)-one(20b): 
Starting with 19b (0.504 g, 1.67 mmol), 20a was isolated (0.200 g, 
52%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid. 1H NMR (DMSO, 250 MHz): δ = 
2.08 (s, 3 H, CH3), 2.21 (s, 3 H, CH3), 7.27 − 7.52 (m, 3 H, CHAr), 
7.74 (s, 1 H, CHAr), 8.34 (d, 3J = 7.5 Hz, 1 H, CHAr), 11.97 (s(br), 1 
H, NH), 13.60 (s, 1 H, OH). 13C NMR (DMSO, 62 MHz): δC = 
10.6, 13.9 (CH3), 107.3 (CAr), 112.4, 116.4, 121.3, (CHAr), 123.0 (CAr), 123.2, 123.6, 129.2 
(CHAr), 135.1, 148.3, 159.2, (CAr), 165.6 (C=O). MS (EI 70 eV): m/z (%) = 239 ([M]+, 89), 
224 (34), 191 (10), 97 (26), 84 (100), 66 (98), 57 (95). Anal.: Calcd for C15H13NO2: C 75.30, 



















Starting with 19c (0.137 g, 0.41 mmol), 20c was isolated (0.070 g, 
70%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid. 1H NMR (DMSO, 250 MHz): δ 
= 1.10 (t, 3J = 8.0 Hz, 3 H, CH3), 2.47 (s, 3 H, CH3), 2.68 (q, 3J = 
7.5 Hz, 2 H, CH2), 7.26 ─ 7.32 (m, 1 H, CHAr), 7.36 − 7.39 (m, 1 
H, CHAr), 7.46 − 7.52 (m, 1 H, CHAr), 7.75 (s, 1 H, CHAr), 8.31 (d, 
3J = 8.4 Hz, 1 H, CHAr), 11.99 (s(br), 1 H, NH), 13.59 (s, 1 H, OH). 13C NMR (DMSO, 62 
MHz): δC = 13.0, 18.5 (CH3), 19.8 (CH2), 107.6 (CAr), 113.5, 116.5 (CHAr), 118.3 (CAr), 
123.0, 123.3, (CHAr), 127.8 (CHAr), 129.3 (CHAr), 132.2, 135.2, 143.6, 158.9 (CAr), 165.8 
(C=O). MS (EI 70 eV): m/z (%) = 253 ([M]+, 39), 238 (100), 220 (2), 190 (5), 165 (6), 104 
(4), 95 (3), 63 (3). HRMS (EI): Calcd. for C16H15NO2: 253.10973; found: 253.10991.  
 
7-Hydroxy-9-methyl-8-octylphenanthridin-6(5H)-one (20d): 
Starting with 19c (0.275 g, 0.68 mmol), 20c was isolated (0.200 g, 
69%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid. 1H NMR (DMSO/CDCl3, 250 
MHz): δ = 0.77 ─ 0.85 (m, 3 H, CH3), 1.85 ─ 1.24 (m, 8 H, CH2), 
1.41 ─ 1.49 (m, 4 H, CH2), 2.41 (s, 3 H, Ch3), 2.60 ─ 2.66 (m, 2 H, 
CH2), 7.16 ─ 7.32 (m, 3 H, CHAr), 7.53 (s, 1 H, CHAr), 8.12 (d, 3J = 
7.8 Hz, 1 H, CHAr), 11.70 (s(br), 1 H, NH), 13.44 (s, 1 H, OH). 13C NMR (DMSO/CDCl3, 62 
MHz): δC = 13.8, 20.1 (CH3), 22.1, 25.3, 28.4, 28.6, 29.0, 29.3, 31.5 (CH2), 107.6 (CAr), 
112.8, 112.9, 116.3 (CHAr), 118.2 (CAr), 122.6 (CHAr), 126.6, 126.7 (CAr), 128.6 (CHAr), 
132.0, 143.2, 159.2 (CAr), 165.6 (C=O). MS (EI 70 eV): m/z (%) = 337 ([M]+, 28), 308 (4), 
276 (3), 252 (7), 238 (100), 224 (5), 192 (3), 160 (4) 128 (25), 97 (14), 69 (15). HRMS (EI): 
Calcd. for C22H27NO2: 337.20363; found: 337.20310.  
 
7-Hydroxy-9-propylphenanthridin-6(5H)-one (20e): 
Starting with 19e (0.563 g, 1.787 mmol), 20e was isolated (0.240 g, 
56%) by column chromatography (silica gel, heptanes/EtOAc = 30:1 
→ 20:1) as a colorless solid. 1H NMR (DMSO, 250 MHz): δ = 0.92 
(t, 3J = 7.1 Hz, 3 H, CH3), 1.63 ─ 1.72 (m, 2 H, CH2), 2.68 (t, 3J = 
7.1 Hz, 2 H, CH2), 6.81 (s(br), 1 H, CHAr), 7.25 − 7.29 (m, 1 H, 



















(s(br), 1 H, CHAr), 8.35 (d, 3J = 7.7 Hz, 1 H, CHAr), 12.01 (s(br), 1 H, NH), 13.25 (s, 1 H, OH). 
13C NMR (DMSO, 62 MHz): δC = 13.6 (CH3), 23.6, 38.6 (CH2), 107.9 (CAr), 112.3, 114.3, 
116.5 (CHAr), 118.2 (CAr), 123.1, 123.7, 129.7 (CHAr), 135.2, 135.5, 150.2, 161.4 (CAr), 165.7 
(C=O). MS (EI 70 eV): m/z (%) = 253 ([M]+, 40), 225 (100), 196 (20), 177 (30), 149 (60), 
115 (15), 89 (12), 69 (20), 44 (70), 43 (9). HRMS (EI): Calcd. for C16H15NO2: 253.10973; 
found: 253.10991  
 
7-Hydroxy-8-methyl-9-propylphenanthridin-6(5H)-one (20f): 
Starting with 19f (0.480g, 1.45 mmol), 20f was isolated (0.190 g, 
50%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid.  1H NMR (DMSO, 250 MHz): δ 
= 0.90 (t, 3J = 7.4 Hz, 3 H, CH3), 1.50 ─ 1.59 (m, 2 H, CH2), 2.12 
(s, 3 H, CH3), 2.65 (t, 3J = 7.5 Hz, 2 H, CH2), 7.18 ─ 7.24 (m, 1 H, 
CHAr), 7.28 − 7.32 (m, 1 H, CHAr), 7.32 − 7.43 (m, 1 H, CHAr), 
7.64 (s, 1 H, CHAr), 8.25 (d, 3J = 8.2 Hz, 1 H, CHAr), 11.89 (s(br), 1 H, NH), 13.55 (s, 1 H, 
OH). 13C NMR (DMSO, 62 MHz): δC = 10.5, 13.8 (CH3), 23.0, 35.9 (CH2), 107.4 (CAr), 
112.3, 116.6 (CHAr), 118.5, 121.5 (CAr), 123.0, 123.3, 129.3 (CHAr), 131.9, 135.2, 148.6, 
159.4 (CAr), 165.7 (C=O). MS (EI 70 eV): m/z (%) = 267 ([M]+, 100), 252 (76), 239 (75), 224 
(34), 210 (5), 190 (7), 165 (7), 78 (34), 63 (43), 43 (9). HRMS (EI): Calcd. for C17H17NO2: 
267.12535; found: 267.12538.  
 
8-Ethyl-7-hydroxy-9-propylphenanthridin-6(5H)-one (20g): 
Starting with 19g (0.202 g, 0.57 mmol), 7a was isolated (0.100 g, 
63%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid..1H NMR (DMSO, 250 MHz): δ 
= 1.00 (t, 3J = 8.1 Hz, 3 H, CH3), 1.13 (t, 3J = 7.2 Hz, 3 H, CH3), 
1.66 (q, 3J = 7.3 Hz, 2 H, CH2), 2.66 ─ 2.77 (m, 4 H, CH2), 7.26 ─ 
7.36 (m, 2 H, CHAr), 7.49 − 7.58 (m, 2 H, CHAr), 8.34 (d, 3J = 8.0 
Hz, 1 H, CHAr), 11.90 (s(br), 1 H, NH), 13.62 (s, 1 H, OH). 13C NMR (DMSO, 62 MHz): δC = 
13.9, 14.0 (CH3), 18.3, 24.0, 35.0 (CH2), 107.5 (CAr), 112.6, 116.6 (CHAr), 118.4 (CAr), 123.0, 
128.8, 131.3 (CHAr), 132.3, 135.2, 147.8, 159.2 (CAr), 165.7 (C=O). MS (EI 70 eV): m/z (%) 
= 281 ([M]+, 100), 238 (76), 207 (12), 224 (30), 190 (7), 165 (5), 78 (40), 63 (23), 43 (8). 
HRMS (EI): Calcd. for C17H17NO2: 267.12535; found: 267.12538. Anal.: Calcd for 















Starting with 19h (0.250g, 0.62 mmol), 20h was isolated (0.150 g, 
74%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid. 1H NMR (CDCl3, 250 MHz): δ 
= 0.83 (t, 3J = 7.8 Hz, 3 H, CH3), 0.99 (t, 3J = 7.5 Hz, 3 H, CH3), 
1.26 ─ 1.48 (m, 8 H, CH2), 1.60 ─ 1.69 (m, 2 H, CH2), 2.66 ─ 
2.72 (m, 4 H, CH2), 7.11 ─ 7.15 (m, 1 H, CHAr), 7.21 − 7.25 (m, 1 H, CHAr), 7.37 − 7.40 (m, 
1 H, CHAr), 7.48 (s, 1 H, CHAr), 8.10 (d, 3J = 8.5 Hz, 1 H, CHAr), 9.49 (s(br), 1 H, NH), 13.92 
(s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 14.1, 14.2 (CH3), 22.6, 24.4, 25.8, 29.5, 29.8, 
31.7, 36.0 (CH2), 107.5 (CAr), 112.0, 112.6, 116.2 (CHAr), 119.4 (CAr), 123.2 (CHAr), 123.5 
(CAr), 127.9 (CHAr), 129.1, 131.4, 133.5, 148.7 (CAr), 160.0 (C=O). MS (EI 70 eV): m/z (%) = 
337 ([M]+, 42), 280 (9), 266 (100), 225 (19), 161 (9), 128 (40), 83 (24), 69 (43) 43 (9). HRMS 
(EI): Calcd. for C22H27NO2: 337.20363; found: 337.20310.  
 
Methyl 2'-amino-3-hydroxy-4,5-dimethylbiphenyl-2-carboxylate (21a): 
Starting with 19j (0.150g, 0.45 mmol), 21a was isolated (0.110 g, 
81%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid. 1H NMR (CDCl3, 250 MHz): δ = 
2.13 (s, 3 H, CH3), 2.21 (s, 3 H, CH3), 3.41 (m(br), 2 H, NH2), 3.44 
(s, 3 H, OCH3), 6.40 (s, 1 H, CHAr), 6.49 − 6.57 (m, 3 H, CHAr), 
7.00 − 7.06 (m, 1 H, CHAr), 10.86 (s, 1 H, OH). 13C NMR (CDCl3, 
62 MHz): δC = 11.4, 20.4 (CH3), 51.6 (OCH3), 109.1 (CAr), 113.3, 114.9, 119.0 (CHAr), 123.6 
(CAr), 123.8, 128.3, (CHAr), 141.6, 142.8, 144.2, 145.7, 159.2 (CAr), 172.0 (C=O). GC-MS (EI 
70 eV): m/z (%) = 271 ([M]+, 72), 239 (100), 224 (87), 210 (13), 196 (21), 180 (6), 167 (13), 
135 (5), 115 (5), 98 (6), 65 (4). HRMS (EI): Calcd. for C16H17NO3: 271.12029; found: 
271.12050.  
 
Ethyl 2'-amino-4-ethyl-3-hydroxy-5-methylbiphenyl-2-carboxylate (21b): 
Starting with 19k (0.250g, 0.82 mmol), 21b was isolated (0.184 g, 
78%) by column chromatography (silica gel, heptanes/EtOAc = 
30:1 → 20:1) as a colorless solid. 1H NMR (CDCl3, 300 MHz): δ 
= 0.74 (t, 3J=7.4 Hz, 3 H, CH3), 1.07 (t, 3J=7.5 Hz, 3 H, CH3), 
2.21 (s, 3 H, CH3), 2.63 (q, 3J=7.4 Hz, 2 H, CH2), 3.42 ─ 3.60 ( 


















1 H, CHAr), 6.49 − 6.54 (m, 3 H, CHAr), 6.96 − 7.03 (m, 1 H, CHAr), 10.95 (s, 1 H, OH). 13C 
NMR (CDCl3, 75 MHz): δC = 13.1, 13.2, 19.4 (CH3), 19.6 (CH2), 60.7 (OCH2), 109.0 (CAr), 
113.2, 115.1, 119.0, 123.9, 128.3 (CHAr), 129.6, 141.8, 141.9, 144.4, 145.7, 159.3 (CAr), 171.5 
(C=O). GC-MS (EI 70 eV): m/z (%) = 299 ([M]+, 96), 253 (64), 238 (100), 220 (34), 210 





To a stirred solution of LDA (75 mmol) in THF (62 mL) was added 
acetone (2.904 g, 50.0 mmol) at -78 °C. After the solution was 
stirred for 1 h, 4-florobenzoyl chloride (9.51 g, 60.0 mmol) was 
added. The temperature of the solution was allowed to rise to 20 °C  
during 12 h. A saturated solution of NH4Cl was added, the layers were separated, and the 
aqueous layer was extracted with ethylacetate (3 x 150 mL). The combined organic layers 
were dried (Na2SO4) and filtered, and the solvent was removed in vacuo. The residue was 
purified by chromatography (silica gel, n-hexane/EtOAc 30:1 → 20:1) to give 23b as a 
colorless solid (3.9 g, 36%) mp = 48-49 °C. 1H NMR (300 MHz, CDCl3): δ = 2.11 (s, 3 H, 
CH3), 6.04 (s, 1 H, CH), 7.04 (m, 2 H, CH), 7.81 (m, 2 H, CH), 16.07 (s(br), 1 H, OH). 13C 
NMR (75 MHz, CDCl3): δ = 24.4 (CH3), 95.3 (CH), 114 (d, 3J = 21.8 Hz, 2CH), 128.4 (d, 2J 
= 8.9 Hz, 2CH), 130.3 (d, 4J = 2.9 Hz, C), 164.3 (d, 1J = 252.0 Hz, CF), 181.9 (C), 191.8 
(C=O). ( IR (KBr, cm-1): ν~  = 1603 (s), 1507 (s), 1297(m), 1246 (s), 1159 (m), 1095 (m), 
1014 (w), 849 (s), 786 (s), 506 (w). MS (EI, 70 eV): m/z (%) = 180 ([M]+, 64), 165 (66), 138 
(6), 123 (100), 109 (6), 95 (48), 85 (11), 75 (20), 69 (50), 50 (5), 43 (23). HRMS (EI): Calcd. 
for C10H9FO2 ([M]+): 180.05811; found: 180.05765. 
 
4-(4-Chlorophenyl)-4-hydroxy-3-buten-2-one (23c): 
To a stirred solution of LDA (75 mmol) in THF (62 mL) was 
added acetone (2.904 g, 50.0 mmol) at -78 °C. After the 
solution was stirred for 1 h, 4-chlorobenzoyl chloride (10.5 g, 
60.0 mmol) was added. The temperature of the solution was 
allowed to rise to 20 °C  during 12 h. A saturated solution of NH4Cl was added, the layers 
were separated, and the aqueous layer was extracted with ethylacetate (3 x 150 mL). The 






vacuo. The residue was purified by chromatography (silica gel, n-hexane/EtOAc 30:1 → 
20:1) to give 23c as a light yellow solid (3.762 g, 38%) mp = 66-68 oC. 1H NMR (300 MHz, 
CDCl3): δ =  2.12 (s, 3 H, CH3), 6.06 (s, 1 H, CH), 7.33 (m, 1 H, CH),  7.35 (m, 1 H, CH), 
7.72 (m, 1 H, CH), 7.75 (m, 1 H, CH),  16.01 (s(br), 1 H, OH). 13C NMR (75 MHz, CDCl3): δ 
= 26.1 (CH3), 96.9 (CH), 128.7 (2CH), 129.3 (2CH), 133.7, 138.9, 182.6 (C), 194.1 (C=O). 
IR (KBr, cm-1): ν~  = 3075 (m), 2847 (m), 1594 (s), 1547 (s), 1486 (s), 1284 (m), 1113 (m), 
1093 (s), 1012 (s), 840 (m), 779 (s), 437 (m). MS (EI, 70 eV): m/z (%) = 198 ([M]+, [37Cl], 
34), 196 ([M]+, [35Cl]), 69), 181 (87), 161 (26), 154 (8), 139 (100), 111 (44), 101 (5), 89 (13), 
85 (25), 75 (36), 69 (79), 63 (6), 50 (11), 43 (36). HRMS (EI): Calcd. for C10H9ClO2 ([M]+, 
[35Cl]): 196.02856; found: 196.02870. 
 
2-Chloro-1-(4-flourophenyl)butane-1,3-dione (24b): 
 A mixture of 23b (4.11 g, 22.8 mmol) and NCS (3.09 g, 22.8 
mmol) in CCl4 (50 mL) was heated at reflux for 4 h. After cooling, 
the precipitate of succinimide was filtered off and water was 
added, the layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (3 x 150 mL). The combined organic layers were dried (Na2SO4) and 
filtered, and the solvent was removed in vacuo. The residue was purified by chromatography 
(silica gel, n-heptane/EtOAc 30:1 → 20:1) to give 24b as dark yellow oil (3.25 g, 66%). 1H 
NMR (CDCl3, 300 MHz): δ = 2.29 (s, 3 H, CH3), 5.46 (s, 1 H, CH), 7.06-7.09 (m, 2 H, Ar), 
7.92-7.97 (m, 2 H, Ar). 13C NMR (CDCl3, 75 MHz): δC = 25.6 (CH3), 63.2 (CH), 115.1, 
115.3, 131.2, 131.3 (CH), 163.7, 167.7 (C), 187.3, 197.6 (C=O). GC-MS (EI 70 eV): m/z (%) 
= 216 ([M]+, [37Cl], 12), 214 ([M]+, [35Cl], 4),, 199 (4), 172 (114), 123 (100), 95 (39), 75 (13), 
43 (19). HRMS (EI): Calcd. for C10H8ClFO2 ([M]+, [35Cl]): 214.01914; found: 214.01824.  
 
3-Chloro-4-(4-chlorophenyl)butane-1,3-dione (24c): 
 A mixture of 23c (4.38 g, 22.3 mmol) and NCS (3.02 g, 22.3 
mmol) in CCl4 (49 mL) was heated at reflux for 4 h. After 
cooling, the precipitate of succinimide was filtered off and water 
was added, the layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (3 x 150 mL). The combined organic layers were dried (Na2SO4) and 
filtered, and the solvent was removed in vacuo. The residue was purified by chromatography 
(silica gel, n-heptane/EtOAc 30:1 → 20:1) to give 24c as yellowish oil (2.60 g, 52%). 1H 








7.87 (m, 2 H, CH3). 13C NMR (CDCl3, 75 MHz): δC = 27.0 (CH3), 64.5 (CH), 128.7 (C), 
129.7 (2CH), 131.1 (2CH), 141.6 (C), 189.1, 198.9 (C=O). GC-MS (EI, 70 eV) : m/z (%) = 
234 ([M]+, [2x37Cl], 1), 232 ([M]+, [37Cl], [35Cl], 6), 230 ([M]+, [2x35Cl], 10), 215 (3), 188 
(13), 139 (100), 111 (38), 75 (21), 43 (26). HRMS (EI): Calcd. for C10H8Cl2O2 ([M]+, 
[2x35Cl]): 229.98959; found: 229.98919. 
 
2-Chloro-1-(2-methoxyphenyl)butane-1,3-dione (24e). 
A mixture of 23e (4.80 g, 25.0 mmol) and NCS (3.33 g, 25 mmol) 
in CCl4 (55 mL) was heated at reflux for 4 h. After cooling, the 
precipitate of succinimide was filtered off and water was added, the 
layers were separated, and the aqueous layer was extracted with 
CH2Cl2 (3 x 150 mL). The combined organic layers were dried (Na2SO4) and filtered, and the 
solvent was removed in vacuo. The residue was purified by chromatography (silica gel, n-
heptane/EtOAc 30:1 → 20:1) to give 24e as yellow oil (2.67 g, 47%). 1H NMR (CDCl3, 300 
MHz): δ = 2.26 (s, 3 H, CH3), 3.78 (s, 3 H, OCH3), 5.56 (s, 1 H, CH), 6.88 (d, J=8.4 Hz, 1 H, 
Ar), 6.91-6.96 (m, 1 H, Ar), 7.40-7.46 (m, 1 H, Ar), 7.74 (dd, J=7.6 Hz, J= 1.9 Hz 1 H, Ar). 
13C NMR (CDCl3, 75 MHz): δC = 26.0, (CH3), 54.5 (OCH3), 66.9 (CH), 110.8, 120.4 (CH), 
123.4 (C), 130.4, 134.3 (CH), 157.4 (C), 189.3, 196.3 (C=O). GCMS (EI, 70 eV): m/z (%) = 
228 ([M]+, [37Cl], 3), 226, ([M]+, [35Cl], 1), 197 ( 37Cl, 8), 195 (35Cl, 24), 135 (100), 108 (7), 




 A mixture of 23f (4.00 g, 18 mmol) and NCS (2.41 g, 18 
mmol) in CCl4 (40 mL) was heated at reflux for 4 h. After 
cooling, the precipitate of succinimide was filtered off and 
water was added, the layers were separated, and the aqueous 
layer was extracted with CH2Cl2 (3 x 150 mL). The combined organic layers were dried 
(Na2SO4) and filtered, and the solvent was removed in vacuo. The residue was purified by 
chromatography (silica gel, n-heptane/EtOAc 30:1 → 20:1) to give 24f as yellowish oil (3.72 
g, 81%). 1H NMR (CDCl3, 300 MHz): δ = 0.80 (t, J= 7.4 Hz, 3 H, CH3), 1.48-1.58 (m, 2 H, 
CH2), 2.51-2.58 (m, 2 H, CH2), 3.73 (s, 3 H, OCH3), 5.64 (s, 1 H, CH), 6.83-6.86 (m, 1 H, 
Ar), 6.87-6.92 (m, 1 H, Ar), 7.36-7.42 (m, 1 H, Ar), 7.71 (dd, J=7.8 Hz, J=1.7 Hz, 1 H, Ar). 











119.3 (CH), 122.6 (C), 129.5, 133.5 (CH), 156.5 (C), 188.5, 197.6 (C=O). IR (KBr, cm–1): ν~  
= 2957 (w), 2926 (w), 1665 (s), 1618 (w), 1440 (s), 1344 (s), 1177 (s), 1094 (m), 805 (s). 
GCMS (EI, 70 eV) : m/z (%) = 256 ([M]+, [37Cl], 6), 254 ([M]+, [35Cl]), 12), 223 (79), 184 
(59), 135 (100), 92 (46), 77 (76), 43 (64). HRMS (EI): Calcd. for C13H15ClO3 ([M]+, [35Cl]): 
254.07042; found: 254.07013.  
 
3-Chloro-4-phenyl-4-[(trimethylsilyl)oxy]-3-buten-2-one (25a): 
  Starting with benzene  (120ml), 24a (9.50 g, 48.3 mmol), 
triethylamine (10.71 mL, 77.3 mmol). And trimethylchlorosilane 
(10.98 mL, 86.9 mmol), 25a as a dark yellow oil (10.10, 90%). 1H 
NMR (CDCl3, 300 MHz): δ = 0.26 (s, 9 H, CH3), 1.99 (s, 3 H, CH3), 
7.33-7.36 (m, 2 H, Ar), 7.40-7.43 (m, 1 H, Ar), 7.70-7.73 (m, 2 H, Ar). 13C NMR (CDCl3, 75 
MHz): δC = 0.5, 0.7, 1.9, 21.4 (CH3), 111.6 (CCl), 128.1 (2CH), 129.1 (2CH), 132.4 (CH), 
137.7, 157.4 (C), 191.8 (C=O).  
 
3-Chloro-4-(4-fluorophenyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (25b): 
 To a stirred benzene solution (45 mL), 24b (3.25 g, 15.11 mmol), 
triethylamine (3.38 mL, 24.17 mmol). and trimethylchlorosilane 
(3.43 mL, 27.2 mmol), 25b as  reddish yellow oil (3.50 g, 80%). 
1H NMR (CDCl3, 300 MHz): δ = 0.24 (s, 9 H, CH3), 1.91 (s, 3 H, 
CH3), 7.00-7.03 (m, 2 H, Ar), 7.72-7.76 (m, 2 H, Ar). 13C NMR (CDCl3, 75 MHz): δC = 0.6, 




 To a stirred benzene solution (33 mL), 24c (2.607 g, 11.27 mmol), 
triethylamine (2.52 mL, 18.0 mmol). and trimethylchlorosilane 
(2.56 mL, 20.3 mmol), 25c as  reddish yellow oil (2.51 g, 73%). 1H 
NMR (CDCl3, 300 MHz): δ = 0.24 (s, 9 H, CH3), 2.01 (s, 3 H, 
CH3), 7.29 (m, 2 H, Ar), 7.62-7.65 (m, 2 H, Ar). 13C NMR (CDCl3, 75 MHz): δC = 0.8, 0.9, 












 To a stirred benzene solution (13.8 mL), 24d (1.16 g, 5.5 mmol), 
triethylamine (1.23 mL, 8.84 mmol),  trimethylchlorosilane (1.25 mL, 
9.9 mmol), 25d as  reddish yellow oil (1.13 g, 72%).1H NMR (CDCl3, 
300 MHz): δ = 0.20 (s, 9 H, CH3), 2.14 (s, 3 H, CH3), 2.57 (s, 3 H, 
CH3),728 (m, 1 H, Ar), 7.35 (m, 1 H, Ar), 7.47 (m, 1 H, Ar), 7.48 (m, 
1 H, Ar),  . 13C NMR (CDCl3, 75 MHz): δC = 0.4, 1.1, 2.1, 25.7 (CH3), 108.4 (C), 125.6, 
127.5, 130.1, 130.5, (CH), 134.8, 135.4, 182.6 (C), 195.3 (C=O).  
 
3-Chloro-4-(2-methoxyphenyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (25e):  
To a stirred benzene solution (35.3 mL), 24f (2.67 g, 11.7 
mmol), triethylamine (2.64 mL, 18.8 mmol), 
trimethylchlorosilane (2.67 mL, 21.19 mmol), 25e as  reddish 
yellow oil (2.70 g, 76%). 1H NMR (CDCl3, 300 MHz): δ = 0.02 
(s, 9 H, CH3), 1.96 (s, 3 H, CH3), 3.72(s, 3 H, OCH3), 6.85-6.88 
(m, 1 H, Ar), 7.10-7.12 (m, 1 H, Ar), 7.30-7.33 (m, 1 H, Ar), 7.70-7.81 (m, 1 H, Ar). 13C 
NMR (CDCl3, 75 MHz): δC = 0.2 (3CH3), 
 
General procedure for the synthesis of biaryls 26a-r: To a CH2Cl2 solution of silyl enol 
ether 25 (1.0 equiv.) and 1,3-bis(silyl enol ether) 4 (1.1 equiv.) was dropwise added TiCl4 (1.1 
equiv.) at –78 oC under argon atmosphere. The solution was stirred at –78 oC for 30 min and 
then allowed to warm to 20 °C during 18 h. To the solution was added a saturated aqueous 
solution of 10 % HCl. The organic layer was separated and the aqueous layer was repeatedly 
extracted with CH2Cl2. The combined organic extracts were dried (Na2SO4) and filtered. The 
filtrate was concentrated in vacuo and the residue was purified by chromatography (silica gel, 
n-hexane/EtOAc) to give salicylates 26. 
 
Methyl 5-chloro-2-hydroxy-4-methyl-6-phenylbenzoate (26a):  
Starting with bis-silyl enol ether 4a (0.429 g, 1.65 mmol), TiCl4 
(0.313 g, 1.65 mmol), CH2Cl2 (3 mL) and silyl enol ether 25a (0.403 
g, 1.5 mmol), 26a was isolated (0.204 g, 49%) by column 
chromatography (silica gel, n-heptane/EtOAc = 30:1 → 20:1) as a 
colorless solid. 1H NMR (CDCl3, 300 MHz): δ = 2.28 (s, 3 H, CH3), 

















Hz, 2 H, Ar), 7.20-7.23 (m, 2 H, Ar), 7.25-7.28 (m, 1 H, Ar) 10.67 (s, 1 H, OH). 13C NMR 
(CDCl3, 75 MHz): δC = 20.2 (CH3), 54.4 (OCH3), 110.4 (CH), 124.3 (C), 125.5 (CH), 126.1 
(2CH), 127.0 (2CH), 139.0, 140.6, 142.2, 158.3 (C), 169.2 (C=O). GC-MS (EI, 70 eV): m/z 
(%) = 278 ([M]+, [37Cl], 10), 276 ([M]+, [35Cl], 30), 246 ([37Cl], 33), 244 ([35Cl], 100), 216 
(22), 181 (10), 152 (27), 76 (14). HRMS (EI): Calcd. for C15H13ClO3 ([M]+, [35Cl]): 
276.05477; found: 276.05475.  
 
Methyl 6-chloro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26b):  
Starting with bis-silyl enol ether 4b (0.452 g, 1.65 mmol), TiCl4 
(0.313 g, 1.65 mmol), CH2Cl2 (3 mL) and silyl enol ether 25a (0.403 
g, 1.5 mmol), 26b was isolated (0.133 g, 31%) by column 
chromatography (silica gel, n-heptane/EtOAc = 30:1 → 20:1) as a 
colorless solid. 1H NMR (CDCl3, 300 MHz): δ = 2.19 (s, 3 H, CH3), 
2.32 (s, 3 H, CH3), 3.25 (s, 3 H, OCH3), 6.99-7.02 (m, 2 H, Ar), 7.21-
7.24 (m, 2 H, Ar), 7.26-7.29 (m, 1 H, Ar), 11.03 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC 
= 11.6, 17.1 (CH3), 50.8 (OCH3), 110.0, 124.6, 125.0 (C), 125.7 (CH), 126.4 (2CH), 127.6 
(2CH), 137.9, 139.5, 140.7, 156.8 (C), 170.2 (C=O). IR (KBr, cm–1): ν~  = 3063 (w), 3025 
(w), 2951 (m), 1655 (s), 1244 (s), 1200 (s), 1175 (s), 1014 (m), 708 (s). GC-MS (EI, 70 eV): 
m/z (%) = 292 ([M]+, [37Cl], 11), 290 ([M]+, [35Cl],, 33), 260 ([37Cl], 19), 258 ([35Cl], 57), 223 
(100), 195 (10), 165 (21) 82 (8). HRMS (EI): Calcd. for C16H15ClO3 ([M]+, [35Cl],): 
290.07042; found: 290.07028.  
 
Ethyl 6-chloro-4-ethyl-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26d). 
 Starting with bis-silyl enol ether 4c (0.452 g, 1.65 mmol), TiCl4 
(0.313 g, 1.65 mmol), CH2Cl2 (3 mL) and silyl enol ether 25a 
(0.403 g, 1.5 mmol), 11d was isolated (0.205 g, 43%) by column 
chromatography (silica gel, n-heptane/EtOAc = 30:1 → 20:1) as a 
colorless solid. 1H NMR (CDCl3, 300 MHz): δ = 0.56 (t, J = 7.2 
Hz, 3 H, CH3), 1.04 (t, J = 7.5 Hz, 3 H, CH3), 2.34 (s, 3 H, CH3), 
2.71 (q, J = 7.4 Hz, 2 H, CH2), 3.77 (q, J = 7.2 Hz, 2 H, OCH2), 6.99-7.03 (m, 2 H, Ar), 7.19-
7.21 (m, 2 H, Ar), 7.25-7.28, (m, 1 H, Ar), 11.19 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): 
δC = 11.8, 12.1, 16.3 (CH3), 19.2 (CH2), 59.9 (OCH2), 110.2, 124.9 (C), 125.6 (CH), 126.4 
(2CH), 127.7 (2CH), 130.9, 138.1, 140.0, 140.2, 156.9 (C), 169.8 (C=O). GC-MS (EI, 70 eV): 














259, ([37Cl], 4), 257 ( [35Cl], 13), 237 (81), 219 (100) 165 (42). 115 (6), 77 (5). HRMS (EI): 
Calcd. for C18H19ClO3 ([M]+, [35Cl]): 318.10172; found: 318.101231.  
 
Methyl 6-chloro-4'-fluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26e): 
Starting with bis-silyl enol ether 4a (0.429 g, 1.65 mmol), TiCl4 
(0.,313 g, 1.65 mmol), CH2Cl2 (3 mL) and silyl enol ether 25b 
(0.430 g, 1.5 mmol), 26e was isolated (0.125 g, 28%) by column 
chromatography (silica gel, n-heptane/EtOAc = 30:1 → 20:1) as a 
colorless solid, mp = 122-124 ºC. 1H NMR (CDCl3, 300 MHz): δ 
= 2.26 (s, 3 H, CH3), 3.28 (s, 3 H, OCH3), 6.81 (s, 1 H, Ar), 6.93 
(m, 2H, Ar), 6.95 (m, 2 H, Ar), 10.70 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 20.6 
(CH3) 50.9 (OCH3), 110.8 (C), 113.4, 113.7, 118.3 (CH), 124.8 (C), 128.4, 128.6 (CH), 135.3, 
139.9, 142.9, 162.5, 162.7 (C), 169.5 (C=O). IR (KBr, cm–1): ν~  = 2955 (m), 2853 (w), 1671 
(s), 1515 (s), 1362 (s), 1235 (s), 1166 (s), 1014 (m), 809 (s). GC-MS (EI, 70 eV): m/z (%) = 
296 ([M]+, [37Cl], 12), 294 ([M]+, [35Cl], 36), 262 (100),  234(36), 199 (14), 170 (31) 85 (13). 
HRMS (EI): Calcd. for C15H12ClFO3 ([M]+, [35Cl]): 294.04535; found: 294.045720.  
 
Methyl 6-chloro-4'-fluoro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26f). 
Starting with bis-silyl enol ether 4b (0.452 g, 1.65 mmol), 
TiCl4 (0.313 g, 1.65 mmol), CH2Cl2 (3 mL) and silyl enol ether 
25b (0.430 g, 1.5 mmol), 26f was isolated (0.224 g, 48%) by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 → 
20:1) as a colorless solid, mp = 65-68 ºC. 1H NMR (CDCl3, 
300 MHz): δ = 2.20 (s, 3 H, CH3), 2.33 (s, 3 H, CH3), 3.32 (s, 3 
H, OCH3), 6.97 (m, 2H, Ar), 6.99 (m, 2 H, Ar), 11.08 (s, 1 H, 
OH). 13C NMR (CDCl3, 75 MHz): δC = 11.7, 17.1 (CH3), 50.9 (OCH3), 110.0 (C), 113.3, 
113.6 (CH), 125.3 (C), 129.2, 129.3 (CH), 135.8, 136.8, 140.9, 157.0, 159.1, 162.4 (C), 170.1 
(C=O). IR (KBr, cm–1): ν~  = 3054 (w), 2960 (m), 1659 (s), 1511 (s), 1470 (s), 1245 (s), 1015 
(s), 806 (w). GC-MS (EI, 70 eV): m/z (%) = 310 ([M]+, [37Cl], 10), 308 ([M]+, [35Cl], 32), 276 
(59),  241 (100), 213 (13), 183 (21), 91 (5). HRMS (EI): Calcd. for C16H14ClFO3 ([M]+, 


















Ethyl 5-chloro-3-ethyl-2-hydroxy-4-methyl-6-(4-fluorophenyl)benzoate (26g). 
Starting with bis-silyl enol ether 4c (0.499 g, 1.65 mmol), 
TiCl4 (0.313 g, 1.65 mmol) CH2Cl2 (3 mL) and silyl enol ether 
25b (0.430 g, 1.5 mmol), 26g was isolated (0.219 g, 44%), by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 
→ 20:1) as a light red solid (mp = 73-75 ºC).  1H NMR 
(CDCl3, 300 MHz): δ = 0.55 (t, J = 7.2 Hz, 3 H, CH3), 0.97 (t, 
J = 7.4 Hz, 3 H, CH3), 2.24 (s, 3 H, CH3), 2.62 (q, J = 7.5 Hz, 2 H, CH2), 3.73 (q, J = 7.2 Hz, 
2 H, OCH2),  6.86 (m, 2 H, Ar), 6.88 (m, 2 H, Ar), 11.11 (s, 1 H, OH). 13C NMR (CDCl3, 75 
MHz): δC = 12.9, 13.1, 17.4 (CH3), 20.4 (CH2), 61.2 (OCH2), 111.3 (C), 114.3, 114.6, 130.3, 
130.4 (CH), 132.3, 137.1, 138.0, 141.2, 158.0, 160.3, 163.6 (C), 170.7 (C=O). IR (KBr, cm–
1): ~ν  = 2970 (m), 2927 (m), 1655 (s), 1511 (s), 1376 (s), 1233 (s), 1217 (s), 1187 (s), 810 (w). 
GC-MS (EI, 70 eV): m/z (%) = 338 ([M]+, [37Cl], 18), 336 ([M]+, [35Cl], 54), 290 (82), 255 
(100), 237 (86), 183 (43), 170 (82), 133 (6), 91 (2), 51 (2). HRMS (EI): Calcd. for 
C18H18ClFO3 ([M]+, [35Cl]): 336.09230; found: 336.09188.  
 
Methyl 4',6-dichloro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate(26h): 
Starting with bis-silyl enol ether 4a (0.567 g, 2.18 mmol), TiCl4 
(0.413 g, 2.18 mmol) CH2Cl2 (3 mL) and silyl enol ether 25c 
(0.606 g, 2.00 mmol), 26h was isolated (0.275 g, 44%), by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 → 
20:1) as a colorless solid, mp = 80-82 ºC. 1H NMR (CDCl3, 300 
MHz): δ = 2.29 (s, 3 H, CH3), 3.32 (s, 3 H, OCH3), 6.85 (m, 1 H, 
Ar), 6.93-6.96 (m, 2 H, Ar), 7.24-7.27 (m, 2 H, Ar), 10.76 (s, 1 H, OH). 13C NMR (CDCl3, 75 
MHz): δC = 21.5 (CH3), 51.9 (OCH3), 111.5 (C), 119.4 (CH), 125.6 (C), 127.8 (2CH), 129.8 
(2CH), 132.8, 138.8, 140.6, 144.0, 159.8 (C), 170.3 (C=O). IR (KBr, cm–1): ~ν = 2952 (m), 
2923 (w), 1671 (s), 1452 (s), 1229 (s), 1190 (s), 1018 (s), 820 (w). GC-MS (EI, 70 eV): m/z 
(%) = 314 ([M]+, [2x37Cl], 3), 312 ([M]+, [37Cl], [35Cl], 18), 310 ([M]+, [2x35Cl], 28), 278 
(100), 250 (13), 215 (15), 187 (8), 152 (9), 93 (8), 76 (9). HRMS (EI): Calcd. for 



















Methyl 4',6-dichloro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26i). 
Starting with bis-silyl enol ether 4b (0.598 g, 2.18 mmol), 
TiCl4 (0.413 g, 2.18 mmol), CH2Cl2 (3 mL) and silyl enol 
ether 25c (0.606 g, 2.00 mmol), 11i was isolated (0.220 g, 
34%) by column chromatography (silica gel, n-
heptane/EtOAc = 30:1 → 20:1) as a light yellow solid, mp = 
95-97 ºC. 1H NMR (CDCl3, 300 MHz): δ =   2.23 (s, 3 H, 
CH3), 2.35 (s, 3 H, CH3), 3.34 (s, 3 H, OCH3), 6.96-6.99 (m, 2 H, Ar), 7.27-7.29 (m, 2 H, Ar), 
11.12 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 13.1, 18.6 (CH3), 52.4 (OCH3), 111.2, 
126.0, 126.9 (C), 128.2 (2CH), 130.5 (2CH), 131.1, 138.0, 139.8, 142.4, 158.5 (C), 171.4 
(C=O). IR (KBr, cm–1): ν~  = 3053 (w), 2957 (m), 2927 (w), 1660 (s), 1441 (s), 1244 (s), 1202 
(s), 1016 (s), 809 (m). GC-MS (EI, 70 eV): m/z (%) = 328 ([M]+, [2x37Cl], 4), 326 ([M]+, 
[37Cl], [35Cl], 17), 324 ([M]+, [2x35Cl],, 27), 292 (53), 257 (100), 229(11), 165 (25), 99 (5), 82 
(12). HRMS (EI): Calcd. for C16H14Cl2O3: 324.03145 ([M]+, [2x35Cl]): found: 324.031296. 
 
Ethyl 4',6-dichloro-4-ethyl-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26j). 
Starting with bis-silyl enol ether 4c (0.659 g, 2.18 mmol), 
TiCl4 (0.413 g, 2.18 mmol), CH2Cl2 (3 mL) and silyl enol 
ether 25c (0.606 g, 2.00 mmol), 26j was isolated (0.335 g, 
47%) by column chromatography (silica gel, n-
heptane/EtOAc = 30:1 → 20:1) as a colorless solid, mp = 94-
96 ºC.1H NMR (CDCl3, 300 MHz): δ = 0.67 (t, J = 7.2 Hz, 3 
H, CH3), 1.09 (t, J = 7.4 Hz, 3 H, CH3), 2.36 (s, 3 H, CH3), 2.74 (q, J = 7.4 Hz, 2 H, CH2), 
3.85 (q, J = 7.2 Hz, 2 H, OCH2), 6.97-6.99 (m, 2 H, Ar), 7.26-7.29 (m, 2 H, Ar), 11.25 (s, 1 
H, OH). 13C NMR (CDCl3, 75 MHz): δC = 12.8, 13.0, 17.4 (CH3), 20.3 (CH2), 61.2 (OCH2), 
110.9, 125.7 (C), 127.7 (2CH), 130.1 (2CH), 132.4, 132.6, 137.7, 139.6, 141.2, 158.0 (C), 
170.6 (C=O). IR (KBr, cm–1): ν~  = 3431 (w), 2966 (m), 2929 (m), 1672 (s), 1382 (s), 1305 
(s), 1219 (s), 1101 (m), 186 (m). MS (EI, 70 eV): m/z (%) = 356 ([M]+, [2x37Cl], 3), 354 
([M]+, [37Cl], [35Cl], 16), 352 ([M]+, [2x35Cl], 25), 306 (35), 271 (100), 199 (4), 165 (15) 152 



















Methyl 6-chloro-3-hydroxy-2'-methoxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26m): 
Starting with bis-silyl enol ether 4a (0.573 g, 2.20 mmol), TiCl4 
(417 g, 2.20 mmol), CH2Cl2 (4 mL) and silyl enol ether 25e 
(0.597 g, 2.00 mmol), 26m was isolated (0.285 g, 47%) by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 → 
20:1) as a slightly yellow oil.  1H NMR (CDCl3, 300 MHz): δ =   
2.28 (s, 3 H, CH3), 3.28 (s, 3 H, OCH3), 3.61 (s, 3 H, OCH3), 
6.80 (m, 1H, Ar), 6.81-6.83 (m, 1 H, Ar), 6.84, (m, 1 H, Ar), 6.85-6.86, (m, 1 H, Ar), 7.18-
7.24, (m, 1 H, Ar), 10.76 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 20.68 (CH3), 50.8, 
54.7 (OCH3), 109.4 (CH), 111.0 (C), 118.0 (CH), 118.1 (C), 119.1 (CH), 125.1 (C), 127.7, 
128.6 (CH), 137.8, 142.8, 155.2, 158.8 (C), 169.6 (C=O). GC-MS (EI, 70 eV): m/z (%) = 308 
([M]+, [37Cl], 12), 306 ([M]+, [35Cl], 37), 274 (100), 245 (8), 231 (8), 211 (8), 183 (7), 168 
(11), 139 (10), 91 (3), 76 (6).  HRMS (EI): Calcd. for C16H15ClO4 ([M]+, [35Cl]): 306.06534; 
found: 306.06620.  
 
Methyl 6-chloro-3-hydroxy-2'-methoxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26n): 
Starting with bis-silyl enol ether 4b (0.604 g, 2.20 mmol), TiCl4 
(417 g, 2.20 mmol), CH2Cl2 (4 mL) and silyl enol ether 25e 
(0.597 g, 2.00 mmol), 26n was isolated (0.319 g, 50%) by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 → 
20:1) as a colorless solid, mp = 78-80 ºC. 1H NMR (CDCl3, 300 
MHz): δ =   2.16 (s, 3 H, CH3), 2.30 (s, 3 H, CH3), 3.27 (s, 3 H, 
OCH3), 3.61 (s, 3 H, OCH3), 6.79-6.82 (m, 1 H, Ar), 6.83-6.87 (m, 2 H, Ar), 7.16-7.22, (m, 1 
H, Ar), 11.10 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 11.7, 17.2 (CH3), 50.8, 54.7 
(OCH3), 109.3 (CH), 110.2 (C), 119.1 (CH), 125.0, 125.1 (C), 127.5, 128.7 (CH), 129.1, 
134.7, 140.8, 155.3, 157.0 (C), 170.2 (C=O). IR (KBr, cm–1): ν~  = 3063 (w), 2953 (m), 2923 
(m), 1668 (s), 1436 (s), 1293 (s), 1200 (s), 1015 (m), 744 (s). GC-MS (EI, 70 eV): m/z (%) = 
322 ([M]+, [37Cl], 17), 320 ([M]+, [35Cl], 56), 288 (100), 273 (32), 257 (97), 181 (19), 165 
(13), 152 (13), 115 (5), 76 (7). HRMS (EI): Calcd. for C17H17ClO4 ([M]+, [35Cl]): 320.08099; 





















(26o):Starting with bis-silyl enol ether 4c (0.665 g, 2.20 mmol), 
TiCl4 (417 g, 2.20 mmol), CH2Cl2 (4 mL) and silyl enol ether 
25e (0.597 g, 2.00 mmol), 26o was isolated (0.290 g, 42%) by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 → 
20:1) as a colorless solid, mp = 90-92 ºC. 1H NMR (CDCl3, 300 
MHz): δ = 0.63 (t, J = 7.1 Hz, 3 H, CH3), 1.09 (t, J = 7.4 Hz, 3 
H, CH3), 2.36 (s, 3 H, CH3), 2.73 (q, J = 7.4 Hz, 2 H, CH2), 3.66 (m, 3 H, OCH3), 3.83 (q, J = 
7.1 Hz, 2 H, OCH2),  6.82-6.85 (m, 1 H, Ar), 6.86-6.88 (m, 2 H, Ar), 7.21-7.27 (m, 1 H, Ar), 
11.24 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 11.9, 12.1, 16.4 (CH3), 19.4 (CH2), 54.6 
(OCH3), 59.9 (OCH2), 109.3 (CH), 110.5 (C), 119.1 (CH), 125.3 (C), 127.4, 128.7 (CH), 
129.4, 130.8, 134.8, 140.0, 155.5, 157.0 (C), 169.9 (C=O). IR (KBr, cm–1): ν~  = 2971 (m), 
2958 (m), 2871 (m), 1649 (s), 1299 (s), 1233 (s), 1114 (s), 1030 (s), 811 (w). GC-MS (EI 70, 
eV): m/z (%) = 350 ([M]+, [37Cl], 15), 348 ([M]+, [35Cl], 46), 302 (74), 287 (19), 271 (100), 
249 (16), 224 (7), 181 (11), 165 (12), 115 (4), 77 (2). HRMS (EI): Calcd. for C19H21ClO4 
([M]+, [35Cl]): 348.11229; found: 348.11171.  
 
Methyl 6-chloro-3-hydroxy-2'-methoxy-5-propyl[1,1'-biphenyl]-2-carboxylate (26p): 
Starting with bis-silyl enol ether 4a (0.573 g, 2.20 mmol), TiCl4 
(417 g, 2.20 mmol), CH2Cl2 (4 mL) and silyl enol ether 25f 
(0.653 g, 2.00 mmol), 26p was isolated (0.229 g, 34%) by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 → 
20:1) as a slightly yellow oil. 1H NMR (CDCl3, 300 MHz): δ = 
0.87 (t, J = 7.4 Hz, 3 H, CH3), 1.50-1.62 (m, 2 H, CH2), 2.52-
2.65 (m, 2 H, CH2), 3.27 (m, 3 H, OCH3), 3.60 (s, 3 H, OCH3), 6.79 (s, 1 H, Ar), 6.82 (m, 1 
H, Ar), 6.83-6.85 (m, 2 H, Ar), 7.17-7.23 (m, 1 H, Ar), 10.73 (s, 1 H, OH). 13C NMR (CDCl3, 
75 MHz): δC = 12.9 (CH3), 21.2, 35.7 (CH2), 50.8, 54.7 (OCH3), 109.4 (CH), 111.1(C), 117.2 
(CH), 117.3 (C), 119.1 (CH), 124.7 (C), 127.6, 128.7 (CH), 138.0, 146.6, 155.3, 158.8 (C), 
169.6 (C=O). GC-MS (EI, 70 eV): m/z (%) = 336 ([M]+, [37Cl], 12), 334 ([M]+, [35Cl], 37), 
302 (100), 274 (43), 230 (10), 181 (5), 152 (9) 139 (8). HRMS (EI): Calcd. for C18H19ClO4 




















(26q):Starting with bis-silyl enol ether 4b (0.604 g, 2.20 mmol), 
TiCl4 (417 g, 2.20 mmol) CH2Cl2 (4 mL) and silyl enol ether 25f 
(0.653 g, 2.00 mmol), 26q was isolated (0.325 g, 47%) by 
column chromatography (silica gel, n-heptane/EtOAc = 30:1 → 
20:1) as a slightly yellow viscous oil. 1H NMR (CDCl3, 300 
MHz): δ = 0.90 (t, J = 7.4 Hz, 3 H, CH3), 1.41-1.49 (m, 2 H, 
CH2), 2.17 (s, 3 H, CH3), 2.67-2.74 (m, 2 H, CH2), 3.25 (m, 3 H, OCH3), 3.59 (s, 3 H, OCH3), 
6.78 (d, J = 8.1 Hz, 1 H, Ar), 6.82-6.83 (m, 2 H, Ar), 7.14-7.20 (m, 1 H, Ar), 11.07 (s, 1 H, 
OH). 13C NMR (CDCl3, 75 MHz): δC = 4.8, 14.2 (CH3), 16.3, 38.0 (CH2), 53.7, 57.6 (OCH3), 
112.3 (CH), 113.3 (C), 122.0 (CH), 127.6, 127.8 (C), 130.4, 131.7 (CH), 132.1, 137.9, 147.7, 
158.3, 160.2 (C), 173.1 (C=O). IR (neat, cm–1): ν~  = 3000 (w), 2958 (s), 2931 (m), 2872 (m), 
1663 (s), 1249 (s), 1218 (s), 1104 (m), 1028 (s), 808 (m). MS (EI, 70 eV): m/z (%) = 350 
([M]+, [37Cl], 13), 348 ([M]+, [35Cl], 37), 316 (100), 301 (15), 285 (14), 257 (21), 181 (11), 




(26r):Starting with bis-silyl enol ether 4c (0.665 g, 2.20 mmol), 
TiCl4 (417 g, 2.20 mmol) CH2Cl2 (4 mL) and monosilyl enol 
ether 25f (0654. g, 2.00 mmol), 26r was isolated (0.384 g, 51%) 
by column chromatography (silica gel, n-heptane/EtOAc = 30:1 
→ 20:1) as a colorless solid, mp = 79-81 ºC. 1H NMR (CDCl3, 
300 MHz): δ = 0.64 (t, J = 7.2 Hz, 3 H, CH3), 0.97 (t, J = 7.4 
Hz, 3 H, CH3), 1.13 (t, J = 7.4 Hz, 3 H, CH3), 1.47-1.54 (m, 2 
H, CH2), 2.67-2.69 (m, 2 H, CH2), 2.72-2.76 (m, 2 H, CH2), 3.67 (s, 3 H, OCH3), 3.83 (q, J = 
7.2 Hz, 2 H, OCH2), 6.84 (d, J = 8.1 Hz, 1 H, Ar), 6.87-6.89 (m, 2 H, Ar), 7.22-7.28, (m, 1 H, 
Ar), 11.19 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 11.9, 13.2, 13.5 (CH3), 19.3, 21.9, 
32.4 (CH2), 54.7 (OCH3), 59.9 (OCH2), 109.4 (CH), 110.7 (C), 119.1 (CH), 124.9 (C), 127.4, 
128.8 (CH), 129.5, 130.5, 135.1, 144.1, 155.5, 157.3 (C), 169.8 (C=O). IR (KBr, cm–1): ν~  = 
3421 (w), 2959 (s), 2932 (s), 2870 (m), 1652 (s), 1392 (s), 1243 (s), 1185 (s), 1049 (m), 801 
(w). MS (EI, 70 eV): m/z (%) = 378 ([M]+, [37Cl], 14), 376 ([M]+, [35Cl], 42), 330 (100), 299 
(84), 287 (7), 271 (8), 181 (9), 165 (6), 131 (8), 69 (19), 43 (12). HRMS (EI): Calcd. for 
















General procedure for synthesis of benzo[c]chromen-6-ones 27a-f by lactonization with 
BBr3: To a CH2Cl2 solution of 26 was added BBr3 at 0 °C. The solution was allowed to warm 
to 20 °C during 18 h. To the solution was added an aqueous solution of KOtBu (0.1 M) and 
the solution was stirred for 15 min. The organic and the aqueous layer were separated and the 
latter was extracted with CH2Cl2. The combined organic layers were dried (Na2SO4), filtered 
and the filtrate was concentrated in vacuo. The product was purified by chromatography 
(silica gel; n-hexane/ EtOAc = 20:1) as a colourless solid. 
 
10-Chloro-7-hydroxy-9-methyl-6H-benzo[c]chromen-6-one (27a): 
Starting with 26m   (0.104 g, 0.31 mmol) in CH2Cl2 (5 mL), BBr3 
(0.339 g, 1.35 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 
27a was isolated as a colourless solid (0.063 g, 73%), mp. 107-110 
°C.  1H NMR (CDCl3, 300 MHz): δ = 2.45 (s, 3 H, CH3), 6.96 (s, 1 
H, Ar), 7.27-7.30 (m, 2 H, Ar), 7.41-7.46 (m, 1 H, Ar), 9.24-9.27 
(m, 1 H, Ar), 11.78 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 21.0 (CH3), 104.0 (C), 
115.7 (CH), 116.1 (C), 117.2 (CH), 119.1 (C), 122.5, 125.8, 128.8 (CH), 129.3, 147.0, 148.5, 
159.1 (C), 163.2 (C=O). IR (KBr, cm–1): ν~  = 3026 (w), 2957 (w), 2924 (w), 1667 (s), 1265 
(s), 1218 (s), 1102 (s), 1031 (s), 763 (s). GC-MS (EI, 70 eV): m/z (%) = 262 ([M]+, [35Cl], 
33), 260 ([M]+, [35Cl], 100), 225 (26), 197 (13), 169 (8), 139 (10), 112 (14) 69 (5). HRMS 
(EI): Calcd. for C14H9ClO3 ([M]+, [35Cl]): 260.02347; found: 260.02249.  
 
10-Chloro-7-hydroxy-8,9-dimethyl-6H-benzo[c]chromen-6-one (27b): 
Starting with 26n  (0.129 g, 0.37 mmol) in CH2Cl2 (5 mL), BBr3 
(0.374 g, 1.49 mmol) and KOtBu (10 mL, 0.1 M aqueous 
solution), 27b was isolated as a colourless solid (0.080 g, 78 %), 
mp. 154-156 °C. 1H NMR (CDCl3, 300 MHz): δ = 2.23 (s, 3 H, 
CH3), 2.41 (s, 3 H, CH3), 7.22-7.24 (m, 1 H, Ar), 7.26 (m, 1 H, 
Ar), 7.36-7.42 (m, 1 H, Ar), 9.17 (dd, J = 8.4 Hz, J = 2.1Hz, 1 H, Ar), 12.18 (s, 1 H, OH). 13C 
NMR (CDCl3, 75 MHz): δC = 10.9, 16.9 (CH3), 102.9 (C), 115.5 (CH), 116.2, 119.3 (C), 
123.3 (CH), 124.7 (C), 125.8 (CH), 126.4 (C), 128.2 (CH), 145.1, 148.2, 157.3 (C), 163.6 
(C=O). IR (KBr, cm–1): ν~  = 3446 (w), 2925 (m), 2851 (m), 1669 (s), 1597 (s), 1397 (s), 1254 
(s), 1168 (s), 1113 (m), 780 (s). GC-MS (EI, 70 eV): m/z (%) = 276 ([M]+, [37Cl], 33), 274 
([M]+, [35Cl], 100), 259 (7), 239 (16), 211 (7), 181 (6), 165 (6), 152 (8), 115 (4), 76 (5). 












Starting with 26o (0.110 g, 0.31 mmol) in CH2Cl2 (5 mL), BBr3 
(0.315 g, 1.26 mmol) and KOtBu (10 mL, 0.1 M aqueous 
solution), 27c was isolated as a colourless solid (0.060 g, 60%). 
1H NMR (CDCl3, 300 MHz): δ = 1.06 (t, J = 7.4 Hz, 3 H, CH3), 
2.40 (s, 3 H, CH3), 2.71 (q, J = 7.4 Hz, 2 H, CH2), 7.17-7.18 (m, 
1 H, Ar), 7.21 (m, 1 H, Ar), 7.32-7.37 (m, 1 H, Ar), 9.08-9.11 (m, 1 H, Ar), 12.12 (s, 1 H, 
OH). 13C NMR(CDCl3, 75 MHz): δC = 13.4, 18.6 (CH3), 20.8 (CH2), 105.4 (C), 117.8 (CH), 
118.5, 121.8 (C), 124.6, 128.0 (CH), 128.8 (C), 130.5 (CH), 132.9, 146.8, 150.5, 159.5 (C), 
165.9 (C=O). IR (KBr, cm–1): ν~  = 2969 (m), 2928 (m), 1663 (s), 1393 (s), 1242 (s), 1166 (s), 
1116 (m), 758 (m). GC-MS (EI, 70 eV): m/z (%) = 290 ([M]+, [37Cl], 16), ,288 ([M]+, [35Cl], 
49), 273 (100), 245 (3), 181 (7), 165 (6), 152 (7), 126 (3), 76 (5). HRMS (EI): Calcd. for 
C16H13ClO3 ([M]+, [35Cl]): 288.05477; found: 288.05465.  
 
10-Chloro-7-hydroxy-9-propyl-6H-benzo[c]chromen-6-one (27d): 
Starting with 26p  (0.107 g, 0.32 mmol) in CH2Cl2 (5 mL), BBr3 
(0..320 g, 1.27 mmol) and KOtBu (10 mL, 0.1 M aqueous 
solution), 27d was isolated as a colourless crystaline (0.078 g, 
88%), mp. 115-117 °C.  1H NMR (CDCl3, 300 MHz): δ = 0.95  (t, 
J = 7.4 Hz, 3 H, CH3), 1.56-1.68 (m, 2 H, CH2), 2.69-2.75 (m, 2 H, 
CH2), 6.89 (s, 1 H, Ar), 7.21-7.22 (m, 1 H, Ar), 7.25 (m, 1 H, Ar), 7.36-7.42 (m, 1 H, Ar), 
9.18-9.21 (m, 1 H, Ar),11.73 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 14.3 (CH3), 
22.7, 37.9 (CH2), 106.3 (C), 117.9 (CH), 118.5 (C), 118.9 (CH), 121.0 (C), 124.7, 128.2, 
131.1 (CH), 131.8, 150.0, 153.0, 161.4 (C), 165.4 (C=O). IR (KBr, cm–1): ν~  = 2965 (m), 
2931 (m), 2876 (m), 1675 (s), 1606 (m), 1421 (s), 1232 (s), 1216 (s), 1105 (w), 765 (s). GC-
MS (EI, 70 eV): m/z (%) = 290 ([M]+, [37Cl], 33), 288 ([M]+, [35Cl], 100), 260 (94), 253 (16), 
225 (38), 197 (13), 181 (10), 168 (14), 152 (18), 139 (23), 126 (6), 75 (5).  HRMS (EI): 


















Starting with 26q (0.129 g, 0.37 mmol) in CH2Cl2 (5 mL), BBr3 
(0.320 g, 1.27 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 
27e was isolated as a light brown solid (0.060 g, 54%), mp. = 98-
100 °C.  1H NMR (CDCl3, 300 MHz): δ = 1.01 (t, J = 7.4 Hz, 3 H, 
CH3), 1.49-1.54 (m, 2 H, CH2), 2.26 (s, 3 H, CH3), 2.83-2.89 (m, 2 
H, CH2), 7.23-7.24 (m, 1 H, Ar), 7.27 (m, 1 H, Ar), 7.36-7.42 (m, 1 H, Ar), 9.20 (d, J = 8.9 
Hz, 1 H, Ar), 12.20 (s, 1 H, OH). 13C NMR (CDCl3, 75 MHz): δC = 11.4, 13.4 (CH3), 20.6, 
33.1 (CH2), 104.0 (C), 116.4 (CH), 117.3, 119.8 (C), 123.2, 126.8 (CH), 127.3, 127.7 (C), 
129.1 (CH), 149.2, 149.9, 158.6 (C), 164.6 (C=O). IR (KBr, cm–1): ν~  = 2968 (m), 2925 (m), 
2861 (m), 1671 (s), 1598 (m), 1394 (s), 1259 (s), 1221 (m), 1166 (s), 774 (s). GC-MS (EI, 70 
eV): m/z (%) = 304 ([M]+, [37Cl], 33), 302 ([M]+, [35Cl], 100), 274 (52), 267 (22), 239 (44),  
181 (16), 152 (17), 115 (5), 76 (5). HRMS (EI): Calcd. for C17H15ClO3 ([M]+, [35Cl]): 
302.07042; found: 302.07123.  
 
10-Chloro-8-ethyl-7-hydroxy-9-propyl-6H-benzo[c]chromen-6-one (27f): 
Starting with 26r (0.200 g, 0.51 mmol) in CH2Cl2 (5 mL), BBr3 
(0.513 g, 2.12 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 
27f was isolated as a light red solid (0.080 g, 48%), mp. = 98-100 
°C.  1H NMR (CDCl3, 300 MHz): δ = 1.03 (t, J = 7.4 Hz, 3 H, 
CH3), 1.13 (t, J = 7.4 Hz, 3 H, CH3), 1.55-1.60 (m, 2 H, CH2), 2.75 
(q, J = 7.4 Hz, 2 H, CH2), 2.83-2.88 (m, 2 H, CH2), 7.24-7.25 (m, 1 H, Ar), 7.27-7.28 (m, 1 H, 
Ar), 7.37-7.42 (m, 1 H, Ar), 9.20-9.23 (m, 1 H, Ar), 12.19 (s, 1 H, OH). 13C NMR (CDCl3, 75 
MHz): δC = 14.1, 14.9 (CH3), 20.8, 23.1, 34.1 (CH2), 105.7 (C), 117.8 (CH), 118.7, 121.4 (C), 
124.6, 128.3 (CH), 129.4 (C), 130.6 (CH), 132.8, 150.6, 150.8, 160.0 (C), 166.1 (C=O). IR 
(KBr, cm–1): ν~  = 2955 (m), 2928 (m), 2869 (m), 1677 (s), 1597 (w), 1383 (s), 1243 (s), 1215 
(s), 1116 (s), 753 (s). GC-MS (EI, 70 eV): m/z (%) = 314 ([M]+, [35Cl], 33), 316 ([M]+, [35Cl], 
100), 302 (8), 301 (40), 273.1 (51), 205 (7), 165 (4),  76 (4). HRMS (EI): Calcd. for 


















To a stirred benzene solution (83 mL), 17b (5.01 g, 27.8 mmol), 
triethylamine (6.236 mL, 16.0 mmol), trimethylchlorosilane (6.326 
mL, 18.0 mmol) was isolated 28b as yellowish oil (6.055 g , 88 %). 
1H NMR (250 MHz, CDCl3): δ = 0.11 (m, 9 H, 3CH3), 2.18 (s , 3 
H, CH3), 6.03 (s, 1 H, CH), 6.79-6.88 (m, 2 H, Ar), 7.63-7.67 (m, 2 H, Ar). 13C NMR (75 
MHz, CDCl3): δ = 0.22 (3CH3), 21.7 (CH3), 104.6 (CH), 115.2 (2CH), 130.0 (2CH), 136.4, 
166.5, 171.0 (C), 188.6 (C=O). 
 
4-(2-methylphenyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (28d): 
To a stirred benzene solution (90 mL), 17d (4.769 g, 27.06 mmol), 
triethylamine (6.068 mL, 43.3 mmol). and trimethylchlorosilane 
(6.150 mL, 48.7 mmol) was isolated 38d as yellowish oil (5.961 , 
88.8 %).  1H NMR (250 MHz, CDCl3): δ = 0.18 (m, 9 H, 3CH3), 
2.48 (s (br), 3 H, CH3), 2.58 (s (br), 3 H, CH3), 6.01 (s (br), 1 H, CH), 7.33 (m, 1 H, CHAr), 
7.35 (m, 1 H, CHAr), 7.38-7.39 (m, 1 H, CHAr), 7.51-7.55 (m, 1 H,CHAr). 13C NMR (75 MHz, 
CDCl3): δ = 1.5 (3CH3), 21.3 (CH3), 108.4 (CH), 125.3, 128.2, 129.4, 130.9 (CHAr), 135.1, 
141.5 (CAr), 170.2 (COTMS) 194.7 (C=O). 
 
4-(2-fluorophenyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (28g): 
To a stirred benzene solution (90 mL), 17g (5.405 g, 30.0 mmol), 
triethylamine (6.727 mL, 48.0 mmol). and trimethylchlorosilane 
(6.821 mL, 54.0 mmol) was isolated 28g as yellowish oil (6.056 , 80 
%). 1H NMR (250 MHz, CDCl3): δ = 0.24 (s, 9 H, 3CH3), 2.33 (s, 3 
H, CH3), 5.99 (s, 1 H, CH), 6.93-6.99 (m, 1 H, Ar), 7.01-7.04 (m, 1 H, Ar), 7.10-7.13 (m, 1 H, 
Ar), 7.66-7.72 (m, 1 H, Ar). 13C NMR (75 MHz, CDCl3): δ = 0.3, 0.4, 1.8, 22.2 (CH3), 101.4, 















To a stirred benzene solution (30 mL) 17k (2.1222 g, 10.0 mmol), 
triethylamine (2.24 mL, 16.0 mmol), trimethylchlorosilane (2.240 mL, 
18.0 mmol) was isolated 28k as yellowish oil (1.990 g , 70 %). 1H 
NMR (250 MHz, CDCl3): δ = 0.23 (s, 9 H, 3CH3), 2.80 (s, 3 H, CH3), 
6.44 (s, 1 H, CH), 7.69-7.71 (m, 1 H, Ar),  7.83-7.86 (m,  H, Ar), 7.99 
(dd, J=6.8 Hz, J=1.1 Hz, 1 H, Ar), 8.11 (m, 1 H, Ar), 8.15-8.19 (m, 1 
H, Ar), 8.46-8.54 (m, 1 H, Ar), 8.74-8.81 (m, 1 H, Ar). 13C NMR (75 MHz, CDCl3): δ = 0.4 
(3CH3), 21.9 (CH3), 109.4, 124.7, 125.7, 126.6, 126.8, 128.3, 130.0, 130.7 (CH), 133.4, 
133.7, 140.1, 171.0 (C), 194.3 (C=O).  
 
General procedure for the synthsis of flourenone 29a-c and 31a-f: Conc. sulfuric acid (12 
mL) was added to 29 ( 1.00 mmol) and the solution was stirred for 1 h. Then water was added 
and aqueous solution was extracted with CH2Cl2 (3 x 50 mL). The organic layers were dried 
(Na2SO4) and filtered, and the solvent was removed in vacuo. The residue was purified by 
chromatography (silica gel, n-heptane/EtOAc 30:1 → 20:1) to give 29 and 31. 
 
Methyl 2'-chloro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (29a):  
Starting with 4b (0.603 g, 2.2 mmol), 28g (0.535 g, 2.0 mmol) and 
TiCl4 (0.417 g, 2.2 mmol), 29a was isolated (0.190 g, 32%). 1H 
NMR (300 MHz, CDCl3): δ = 2.13 (s, 3 H, CH3), 2.20 (s, 3 H, 
CH3), 3.38 (s, 3 H, OCH3), 6.42 (s, 1 H, CHAr), 7.06-7.10 (m, 1 H, 
CHAr), 7.12-7.16 (m, 2 H, CH), 7.25-7.28 (m, 1 H, CHAr), 11.34 (s, 
1 H, OH) . 13C NMR (75 MHz, CDCl3): δ = 11.9, 20.9 (CH3), 52.5 
(OCH3), 109.5  (CAr), 124.1 (CHAr), 125.1 (CAr), 126.6, 128.3, 128.9, 130.2 (CHAr), 133.1, 
138.5, 142.4, 143.8 (CAr), 160.3 (COHAr), 171.9 (CO). IR (KBr, cm-1): ν~  = 2958 (s), 2870 
(m), 1655 (s), 1616 (m), 1503 (m), 1468 (m), 1415 (m), 1399 (m), 1246 (s), 1233 (s), 1097 
(m), 750 (s). GC-MS (EI, 70 eV): m/z (%) = 290 ([M+], 9), 255 (57), 240 (5), 223 (100), 195 














Ethyl 2'-chloro-4-ethyl-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (29b):  
 Starting with 4c (0.651 g, 2.2 mmol), 28g (0.535 g, 2.0 mmol) 
and TiCl4 (0.417 g, 2.2 mmol), 29b was isolated (0.224 g, 35%). 
1H NMR (300 MHz, CDCl3): δ = 0.66 (t, 3J = 7.5 Hz, 3 H, 
CH2CH3), 1.08 (t, 3J = 7.4 Hz, 3 H, OCH2CH3), 2.23 (s, 3 H, 
CH3), 2.58-2.79 (m, 2 H, CH2CH3), 3.81-3.91 (m, 2 H, 
OCH2CH3), 6.40 (s, 1 H, CHAr), 7.07-7.10 (m, 1 H, CHAr), 7.11-7.15 (m, 2 H, CH), 7.24-7.27 
(m, 1 H, CHAr), 11.47 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3): δ = 12.0 (CH2CH3), 18.4 
(OCH2CH3), 18.5 (CH3), 18.6 (CH2CH3), 59.8 (OCH2CH3), 108.3  (CAr), 122.8 , 126.7, 127.4, 
128.8, 129.5 (CHAr), 131.9, 137.3, 141.4, 141.5 (CAr), 158.9 (COHAr), 170.0 (COGC-MS (EI, 
70 eV): m/z (%) = 318 ([M+], 10), 283 (50), 272 (11), 255 (17), 237 (100), 165 (21), 152 (6). 
HRMS (EI): Calcd. for C18H19ClO3 : 318.10172; found: 318.102. 
 
Methyl 2'-fluoro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (29c):  
Starting with 4b (0.452 g, 1.65 mmol), 28h (0.412 g, 1.5 mmol) 
and TiCl4 (0.313 g, 1.65 mmol), 29c was isolated as a yellow solid 
(0.150 g, 32%). 1H NMR (300 MHz, CDCl3): δ = 2.13 (s, 3 H, 
CH3), 2.21 (s, 3 H, CH3), 3.43 (s, 3 H, OCH3), 6.51 (s, 1 H, CHAr), 
6.90-6.96 (m, 1 H, CHAr), 7.04-7.07 (m, 1 H, CHAr), 7.11-7.22 (m, 
2 H, CHAr), 11.27 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3): δ = 
11.5, 20.4 (CH3), 51.7 (OCH3), 109.3  (CAr), 114.4  (d, 2J = 21.9 Hz, CHAr), 123.6 (d, 3J = 3.9 
Hz, CHAr), 124.3 (CHAr), 124.8 (CAr), 128.6 (d, 3J = 7.8 Hz, CHAr), 130.1 (d, 3J = 3.9 Hz, 
CHAr), 130.8 (d, 2J = 8.5 Hz, CAr), 134.4, 143.4 (CAr), 159.7 (d, 1J = 240.9 Hz, CFAr ), 159.9 
(COHAr), 171.6 (CO). GC-MS (EI, 70 eV): m/z (%) = 274 ([M+], 45), 242 (100), 227 (58), 
213 (10), 199 (59), 183 (12), 170 (16). HRMS (EI): Calcd. for C16H15FO3 : 274.09997; found: 
274.09978. 
 
5-Chloro-1-hydroxy-2,3-dimethyl-9H-fluoren-9-one (30a):  
Conc. sulfuric acid (1.5 mL) and 29a (31 mg, 0.12 mmol) 30a 
was isolated  as yellow solid (25 mg, 80%).1H NMR (300 MHz, 
CDCl3): δ = 2.04 (s, 3 H, CH3), 2.22 (s, 3 H, CH3), 7.05-7:11 (m, 
1 H, CHAr), 7.26-7.29 (m, 2 H, CHAr), 7.41 (dd, 3J = 7.3 Hz, 4J = 
1.0 Hz, 1 H, CHAr), 8.65 (s, 1 H, OH) . 13C NMR (75 MHz, 

















129.4 (CAr), 135.6 (CHAr), 136.9, 138.9, 140.4, 147.3 (CAr), 156.0 (COHAr), 194.8 (CO). GC-
MS (EI, 70 eV): m/z (%) = 258 ([M+], 100), 243 (59), 215 (12), 195 (8), 176 (11), 165 (22), 
152 (14). HRMS (EI): Calcd. for C15H11ClO2 : 258.04421; found: 258.04370 
 
5-Chloro-2-ethyl-1-hydroxy-3-methyl-9H-fluoren-9-one (30b):  
Conc. sulfuric acid (301 mL) and 29b (80 mg, 0.30 mmol) 30b 
was isolated  as yellow solid (57 mg, 60%).1H NMR (300 MHz, 
CDCl3): δ = 1.04 (t, 3J = 7.8 Hz, 3 H, CH2CH3), 2.25 (s, 3 H, 
CH3), 2.54 (q, 3J = 7.3 Hz, 2 H, CH2CH3), 7.02-7.08 (m, 1 H, 
CHAr), 7.22-7.26 (m, 2 H, CHAr), 7.38 (dd, 3J = 8.0 Hz, 4J = 0.9 
Hz,1 H, CHAr), 8.61 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ 
= 13.1 (CH2CH3), 28.2 (CH2CH3), 20.1 (CH3), 115.2  (CAr), 119.2, 121.9, 129.3 (CHAr), 
129.5, 132.5 (CAr), 135.5 (CHAr), 137.0, 139.0, 140.2, 146.4 (CAr), 156.0 (COHAr), 194.8 
(CO). GC-MS (EI, 70 eV): m/z (%) = 272 ([M+], 40), 257 (100), 229 (7), 189 (4), 165 (15). 
HRMS (EI): Calcd. for C16H13ClO2 : 272.05986; found: 272.05940. 
 
5-Fluoro-1-hydroxy-2,3-dimethyl-9H-fluoren-9-one (30c):  
Conc. sulfuric acid (4.8 mL) and 29c (111 mg, 0.41 mmol) 30c 
was isolated  as yellow solid (50 mg, 51%). 1H NMR (300 MHz, 
CDCl3): δ = 2.04 (s, 3 H, CH3), 2.21 (s, 3 H, CH3), 6.88 (s, 1 H, 
CHAr), 7.00-7.18 (m, 2 H, CHAr), 7.29-7.32 (m, 1 H, CHAr), 
8.51 (s, 1 H, OH) . 13C NMR (62 MHz, CDCl3): δ = 10.6, 21.0 
(CH3), 114.7 (CAr), 118.6 (d, 4J = 4.1 Hz, CHAr), 119.7 (d, 4J = 3.4 Hz, CHAr), 122.2 (d, 2J 
= 19.6 Hz, CHAr), 125.9 (CAr), 129.7 (d, 2J = 17.6 Hz, CHAr), 130.2 (d, 3J = 5.9 Hz, 
CHAr), 137.3 (d, 3J = 4.4 Hz, CAr), 137.4 (CAr), 147.5 (CAr), 155.9 (COHAr), 157.6 (d, 1J 
= 253.5 Hz, CFAr), 195.0 (d, 4J = 2.6 Hz, CO. GC-MS (EI, 70 eV): m/z (%) = 242 ([M+], 
100), 227 (81), 213 (9), 199 (22), 183 (12), 170 (16). HRMS (EI): Calcd. for C15H11FO2 : 



















Conc. sulfuric acid (8.5 mL) and  26a (195 mg, 0.71 mmol) 31a was 
isolated  as yellow solid (70 mg, 40%). 1H NMR (300 MHz, 
CDCl3): δ = 2.27 (s, 3 H, CH3), 6.57 (s, 1 H, Ar), 7.18-7.25 (m, 1 H, 
Ar), 7.38-7.44 (m, 1 H, Ar), 7.55 (d, J = 7.2 Hz, 1 H, Ar), 8.03 (d, J 
= 7.6 Hz, 1 H, Ar), 8.43 (s, 1 H OH). 13C NMR (75 MHz, CDCl3): δ 
= 21.3 (CH3), 117.5 (C), 120.5 (CH), 122.0 (C), 124.4, 124.8, 129.6 (CH), 135.0 (C), 135.1 
(CH), 139.9, 143.3, 147.9. 156.0 (C), 195.2 (C=O). GC-MS (EI, 70 eV): m/z (%) = 246 ([M]+, 
[37Cl], 50), 244 ([M]+, [35Cl], 100), 216 (10), 181 (21), 152 (37), 126 (3), 90 (7), 76 (17). 
HRMS (EI): Calcd. for C14H9ClO2 ([M]+, [35Cl]): 244.02856; found: 244.02847.  
 
4-Chloro-1-hydroxy-2,3-dimethyl-9H-fluoren-9-one (31b): 
Conc. sulfuric acid (3.1 mL) and 26b (74 mg, 0.27 mmol) 31b was 
isolated as yellow solid (60 mg, 86%). 1H NMR (250 MHz, 
CDCl3): δ = 2.07 (s, 3 H, CH3), 2.22 (s, 3 H, CH3), 7.11-7.22 (m, 1 
H, Ar), 7.36-7.42 (m, 1 H, Ar), 7.50-7.53 (m, 1 H, Ar), 7.96-7.99 
(m, 1 H, Ar), 8.76 (s, 1 H OH). 13C NMR (62 MHz, CDCl3): δ = 
11.8, 17.1 (CH3), 116.0, 122.0 (C), 123.8, 124.1 (CH), 127.9 (C), 128.7 (CH), 134.3 (C), 
134.5 (CH), 136.5, 143.3, 144.9, 154.3 (C), 195.5 (C=O). GC-MS (EI, 70 eV): m/z (%) = 260 
([M]+, [37Cl], 50), 258 ([M]+, [35Cl], 100), 243 (12), 223 (29), 195 (11), 176 (9), 165 (27), 152 




Conc. sulfuric acid (2.31 mL) and 26e (57 mg, 0.19 mmol), 31c 
was isolated  as yellow solid (30 mg, 61%). 1H NMR (300 MHz, 
CDCl3): δ = 2.29 (s, 3 H, CH3), 6.58 (s, 1 H, Ar), 7.06-7.13 (m, 1 
H, Ar), 7.09 (dd, J = 7.2 Hz, J = 2.4 Hz, 1 H, Ar), 8.01-8.05 (m, 1 
H, Ar), 8.33 (s, 1 H OH). 13C NMR (75 MHz, CDCl3): δ = 19.9 
(CH3), 110.5 (CH), 116.3, 118.9 (C), 119.7, 120.4, 124.7 (CH), 135.9, 137.6, 137.9, 147.1, 
154.7 (C), 162.5 (d, 1J = 251.1 Hz, CF), 192.2 (C=O). GC-MS (EI, 70 eV): m/z (%) = 264 
([M]+, [37Cl], 50), 262 ([M]+, [35Cl], 100), 234 (15), 199 (13), 152 (7), 132 (7), 110 (8), 99 


















 Conc. sulfuric acid  (3.06 mL) and 26f (79 mg, 0.25 mmol), 
31d was isolated as yellow solid (38 mg, 55%). 1H NMR (300 
MHz, CDCl3): δ = 2.04 (s, 3 H, CH3), 2.19 (s, 3 H, CH3), 6.98-
7.05 (m, 1 H, Ar), 7.13-7.18 (m, 1 H, Ar), 7.85-7.89 (m, 1 H, 
Ar), 8.58 (s, 1 H OH). 13C NMR (75 MHz, CDCl3): δ = 9.8, 
15.2 (CH3), 109.6 (CH), 114.3 (C), 118.3 (CH), 119.6 (C), 
123.5 (CH), 125.8, 133.9, 134.8, 136.9, 148.4, 152.4 (C), 161.5 (d, 1J = 251.0 Hz, CF), 191.7 
(C=O). GC-MS (EI, 70 eV): m/z (%) = 278 ([M]+, [37Cl], 50), 276 ([M]+, 100), 261 (16), 241 
(31), 213 (12), 183 (25), 170 (11), 138 (6), 91 (7). HRMS (EI): Calcd. for C15H10ClFO2 ([M]+, 
[35Cl]): 276.03479; found: 276.03433.  
 
4,7-Dichloro-1-hydroxy-3-methyl-9H-fluoren-9-one (31e): 
Conc. sulfuric acid (3.3 mL) and 26h (85 mg, 0.27 mmol), 31e 
was isolated as yellow solid (65 mg, 84%). 1H NMR (300 
MHz, CDCl3): δ = 2.31 (s, 3 H, CH3), 6.63 (s, 1 H, Ar), 7.44 
(dd, J = 8.1 Hz, J = 2.1 Hz, 1 H, Ar), 7.53 (m, 1 H, Ar), 8.00 
(d, J = 8.0 Hz, 1 H, Ar), 8.35 (s, 1 H OH). 13C NMR (75 MHz, 
CDCl3): δ = 21.3 (CH3), 117.4 (C), 120.8 (CH), 122.2 (C), 124.7, 125.8, 135.4 (CH), 135.9, 
136.6, 139.2, 141.4, 148.5, 156.2 (C), 193.7 (C=O). GC-MS (EI, 70 eV): m/z (%) = 282 
([M]+, [2x37Cl], 15), 280 ([M]+, [37Cl], [35Cl], 65), 278 ([M]+, [2x35Cl] 100), 251 (11), 215 
(12), 186 (24), 152 (57), 137 (8/), 123 (12) 107 (21), 93 (17), 75 (9). HRMS (EI): Calcd. for 
C14H8Cl2O2 ([M]+, [2x35Cl]): 277.98959; found: 277.98973.  
 
4,7-Dichloro-1-hydroxy-2,3-dimethyl-9H-fluoren-9-one (31f): 
Conc. sulfuric acid   (2.76 mL) and 26i (74 mg, 0.23 mmol), 
31f was isolated  as yellow solid (50 mg, 74%). 1H NMR (300 
MHz, CDCl3): δ = 2.11 (s, 3 H, CH3), 2.27 (s, 3 H, CH3), 7.36 
(dd, J = 8.1 Hz, J = 2.1 Hz, 1 H, Ar), 7.49-7.50 (m, 1 H, Ar), 
7.94-7.97 (m, 1 H, Ar), 8.58 (s, 1 H OH). 13C NMR (75 MHz, 
















(CH), 128.8 (C), 134.4 (C), 135.3, 136.3, 136.5, 141.8, 145.9, 154.9 (C), 194.4 (C=O).GC-
MS (EI, 70 eV): m/z (%) = 296 ([M]+, [2x37Cl], 15),294 ([M]+, [37Cl], [35Cl], 65), 292 ([M]+, 
[2x35Cl], 277 (10), 257 (15), 229 (9), 199 (5), 165 (11), 150 (6), 111 (7), 82 (10). 
 
General procedure for synthesis of Aryl-1,3-Bis(silylenol ehters) (32a-l): 
The reaction was carried out analogously to a known procedure. To a stirred THF solution (30 
mL) of LDA (36 mmol, 1.5 equiv) was added 28 ( 7.788 g, 24.0 mmol) at -78 °C. After the 
solution was stirred for 1 h, trimethylchlorosilane (4.548 mL, 36 mmol) was added. The 
solution was allowed to warm to room temperature during 12 h with stirring. The solvent was 
removed in vacuo, and to the residue was added hexane (100 mL) to give asuspension. The 
latter was filtered under argon atmosphere. The filtrate was distilled in vacuo to give 32.The 
compounds were used directly after there preparation.  
 
4-(4-fluorophenyl)-2,2,8,8-tetramethyl-6-methylene-3,7-dioxa-2,8-disila-4-nonene (32b): 
To a stirred THF solution (30 mL) of LDA (36 mmol, 1.5 
equiv), 28b ( 7.788 g, 24.0 mmol), trimethylchlorosilane 
(4.548 mL, 36 mmol) 32b was isolated a dark red oil (6.490 
g, 83 %): The compound was used directly after its 
preparation. 1H NMR (250 MHz, CDCl3): δ = 0.01-0.09 (m, 9 H, 3CH3), 0.12 (m, 9 H, 3CH3), 
4.36-4.37 (m, 1 H, CH2), 4.79-4.81 (m, 1 H, CH2), 5.30-5.31 (s, 1 H, CH), 6.78-6.87 (m, 2 H, 
Ar), 7.30-7.34 (m, 2 H, Ar). 13C NMR (75 MHz, CDCl3): δ = 0.3, (3CH3), 0.8 (3CH3), 95.8 
(CH2), 109.1 (CH), 114.9 (2CH), 128.0 (2CH), 135.5, 150.0, 152.8, 161.1(C). 
 
2,2,8,8-tetramethyl-6-methylene-4-(2-methylphenyl)-3,7-dioxa-2,8-disila-4-nonene (32d): 
To a stirred THF solution (25 mL) of LDA (30 mmol, 1.5 
equiv), 28d (4.967 g, 20.0 mmol), trimethylchlorosilane (3.789 
mL, 30.0 mmol) 32d was isolated as a dark red oil (4.808 g, 75 
%): The compound was used directly after its preparation.1H 
NMR (250 MHz, CDCl3): δ = 0.13-0.20 (s, 9 H, 3CH3), 0.31-0.36 (s, 9 H, 3CH3), 2.50  (s, 3 
H, CH3), 4.59-4.60 (m, 1 H, CH2), 5.11 (m, 1 H, CH2), 5.12-5.18 (s, 1 H, CH), 7.24-7.25 (m, 
1 H, Ar), 7.27 (m, 1 H, Ar), 7.28-7.30 (m, 1 H, Ar), 7.32-7.38 (m, 1 H, Ar). 13C NMR (75 
MHz, CDCl3): δ = 0.4, (3CH3), 0.5 (3CH3), 20.2 (CH3) ,95.1 (CH2), 111.1, 125.5, 128.4, 








(32e): To a stirred THF solution (21.6 mL) of LDA (26 mmol, 
1.3 equiv), 28e (5.284 g, 20.0 mmol), trimethylchlorosilane 
(3.789 mL, 30.0 mmol) 32e was isolated  as a reddish yellow 
oil (4.70 g, 70%): The compound was used directly after its 
preparation. 1H NMR (250 MHz, CDCl3): δ = 0.16 (s, 9 H, 
3CH3), 0.35 (s, 9 H, 3CH3), 3.79 (s, 3 H, OCH3), 4.60 (d, J=1.7 Hz, 1 H, CH2), 5.14 (s, 1 H, 
CH2), 5.39 (d, J=1.7 Hz, 1 H, CH2),  6.96-7.00 (m, 1 H, Ar), 7.02-7.06 (m, 1 H, Ar), 7.35-7.39 
(m, 1 H, Ar), 7.42-7.45 (m, 1 H, Ar). 13C NMR (75 MHz, CDCl3): δ = 0.5, 0.6, 0.7, 0.8, 0.9, 
2.3 (CH3), 55.6 (OCH3), 95.6 (CH2), 111.5, 111.8, 120.6, 129.9, 130.6 (CH), 131.4, 132.4, 
149.8, 153.0 (C). 
 
4-(2-fluorophenyl)-2,2,8,8-tetramethyl-6-methylene-3,7-dioxa-2,8-disila-4-nonene (32g): 
To a stirred THF solution (25 mL) of LDA (30 mmol, 1.5 
equiv), 28g (5.046 g, 20.0 mmol), trimethylchlorosilane (3.789 
mL, 30.0 mmol) 32g was isolated as a dark red oil (4.868 g, 75 
%): The compound was used directly after its preparation. 1H 
NMR (250 MHz, CDCl3): δ = 0.19-0.20 (s, 9 H, 3CH3), 0.34-0.37 (s, 9 H, 3CH3), 4.61-4.63 
(m, 1 H, CH2), 5.10-5.11 (m, 1 H, CH2), 5.54-5.55 (s, 1 H, CH), 7.01-7.17 (m, 1 H, Ar), 7.19-
7.22 (m, 1 H, Ar), 7.31-7.38 (m, 1 H, Ar), 7.51-7.56 (m, 1 H, Ar). 13C NMR (75 MHz, 
CDCl3): δ = 0.3, (3CH3), 0.6 (3CH3), 96.4 (CH2), 113.0, 116.2, 123.8, 127.4, 130.0 (CH), 
146.1, 152.6, 157.9 161.1 (C). 
 
4-(5,8-dihydro-1-naphthalenyl)-2,2,8,8-tetramethyl-6-methylene-3,7-dioxa-2,8-disila-4-
nonene(32k): To a stirred THF solution (8.75 mL) of LDA (10.5 
mmol, 1.5 equiv) 28k (1.990 g, 10.0 mmol), trimethylchlorosilane 
(1.062 mL, 10.5 mmol) 32k was iosolated as a dark yellow viscos 
(1.7828 g, 71.4 %): The compound was used directly after its 
preparation. 1H NMR (250 MHz, CDCl3): δ = 0.28 (s, 9 H, 3CH3), 
0.66 (s, 9 H, 3CH3), 4.94 (m, 1 H, CH2), 5.51 (s, 1 H, CH2), 5.68 (m, 1 H, CH2),  7.85-7.86 
(m, 2 H, Ar), 7.89-7.92 (m, 2 H, Ar), 8.19-8.23 (m, 2 H, Ar), 8.64-8.67 (m, 1 H, Ar). 13C 
NMR (75 MHz, CDCl3): δ = 0.4 (3CH3), 0.6 (3CH3), 95.3 (CH2), 112.0, 126.0, 126.3, 126.6, 









General procedure 1 (synthesis of benzophenones) 34a-s: 
To 3-formylchromone 33 (1.0 equiv.) was added Me3SiOTf (0.3 equiv.) at 20 °C. After 
stirring for 10 min CH2Cl2 (8 mL) was added, the solution was cooled to 0 °C and the 1,3-bis-
silyl enol ether 32 (1.3 equiv.) was added. The mixture was stirred for 12 h at 20 °C and was 
subsequently poured into an aqueous solution of hydrochloric acid (10%). The organic and 
the aqueous layer were separated and the latter was extracted with CH2Cl2 (3 x 80 mL). The 
combined organic layers were washed with water, dried (Na2SO4), filtered and the filtrate was 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, n-




Starting with 33a (188 mg 1.0 mmol), Me3SiOTf (66 
mg, 0.3 mmol) and 1,3-bis-silyl enol ether 32a (398 
mg, 1.3mmol), 34a was isolated as a yellow viscous 
oil (118 mg, 34%). 1H NMR (300 MHz, CDCl3): δ = 
2.19 (s, 3 H, CH3), 6.85 (d, J = 8.2 Hz, 1 H, CHAr), 7.09 (d, J = 8.7 Hz, 1 H, CHAr), 7.16-7.26 
(m, 2 H, CHAr), 7.41-7.44 (m, 2 H, CHAr), 7.48-7.53 (m, 1 H, CHAr), 7.60-7.63 (m, 2 H, 
CHAr), 7.81 (dd, J = 8.7 Hz, J = 2.1 Hz, 1 H, CHAr), 7.94-7.95(m, 1 H, CHAr), 11.47 (s, 1 H, 
OH), 12.35 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 19.5 (CH3), 95.6 (C), 117.3 
(CHAr), 117.4, 117.63 (CAr), 117.66, 125.9 (CHAr), 126.7 (C), 127.5 (CHAr), 127.7 (CAr), 
128.0 (CH), 131.2 (C), 131.3, 131.5, 136.0, 136.1, 136.2 (CH), 159.9, 165.2 (C), 197.7, 200.2 
(C=O). IR (neat): ~ν  = 3061 (m), 3038 (m), 2959 (s), 2924 (s), 1630 (s), 1590 (s), 1480 (s), 
1486 (m), 1408 (m), 1423 (m), 1350 (s), 1290 (s), 1256 (s), 1135 (m), 978 (m), 924 (w), 826 
(s), 791 (s), 636 (m) cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = .221 (4.33), 257 (4.17), 340 
(3.69). GC-MS (CI, 70 eV): m/z (%) = 333 ([M+1]+, 100), 285 (10), 257 (10), 225 (10), 189 
(10), 93 (20). HRMS (CI): Calcd. for C21H17O4 ([M+1]+): 333.1121; found: 333.1116.  
 
(3-Benzoyl-4-hydroxyphenyl)-(2-hydroxy-5-isopropylphenyl)methanone (34b): 
Starting with 33b (147 mg, 0.67 mmol), 
Me3SiOTf (39 mg, 0.18 mmol) and 1,3-bis-silyl 
enol ether 32a (270 mg, 0.83 mmol), 34b was 
isolated as a yellow viscous oil (81 mg, 37%). 









6.96 (d, J = 8.3 Hz, 1 H, CHAr), 7.13 (d, J = 8.7 Hz, 1 H, CHAr), 7.27-7.31 (m, 2 H, CHAr), 
7.40-7.45 (m, 2 H, CHAr), 7.49-7.54 (m, 1 H, CHAr), 7.60-7.61 (m, 1 H, CHAr), 7.62-7.63 (m, 
1 H, A CHAr), 7.84 (dd, J = 8.7 Hz, J = 2.1 Hz, 1 H, CHAr), 8.01(m, 1 H, CHAr), 11.55 (s, 1 H, 
OH), 12.44 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ =24.3 (2CH3 ), 33.6 (CH ), 118.8, 
(CHAr), 118.9, 119.0 (CAr), 129.0 (2CHAr), 129.0 (2CAr), 129.3 (2CHAr), 130.3, 132.8, 135.0, 
136.2 (CHAr), 137.5 (CAr), 137.6 (CHAr), 139.4 (CAr), 161.5, 166.8 (CAr), 199.1, 201.8 (C=O). 
IR (KBr): ~ν  = 2958 (m), 2922 (m), 2856 (w), 1632 (s), 1598 (s), 1481 (m), 1445 (w), 1355 
(s), 1288 (m), 1255 (s), 1115 (w), 981 (w), 949 (w), 840 (w), 794 (m), 635 (w) cm-1. UV-Vis 
(nm, CH3CN): λmax (lg ε) = 218 (4.50), 263 (4.47), 341 (3.95). GC-MS (EI, 70 eV): m/z (%) = 
360 ([M]+, 75), 345 (20), 281 (11), 225 (10), 197 (11), 172 (10), 163 (43) 147 (100), 101 (6), 
77 (20), 51 (4). HRMS (EI): Calcd. for C23H20O4 ([M]+): 360.1356; found: 360.1345.  
(3-Benzoyl-4-hydroxyphenyl)-(2-hydroxy-3,5-dimethylphenyl)methanone (3c): 
Starting with 33c (139 mg, 0.6 mmol), Me3SiOTf (39 
mg, 0.18 mmol) and 1,3-bis-silyl enol ether 32a (239 
mg, 0.78 mmol), 34c was isolated as a yellow solid 
(70 mg, 31%), m.p. = 116-118 °C. 1H NMR (300 
MHz, CDCl3): δ = 2.86 (br s, 6 H, CH3), 7.07 (s, 1 H, 
CHAr), 7.10 (m, 2 H, CHAr), 7.39-7.43 (m, 2 H, CHAr), 7.47 - 7.53 (m, 1 H, CHAr), 7.60-7.63 
(m, 2 H, CHAr), 7.80 (dd, J = 8.5 Hz, J = 1.9 Hz, 1 H, CHAr), 7.93 (m, 1 H, CHAr), 11.77 (s, 1 
H, OH), 12.34 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 14.5, 19.5 (CH3), 116.9, 117.3, 
(CAr), 117.5, 125.9 (CHAr), 126.0, 126.3 (CAr), 127.5, 128.0 (CHAr), 128.1 (2CAr), 129.0, 
131.2, 131.4, 134.6, 136.1, 137.2 (CHAr), 158.0, 165.1 (CAr), 198.0, 200.2 (C=O). IR (KBr): 
~ν  = 2960 (m), 2923 (m), 2867 (w), 1633 (s), 1597 (s), 1433 (m), 1445 (w), 1355 (s), 1318 
(w), 1288 (s), 1256 (s), 1215 (s), 1139 (m), 1049 (w), 795 (s) cm-1. UV-Vis (nm, CH3CN): 
λmax (lg ε) = 218 (4.51), 262 (4.40), 340 (4.00). GC-MS (EI, 70 eV): m/z (%) = 346 ([M]+, 
56), 148 (100), 120 (36), 105 (14), 91 (12), 77 (26), 65 (4). HRMS (EI): Calcd. for C22H18O4 
([M]+):346.1199; found: 346.1202.  
 
[3-(4-Fluorobenzoyl)-4-hydroxyphenyl]-(2-hydroxy-5-isopropylphenyl)methanone (34d): 
Starting with 33b (216 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-
silyl enol ether 32b (421 mg, 1.3 mmol), 
34d was isolated as a yellow solid (115 mg, 










2.72 (m, 1 H, CH), 6.92 (d, J = 8.4 Hz, 1 H, CHAr), 7.08-7.13 (m, 3 H, CHAr), 7.26 (m, 1 H, 
CHAr), 7.30 (dd, J = 8.5 Hz, J = 2.5 Hz, 1 H, CHAr) , 7.64-7.69 (m, 2 H, CHAr), 7.84 (dd, J = 
8.5 Hz, J = 2.1 Hz, 1 H, CHAr), 7.97-7.98 (m, 1 H, CHAr), 11.52 (s, 1 H, OH), 12.28 (s, 1 H, 
OH). 13C NMR (75 MHz, CDCl3): δ = 22.9 (2CH3), 32.7 (CH), 114.8, 115.1, 117.4, 117.6 
(CHAr), 127.8, (CAr), 128.8, 130.6, 130.7 (CHAr), 132.2, 132.3 (CAr), 133.7, 134.4, 136.2 
(CHAr), 138.0, 160.1, 162.5, 165.2, 165.9 (CAr), 197.5, 198.6 (C=O). IR (neat): ~ν  = 3062 (w), 
2959 (m), 2871 (m), 1635 (w), 1472 (w), 1201 (w), 1158 (m), 1110 (m), 1073 (m), 871 (m), 
852 (m), 793 (m), 638 (m) cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = 218 (4.65), 263 (4.50), 
340 (4.12). MS (EI, 70 eV): m/z (%) = 378 ([M]+ , 47), 363 (12), 162 (43), 147 (100), 123 
(11), 91 (13), 69 (7), 57 (6). HRMS (EI): Calcd. for C23H19O4F: 378.1262; found: 378.1257.  
 
(5-Chloro-2-hydroxyphenyl)-[3-(4-fluorobenzoyl)-4-hydroxyphenyl]methanone (34e): 
Starting with 33d (208 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-silyl 
enol ether 32b (421 mg, 1.3 mmol), 34e was 
isolated as a yellow viscous oil (101 mg, 27%). 
1H NMR (300 MHz, CDCl3): δ = 6.95(d, J = 8.7 Hz, 1 H, CHAr), 7.06-7.09 (m, 1 H, CHAr), 
7.11-713 (m, 1 H, CHAr), 7.17 (d, J = 7.1 Hz, 1 H, CHAr), 7.38 (dd, J = 8.7 Hz, J = 2.5 Hz, 1 
H, CHAr), 7.49-7.50 (m, 1 H, CHAr), 7.63-7.68, (m, 1 H, CHAr), 7.72-7.75 (m, 1 H, CHAr), 
7.84 (dd, J = 8.6 Hz, J = 2.1 Hz, 1 H, CHAr), 7.96-7.97 (m, 1 H, CHAr), 11.51 (s, 1 H, OH), 
12.39 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 113.5, 113.9 (CH), 117.5 (CAr), 118.0 
(CHAr), 118.5 (CAr), 119.2 (2CHAr), 122.3, 126.9, 127.4 (CAr), 131.7 (2CHAr), 134.7, 135.05 
(CHAr), 135.08 (CAr), 135.9 (CHAr), 160.3, 165.6 (CAr), 195.5, 199.1 (C=O). IR (KBr): ~ν  = 
2960 (w), 2925 (w), 1626 (s), 1581 (s), 1468 (m), 1255 (s), 1217 (s), 841 (s), 796 (m) cm-1. 
UV-Vis (nm, CH3CN): λmax (lg ε) = 218 (4.30), 259 (4.06), 338 (3.64). MS (CI, 70 eV): m/z 
(%) = 373 ([M+1]+, [37Cl], 10), 371 ([M+1]+, [35Cl], 20), 342([37Cl], 14), 340 ([35Cl], 28), 285 
(18), 229 (20), 177 (100), 111 (8), 85 (12), 69 (20). HRMS (CI): Calcd. for C20H12O4ClF 
([M+1]+, 35Cl): 371.3142; found: 371.3143.  
 
(5-Bromo-2-hydroxyphenyl)-[3-(4-fluorobenzoyl)-4-hydroxyphenyl]methanone (34f): 
Starting with 33e (253 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3mmol) and 1,3-bis-silyl 
enol ether 32b (421 mg, 1.3 mmol), 34f was 








118-120 °C. 1H NMR (300 MHz, CDCl3): δ = 6.89 (d, J = 8.9 Hz, 1 H, CHAr), 7.14-7.19 (m, 
3 H, CHAr), 7.50 (dd, J = 8.9 Hz, J = 2.4 Hz, 1 H, CHAr), 7.65 (m, 1 H, CHAr), 7.67-7.72 (m, 2 
H, CHAr), 7.86 (dd, J = 8.5 Hz, J = 2.1 Hz, 1 H, CHAr), 7.90-7.91 (m, 1 H, CHAr), 11.50 (s, 
1H, OH), 12.33 (s, 1H, OH). 13C NMR (75 MHz, CDCl3): δ = 110.6 (CAr), 116.3, 116.6 
(CHAr), 118.5 (CAr), 119.8 (CHAr), 120.6 (CAr), 121.1 (CHAr), 128.3 (CAr), 132.1, 132.2 
(CHAr), 133.4, 133.5 (CAr), 135.0, 136.0, 137.5, 139.2 (CHAr), 162.2, 167.1 (CAr), 197.9, 
199.8 (C=O). IR (KBr): ~ν  = 3069 (w), 2956 (m), 2900 (w), 1627 (s), 1585 (s), 1466 (s), 1341 
(m), 1287 (m), 1253 (s), 1213 (s), 1072 (m), 843 (s), 610 (w) cm-1. UV-Vis (nm, CH3CN): 
λmax (lg ε) = 218 (4.30), 259 (4.06), 338 (3.64). MS (EI, 70 eV): m/z (%) = 416 ([M]+, [81Br], 
100), 414 ([M]+, [79Br], 100),  319 (7), 243 (12), 216 ([81Br], 80), 214 ([79Br], 80),  200 
([81Br], 96), 198 ([79Br], 96), 172 (10), 147 (67), 123 (75), 95 (55), 57 (25). HRMS (EI): 
Calcd. for C20H12O479BrF ([M]+, 81Br): 413.9897; found: 413.9897.  
 
(5-Ethyl-2-hydroxyphenyl)-[3-(4-fluorobenzoyl)-4-hydroxyphenyl]methanone (34g):  
Starting with 33f (202 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-
silyl enol ether 32b (421 mg, 1.3 mmol), 34g 
was isolated as yellow viscous (135 mg, 
37%). 1H NMR (300 MHz, CDCl3): δ = 1.06 (t, J = 7.6 Hz, 3 H, CH3), 2.48 (q, J = 7.8 Hz, 2 
H, CH2), 6.89-6.92 (m, 1 H, CHAr), 7.09-7.14 (m, 3 H, CHAr), 7.25-7.29 (m, 2 H, CHAr), 7.65-
7.70 (m, 2 H, CHAr), 7.82-7.85 (m, 1 H, CHAr), 7.95-7.96 (m, 1 H, CHAr), 11.50 (s, 1H, OH), 
12.24 (s, 1H, OH). 13C NMR (75 MHz, CDCl3): δ =  16.9 (CH3), 29.2 (CH2), 116.2, 116.5 
(CHAr),  118.8 (CAr), 118.9, 119.0 (CHAr), 129.2 (2CHAr), 131.6, 132.1 (CAr), 132.2 (CHAr), 
133.6 (CAr), 134.7 (2CHAr), 135.7 (CHAr), 136.6, 137.6, 161.5, 166.5 (CAr), 199.0, 200.0 
(C=O). IR (neat): ~ν  = 3063 (w), 2964 (m), 2930 (m), 2872 (w), 1631 (s), 1599 (s), 1481 (s), 
1409 (w), 1351 (s), 1292 (s), 1255 (s), 1214 (s), 1157 (s), 1073 (w), 882 (w), 844 (s), 612 (w) 
cm-1. MS (CI, 70 eV): m/z (%) = 365 ([M+1]+, (100), 340 (10), 303 (7), 243 (8), 177 (20), 149 












Starting with 33e (253 mg, 1.0 mmol), Me3SiOTf 
(66 mg, 0.3 mmol) and 1,3-bis-silyl enol ether 32d 
(416 mg, 1.3 mmol), 34h was isolated as a yellow 
solid (160 mg, 39%), m.p. = 119-121 °C. 1H NMR 
(300 MHz, CDCl3): δ = 2.25 (s, 3 H, CH3), 6.84 (d, J = 8.7 Hz, 1 H, CHAr), 7.13 (d, J = 7.7 
Hz, 1 H, CHAr), 7.17 (m, 1 H, CHAr), 7.25-7.26 (m, 1 H, CHAr), 7.28 (m, 1 H, CHAr), 7.30-
7.33 (m, 1 H, CHAr), 7.44 (dd, J = 8.9 Hz, J = 2.5 Hz, 1 H, CHAr), 7.52-7.53 (m, 1 H, CHAr), 
7.64-7.65 (m, 1 H, CHAr), 7.83 (dd, J = 8.5 Hz, J = 2.3 Hz, 1 H, CHAr), 11.54 (s, 1 H, OH), 
12.68 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 20.5 (CH3), 110.5, 119.4 (CAr), 119.6 
(CHAr), 120.5 (CHAr), 121.0, 126.0, 127.8 (CHAr), 128.3 (CAr), 131.2, 131.7, 134.9 (CHAr), 
136.2, 136.5, 136.9 (CAr), 137.8, 139.1 (CHAr), 162.2, 167.2 (CAr), 197.8, 204.4 (C=O). IR 
(KBr): ~ν  = 3431 (w), 3064 (w), 3022 (w), 2957 (w), 2924 (w), 2854 (w), 1632 (s), 1597 (s), 
1463 (s), 1381 (m), 1319 (s), 1255 (s), 1237 (m), 1209 (s), 1101 (w), 992 (w), 931 (m), 769 
(m), 769 (s), 708 (w), 652 (w) cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = 252 (4.52), 330 
(4.18). MS (EI, 70 eV): m/z (%) = 412 ([M]+, [81Br], 52), 410 ([M]+, [79Br], 51), 397 ([81Br], 
16), 395 ([79Br], 17), 340 (2), 267 (15), 237 (11), 211 (100), 199 ([81Br], 33), 197 ([79Br], 31), 
194 (22), 161 (10), 147 (22), 119 (52), 91 (63), 69 (22). HRMS (EI): Calcd. for C21H15O4Br 
([M]+, 79Br): 410.0148; found: 410.0140.  
 
(2-Hydroxy-5-isopropylphenyl)-[4-hydroxy-3-(2-methylbenzoyl)phenyl]methanone (34i): 
Starting with 33b (216 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-silyl 
enol ether 32d (416 mg, 1.3 mmol), 34i was 
isolated as a yellow solid (105 mg, 28%), m.p. 
= 138-140 °C. 1H NMR (300 MHz, CDCl3): δ = 1.04 (d, J = 7.1 Hz, 6 H, CH3), 2.26 (s, 3 H, 
CH3), 2.61-2.75 (m, 1 H, CH), 6.88 (d, J = 8.5 Hz, 1 H, CHAr), 7.12 (d, J = 8.7 Hz, 1 H, 
CHAr), 7.17 (m, 1 H, CHAr), 7.18-7.19 (m, 2 H, CHAr), 7.22 (s, 1 H, CHAr), 7.24-7.25 (m, 1 H, 
CHAr), 7.27-7.31 (m, 1 H, CHAr), 7.68 (m, 1 H, CHAr) 7.84 (dd, J = 8.5 Hz, J = 2.1 Hz, 1 H, 
CHAr), 11.56 (s, 1 H, OH), 12.65 (s, 1 H, OH). 13C NMR (75.5 MHz, CDCl3): δ = 20.0 (CH3), 
24.3 (2CH3), 33.6 (CH), 118.8, 119.2 (CHAr), 119.5 (CAr), 125.9, 127.7 (CHAr), 129.3 (CAr), 
130.3, 131.0, 131.6, 135.0 (CHAr), 135.1, 136.0 (CAr), 136.2 (CHAr), 137.2 (CAr), 138.1 
(CHAr), 139.4, 161.6, 166.8 (CAr), 199.0, 204.6 (C=O). IR (KBr): ~ν  = 3430 (w), 3055 (w), 










1256 (s), 1211 (s), 1140 (w), 1118 (w), 1097 (w), 981 (w), 900(w), 846 (w), 794 (s), 636 (m) 
cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = 255 (4.20), 339 (3.80). MS (EI, 70 eV): m/z (%) = 
374 ([M]+, 78), 359 (19), 316 (3), 139 (5), 211 (16), 172 (8), 163 (48), 162 (46), 147 (100), 
119 (10), 97 (8), 91 (26), 83 (10), 69 (18), 57 (16). HRMS (EI): Calcd. for C24H22O4 ([M]+): 
374.1513; found: 374.1505.  
 
[4-Hydroxy-3-(2-methoxybenzoyl)phenyl]-(2-hydroxy-5-methylphenyl)methanone (3j): 
Starting with 33a (188 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-silyl 
enol ether 32e (437 mg, 1.3 mmol), 34j was 
isolated as a yellow viscous oil (131 mg, 36%). 
1H NMR (300 MHz, CDCl3): δ = 2.15 (s, 3 H, CH3), 3.72 (s, 3 H, OCH3), 6.84-6.88 (m, 1 H, 
CHAr), 6.96 (d, J = 8.5 Hz, 1 H, CHAr), 7.01 (dd, J = 7.6 Hz, J = 1.5 Hz, 1 H, CHAr), 7.08 (d, J 
= 8.8 Hz, 1 H, CHAr), 7.18-7.27 (m, 3 H, CHAr), 7.41 (ddd, J= 8.5 Hz, J = 8.5 Hz, J = 1.8 Hz, 
1 H, CHAr), 7.73 (m, 1H, CHAr), 7.80 (dd, J = 8.8 Hz, J = 2.1 Hz, 1 H, CHAr), 11.54 (s, 1 H, 
OH), 12.53 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 20.9 (CH3), 56.2 (OCH3), 112.2, 
118.6, 118.7 (CHAr), 119.0, 120.0 (CAr), 121.1 (CHAr), 127.3, 128.0, (CAr), 129.1 (CHAr), 
132.7, (CAr), 132.8, 132.9, 136.5, 137.5, 137.7 (CHAr), 157.0, 161.2, 166.2 (CAr), 199.0, 202.3 
(C=O). IR (neat): ~ν  = 2957 (s), 2934 (s), 2853 (s), 1731 (m), 1670 (w), 1603 (s), 1491 (s), 
1446 (s), 1464 (s), 1363 (m), 1286 (m), 1258 (s), 1184 (m), 1163 (m), 1079 (m), 1024 (m), 
847 (w), 754 (m), 647 (w) cm-1. MS (EI, 70 eV): m/z (%) = 362 ([M]+, 71), 347 (5), 331 (27), 
227 (18), 197 (23), 167 (8), 149 (23), 135 (100), 77 (18), 57 (14), 43 (12). HRMS (EI): Calcd. 
for C22H18O5 ([M]+): 362.1149; found: 362.1139.  
  
(5-Chloro-2-hydroxyphenyl)-[4-hydroxy-3-(2-methoxybenzoyl)phenyl]methanone (34k): 
Starting with 33d (208 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-silyl 
enol ether 32e (437 mg, 1.3 mmol), 34k was 
isolated as a yellow viscous oil (121 mg, 34%). 
1H NMR (300 MHz, CDCl3): δ = 3.85 (s, 3 H, OCH3), 6.92 (d, J = 8.9 Hz, 1 H, CHAr), 6.97 
(d, J = 8.4 Hz, 1 H, CHAr), 7.11 (d, J = 8.8 Hz, 1 H, CHAr), 7.19 (s, 1 H, CHAr), 7.26 (dd, J = 
7.5 Hz, J = 2.5 Hz, 1 H, CHAr), 7.34 (dd, J = 8.9 Hz, , J = 2.6 Hz 1 H, CHAr), 7.39-7.45 (m, 2 
H, CHAr), 7.70-7.71 (m, 1 H, CHAr), 7.83 (dd, J= 8.7 Hz, J = 2.3 Hz, 1 H, CHAr), 11.60 (s, 1 












117.9, 118.6 (CAr), 119.1, 119.9 (CHAr), 122.2 (CAr), 125.8 (CHAr), 126.8 (CAr), 127.7 
(2CHAr), 130.5 (CAr), 131.6, 134.9, 135.2, 136.1 (CHAr), 155.6, 160.4, 165.3 (CAr), 196.6, 
200.8 (C=O). IR (KBr): ~ν  = 3433 (w), 2960 (s), 2924 (s), 2853 (s), 1634 (s), 1590 (m), 1465 
(m), 1433 (w), 1354 (m), 1281 (w), 1260 (s), 1100 (s), 1019 (s), 802 (s), 754 (w), 637 (w) cm-
1. UV-Vis (nm, CH3CN): λmax (lg ε) = 218 (4.20), 256 (3.97), 337 (3.32). MS (EI 70 eV): m/z 
(%) = 384 ([M]+, [37Cl], 37), 382 ([M]+, 35Cl], 92), 367 (22), 353 ([37Cl], 51), 351, ([35Cl], 
100), 249 ([37Cl], 51), 247, ([35Cl], 24), 210 (32), 197  (96), 157 ([37Cl], 19), 155 ([35Cl], (68), 
147 (44), 135 (86), 108 (64), 97 (32), 83 (32), 77 (43), 57 (57), 43 (12). HRMS (EI): Calcd. 
for C21H15O5Cl ([M]+, 35Cl): 382.0602; found: 382.0602.  
  
(5-Bromo-2-hydroxyphenyl)[4-hydroxy-3-(2-methoxybenzoyl)phenyl]methanone (34l):  
Starting with 33e (253 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-silyl 
enol ether 32e (437mg, 1.3 mmol), 33l was 
isolated as yellow solid (163 mg, 38%), m.p. = 
151-152 °C. 1H NMR (250 MHz, CDCl3): δ = 3.78 (s, 3 H, OCH3), 6.86 (d, J = 8.5 Hz, 1 H, 
CHAr), 6,96-6.99 (m, 2 H, CHAr), 7.10 (d, J = 8.5 Hz, 1 H, CHAr), 7.26 (dd, J = 7.6 Hz, J = 1.9 
Hz, 1 H, CHAr), 7.38-7.48 (m, 2 H, CHAr), 7.55-7.56 (m, 1 H, CHAr), 7.70-7.71(m, 1 H, 
CHAr), 7.81 (dd, J = 7.4 Hz, J = 2.1 Hz, 1 H, CHAr), 11.61 (s, 1 H, OH), 12.59 (s, 1 H, OH). 
13C NMR (75 MHz, CDCl3): δ = 56.4 (OCH3), 110.0 (CAr), 112.4, 119.2 (CHAr), 119.9, 120.6 
(CAr), 120.9, 121.3 (CHAr), 127.1, 128.2 (CAr), 129.1, 133.0, 134.9, 136.6, 137.5, 139.1 
(CHAr), 157.0, 162.2, 166.7 (CAr), 198.0, 202.2 (C=O). IR (KBr): ~ν  = 3441 (m), 2958 (m), 
2923 (s), 2852 (m), 1637 (s), 1596 (s), 1480 (m), 1464 (s), 1431 (w), 1342 (m), 1320 (s), 1285 
(s), 1160 (w), 1102 (m), 1024 (m), 839 (w), 795 (s) cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = 
218 (3.90), 255 (3.64), 336 (3.19). MS (EI, 70 eV): m/z (%) = 428 ([M]+ , [81Br], 62), 426 
([M]+ , [79Br], 60), 397 [81Br], 81), 395 ([79Br], 82), 293 ([81Br], 12), 291([79Br], 13), 197 
(100), 173 (7), 147 (31), 135 (57), 108 (37), 77 (27), 57 (19), 43 (15). HRMS (EI): Calcd. for 
C21H15O5Br ([M]+ , 79Br): 426.0097; found: 426.0088. Anal.: calcd. for C21H15O5Br (426.00, 













Starting with 33e (253 mg, 1.0 mmol), Me3SiOTf 
(66 mg, 0.3 mmol) and 1,3-bis-silyl enol ether 32g 
(421 mg, 1.3 mmol), 34m was isolated as yellow 
solid (155 mg, 38%), m.p. = 105 °C. 1H NMR (300 
MHz, CDCl3): δ = 6.86 (d, J = 8.3 Hz, 1 H, CHAr), 7.14 (d J = 8.7 Hz, 1 H, CHAr), 7.18-7.23 
(m, 1 H, CHAr), 7.25-7.28 (m, 1 H, CHAr), 742-7.46 (m, 1 H, CHAr), 7.47 (m, 1H, CHAr), 7.49-
7.51 (m, 1H, CHAr), 7.65-7.66 (m, 1H, CHAr), 7.74-7.76 (m, 1 H, CHAr), 7.88 (dd, J = 8.5 Hz, 
J = 2.3 Hz, 1 H, CHAr), 11.55 (s, 1 H, OH), 12.36 (s, 1 H, OH). 13C NMR (75.5 MHz, CDCl3): 
δ = 110.6 (CAr), 116.8, 117.1 (CHAr), 119.2 (CAr), 119.7 (CHAr), 120.5 (CAr), 120.9, 125.6 
(CHAr), 128.5, 130.5 (CAr), 134.9, 136.2, 136.3, 138.0, 139.2 (CHAr), 139.3,  162.2, 166.8 
(CAr), 197.8, 198.6 (C=O). IR (neat): ~ν  = 3054 (w), 2956 (s), 2924 (s), 2852 (s), 1629 (s), 
1590 (s), 1465 (s), 1418 (s), 1418 (s), 1304 (m), 1253 (s), 1208 (s), 1122 (s), 927 (m), 844 (s), 
763 (s), 629 (m) cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = 218 (4.50), 256 (4.23), 340 (3.79). 
MS (EI, 70 eV): m/z (%) = 416 ([M]+, [81Br], 97), 414 ([M]+, [79Br], 97), 397 ([81Br], 6), 395 
([79Br], 6),  216 ([81Br], 71), 214 ([79Br], 71), 199 ([81Br], 100), 197 ([79Br], 100), 147 (47), 
123 (51), 95 (22), 57 (11). HRMS (EI): Calcd. for C20H12O4BrF ([M]+, 79Br): 413.9897; 
found: 413.9891.  
 
[3-(2-Fluorobenzoyl)-4-hydroxyphenyl]-(2-hydroxy-5-isopropylphenyl)methanone (34n): 
Starting with 33b (216 mg, 1.0 mmol), 
Me3SiOTf (66mg, 0.3 mmol) and 1,3-bis-silyl 
enol ether 32g (421 mg, 1.3 mmol), 34g was 
isolated as a yellow solid (130 mg, 35%), m.p. 
= 105-107 °C. 1H NMR (300 MHz, CDCl3): δ = 0.86 (d, J = 7.1 Hz, 6 H, CH3), 2.25 (m, 1 H, 
CH), 6.75 (d, J = 8.5 Hz, 1 H, CHAr), 6.95-6.98 (m, 1 H, CHAr), 7.01-7.07 (m, 3 H, CHAr), 
7.12 (dd, J = 8.5 Hz, J = 2.3, 1 H, CHAr), 7.23-7.28 (m, 1 H, CHAr), 7.33-7.38 (m, 1 H, CHAr), 
7.70-7.72 (m, 2 H, CHAr), 11.34 (s, 1 H, OH), 12.30 (s, 1 H, OH). 13C NMR (75 MHz, 
CDCl3): δ = 24.9, 25.0 (CH3), 34.2 (CH), 117.3, 117.6, 119.4, 120.0 (CH) Ar, 120.5 (C), 124.0 
(CHAr), 125.0 (CAr), 125.7 (CHAr), 126.4, 126.7, 130.1 (CAr), 131.0, 135.6, 136.5, 139.9 
(CHAr), 140.1, 161.6, 167.0 (CAr), 199.4, 199.6 (C=O). IR (KBr): ~ν  = 3431 (w), 2960 (m), 
2924 (w), 2868 (w), 1634 (s), 1612 (s), 1588 (s), 1483 (s), 1357 (s) 1251 (s), 1212 (s), 840 










378 ([M]+,13), 343 (5), 163 (25), 162 (29), 147 (100), 123 (68), 121 (7), 91 (31), 69 (14), 57 
(19), 41 (19). HRMS (EI): Calcd. for C23H19O4F ([M]+): 378.1262; found: 378.1257.  
 
(5-Chloro-2-hydroxyphenyl)-[3-(2-fluorobenzoyl)-4-hydroxyphenyl]methanone (34o). 
Starting with 33d (208 mg, 1.0 mmol), Me3SiOTf 
(66 mg, 0.3 mmol) and 1,3-bis-silyl enol ether 32g 
(421 mg, 1.3 mmol), 34o was isolated as a yellow 
solid (163 mg, 44%), m.p. = 123-125 °C. 1H NMR 
(300 MHz, CDCl3): δ = 6.91 (d, J = 8.9 Hz, 1 H, CHAr), 7.14 (d, J = 8.7 Hz, 1 H, CHAr), 7.18-
7.19 (m, 1 H, CHAr), 7.22-7.25 (m, 1 H, CHAr), 7.35 (dd, J = 8.9 Hz, J = 2.6 Hz, 1 H, CHAr), 
7.42-7.45 (m, 1 H, CHAr), 7.46-7.50 (m, 1H, CHAr), 7.53 (m, 1 H, CHAr), 7.75-7.77 (m, 1 H, 
CHAr), 7.89 (dd, J = 8.9 Hz, J = 2.1 Hz, 1 H, CHAr), 11.53 (s, 1 H, OH), 12.34 (s, 1 H, OH). 
13C NMR (75 MHz, CDCl3): δ = 117.5, 117.8 (CHAr), 119.9, 120.0 (CAr), 120.6, 121.3, 124.6 
(CHAr), 126.4, 126.6, 129.3 (CAr), 131.1, 132.8 (CHAr), 134.9 (CAr), 135.0, 137.2, 138.8 
(CHAr), 162.5, 167.5 (CAr), 198.5, 199.3 (C=O). IR (neat): ~ν  = 3077 (w), 2956 (s), 2924 (s), 
2853 (s), 1675 (s), 1633 (s), 1598 (s), 1466 (s), 1417 (s), 1253 (s), 1208 (s), 1140 (s), 1097 
(m), 950 (m), 844 (s), 763 (s) cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = 221 (4.41), 258 
(4.27), 340 (3.82). MS (EI, 70 eV): m/z (%) = 372 ([M]+, [37Cl], 38), 370 ([M]+, [37Cl], 100), 
340 ([37Cl], 8), 338 ([35Cl],10), 267 (26), 243 (10), 216 (51), 197 (20), 177 (19), 155 (96), 147 




Starting with 33b (216mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-
bis-silyl enol ether 32k (463 mg, 1.3 
mmol), 34p was isolated as a yellow 
viscous oil (130 mg, 32%). 1H NMR (300 
MHz, CDCl3): δ = 0.90 (d, J = 6.9 Hz 6 
H, CH3), 2.44-2.56 ( m, 1 H, (CH), 7.11 (m, 1 H, CHAr), 7.16-7.18 (m, 1 H, CHAr), 7.19-7.22 
(m, 1 H, CHAr), 7.41-7.44 (m, 1 H, CHAr), 7.45 (m, 1 H, CHAr), 7.47 (m, 2 H, CHAr), 7.48-
7.52 (m, 1 H, CHAr), 7.74-7.75 (m, 1 H, CHAr), 7.82-7.84 (m, 1 H, CHAr), 7.85-7.86 (m, 1 H, 
CHAr), 7.87-7.89 (m, 1 H, CHAr), 7.92 (dd, J = 7.6 Hz, J = 1.2 Hz, 1 H, CHAr), 11.52 (s, 1 H, 










119.3 (CHAr), 120.0 (CAr), 124.7, 125.2, 126.7, 127.2, 128.0, 129.0 (CHAr), 129.3 (CAr), 130.2 
(CHAr), 130.6 (CAr), 131.8 (CHAr), 134.1, 134.9 (CAr), 135.0, 136.3, 138.2 (CHAr), 139.6, 
161.5, 166.9, 189.6 (CAr), 198.8, 204.0 (C=O). IR (neat): ~ν  = 3058 (m), 2959 (s), 2926 (m), 
2870 (m), 1630 (s), 1589 (s), 1508 (m), 1480 (s), 1354 (s), 1296 (m), 1252 (s), 1211 (s), 1146 
(m), 1129 (w), 1045 (w), 908 (m), 843 (s), 793 (s), 733 (s) cm-1. GC-MS (EI, 70 eV): m/z (%) 
= 410 ([M]+, 86), 395 (16), 247 (14), 197 (17), 163 (49), 147 (100), 127 (30), 91 (19), 65 (5). 
HRMS (EI): Calcd. for C27H22O4 ([M]+): 410.1513; found: 410.1512.  
 
(2-Hydroxy-5-methylphenyl)-[4-hydroxy-3-(1-naphthoyl)phenyl]methanone (34q):  
Starting with 33a (188 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-
silyl enol ether 32k (463 mg, 1.3 mmol), 
34q was isolated as a yellow solid (130 mg, 
34%), m.p. = 112-114 °C. 1H NMR (300 
MHz, CDCl3 ), δ = 2.00 (s, 3 H, CH3), 6.77 ( 
d, J = 8.4 Hz, 1 H, CHAr), 7.06-7.07 (m, 1 H, CHAr), 7.08-7.11 (m, 1 H, CHAr), 7.13 (m, 1 H, 
CHAr), 7.41-7.42 (m, 1 H, CHAr), 7.43 (m, 1 H, CHAr), 7.44-7.47 (m, 2 H, CHAr), 7.68-7.69 
(m, 1 H, CHAr), 7.78-7.80 (m, 1 H, CHAr), 7.81-7.82 (m, 1 H, CHAr), 7.83-7.85 (m, 1 H, 
CHAr), 7.89 (dd, J = 7.6 Hz, J = 1.5 Hz, 1 H, CHAr), 11.42 (s, 1 H, OH), 12.65 (s, 1 H, OH). 
13C NMR (75 MHz, CDCl3): δ = 19.3 (CH3), 117.2 (CHAr), 117.3 (CAr), 117.7 (CHAr), 118.6 
(CAr), 123.2, 123.8, 125.4, 125.8, 126.6, 127.5 (CHAr), 127.7, 129.1 (CAr), 130.4, 131.2 
(CHAr), 132.2, 133.5 (CAr), 135.0, 136.1, 136.7 (CHAr), 159.8, 165.4, 188.1 (CAr), 197.3, 
202.4 (C=O). UV-Vis (nm, CH3CN): λmax (lg ε) = 222 (4.88), 256 (4.32), 341 (4.02. GC-MS 
(CI 70 eV): m/z (%) = 383 ([M+1]+,100), 305 (5), 267 (4), 229 (3), 177 (5), 122 (3), 88 (3). 
HRMS (CI): Calcd. for C25H19O4 ([M+1]+): 383.1278: found: 383.1297.  
 
(5-Bromo-2-hydroxyphenyl)-[4-hydroxy-3-(1-naphthoyl)phenyl]methanone (3r): 
Starting with 33e (253 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-
silyl enol ether 32k (463 mg, 1.3 mmol), 34r 
was isolated as a yellow solid (166 mg, 36%), 
m.p. = 125-127 °C. 1H NMR (300 MHz, 
CDCl3): δ = 6.79 ( d, J = 8.9 Hz, 1 H, CHAr), 








7.44-7.45 (m, 1 H, CHAr), 7.49-750 (m, 1 H, CHAr), 7.52-7.53 (m, 1 H, CHAr), 7.71-7.72 (m, 1 
H, CHAr), 7.80-7.82 (m, 1 H, CHAr), 7.83-7.84 (m, 1 H, CHAr), 7.85-7.88 (m, 1 H, CHAr), 7.92 
(dd, J = 7.3 Hz, J = 1.9 Hz, 1 H, CHAr), 11.46 (s, 1 H, OH), 12.74 (s, 1 H, OH). 13C NMR (75 
MHz, CDCl3): δ = 109.1 (CAr), 118.2 (CHAr), 118.5, 119.0 (CAr), 119.5, 123.3, 123.8, 125.7, 
125.8, 126.6 (CHAr), 126.8 (CAr), 127.6 (CHAr), 129.2 (CAr), 130.7 (CHAr), 132.8, 133.1 (CAr), 
133.5, 135.1, 136.5, 137.7 (CHAr), 160.7, 165.9 (CAr), 196.4, 202.2 (C=O). IR (KBr): ~ν  = 
3047 (w), 2957 (w), 2924 (w), 2853 (w), 1626 (s), 1588 (s), 1507 (w), 1464 (s), 1336 (s), 
1251 (s), 1209 (s), 1045 (w), 915 (s), 777 (s) cm-1. UV-Vis (nm, CH3CN): λmax (lg ε) = 257 
(3.89), 339 (3.48). GC-MS (EI 70 eV): m/z (%) = 448 ([M]+, [81Br], 89), 446 ([M]+, [79Br], 
90), 368 (6), 249 ([81Br], 89), 247 ([79Br], 89), 231 (13), 155 (35), 128 (100), 63 (10). HRMS 
(EI): Calcd. for C24H15O479Br: 446.0148 ([M]+, 79Br): found: 446.0161.  
 
(5-Chloro-2-hydroxyphenyl)-[4-hydroxy-3-(1-naphthoyl)phenyl]methanone (34s): 
Starting with 33d (208 mg, 1.0 mmol), 
Me3SiOTf (66 mg, 0.3 mmol) and 1,3-bis-
silyl enol ether 32k (463 mg, 1.3 mmol), 34s 
was isolated as a yellow viscous oil (144 
mg, 36%). 1H NMR (300 MHz, CDCl3): δ = 
6.84 (d, J = 8.1 Hz, 1 H, CHAr), 7.15-7.16 
(m, 1 H, CHAr), 7.18 (s, 1 H, CHAr), 7.28 (dd, J = 8.9 Hz, J = 2.5 Hz, 1 H, CHAr), 7.35 (m, 1 
H, CHAr), 7.44-7-47 (m, 2 H, CHAr), 7.51-7.52 (m, 1 H, CHAr), 7.53 (s, 1 H, CHAr), 7.71-7.72 
(m, 1 H, CHAr), 7.81-7.83 (m, 1 H, CHAr), 7.85-7.86 (m, 1 H, CHAr), 7.91-7.95 (m, 1 H, 
CHAr), 11.45 (s, 1 H, OH), 12.73 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3): δ = 119.6 (CHAr), 
119.8, 120.0 (CAr), 120.5 (CHAr), 123.6 (CAr), 124.7, 125.2 (CHAr), 127.3 (2CHAr), 128.1 
(CHAr), 128.3 (CAr), 129.0 (CHAr), 130.6 (CAr), 131.9, 132.1 (CHAr), 134.2, 134.6 (CAr), 
136.3, 136.6, 137.9 (CHAr), 161.7, 167.3 (CAr), 197.9, 203.6 (C=O). MS (CI, 70 eV): m/z (%) 
= 405 ([M+1]+, [37Cl], 50), 403 ([M+1]+, [37Cl], 100), 285 (10), 257 (12), 229 (10), 177 (13), 
125 (14), 97 (15), 85 (20), 69 (21). HRMS (CI): Calcd. for C24H16O435Cl ([M+1]+, 37Cl): 










General procedure for the synthesis of 36a-r and 38f-g: To a CH2Cl2 solution (40 mL) of 
isoquinoline (0.520 g, 4.0 mmol) was added the 1,3-bis-silyl enol ether (8.0 mmol) and 
methyl chloroformate (0.460 g, 4.8 mmol) at 0 °C. The solution was stirred for 2 h at 0 °C and 
for 12 h at 20 °C. A saturated aqueous solution of ammonium chloride (20 mL) was added 
and the organic and the aqueous layers were separated. The latter was extracted with CH2Cl2 
(3 x 100 mL). The combined organic layers were dried (Na2SO4), filtered and the filtrate was 
concentrated in vacuo. The residue was purified by chromatography (silica gel, hexane → 
hexane/EtOAc = 2:1).  
 
1-[(Z)-4-(4-Fluorophenyl)-2-hydroxy-4-oxo-2-butenyl]-2-(methoxycarbonyl)- 
isoquinolinium (36a):  Starting with isoquinoline (0.258 g, 
2.00 mmol), 32b (0.973 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36a was prepared as 
an orange red solid (0.450 g, 68%). 1H NMR (250 MHz, 
CDCl3,): δ = 2.39 – 2.72 (m, 2 H, NCHCH2, isomer 1, 
isomer 2), 3.67 (s, 3 H, COOCH3, isomer 1, isomer 2), 5.77 (m, 1 H, NCH, isomer 1, isomer 
2), 5.80 (m, 1 H, COCH, isomer 1, isomer 2), 5.84 – 5.91 (m, 1 H, CH, isomer 1, isomer 2), 
6.73 (d, 3J = 7.8 Hz, 1 H, CH, isomer 1), 6.73 (d, 3J = 7.8 Hz, 1 H, CH, isomer 2), 6.96 – 7.16 
(m, 6 H, CHAr), 7.68 – 7.74 (m, 2 H, CHAr), 15.90 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 
MHz): δC = 44.5/44.8 (NCHCH2), 54.2/54.4 (OCH3), 54.5/55.0 (NCH), 98.4/98.5 
(COOCH3), 110.0/110.3 (CH), 116.8/117.0 (d, 2J = 20.2 Hz, 2CHAr), 125.3 (CH), 
125.9/126.0, 127.2/127.4, 128.2, 129.2/129.3 (CHAr), 130.7 (d, 3J = 6.5 Hz, 2CHAr), 
130.8/130.9, 131.1/131.3, 132.3/132.4 (CAr), 154.3/154.9 (COH), 166.4/166.5 (d, 1J = 250.5 
Hz, CFAr),  184.9/185.7, 190.8/191.4 (CO); GC-MS (EI, 70 eV): m/z (%) = 367 (M+, 1), 276 
(2), 201 (2), 188 (100), 144 (25), 129 (10), 103 (7), 59 (5); HRMS (EI): Calcd. for 











acid methyl ester (36b): Starting with isoquinoline 
(0.258 g, 2.00 mmol), 32c (1.023 g, 3.00 mmol) and 
methyl chloroformate (0.226 g, 2.40 mmol), 36b was 
prepared as a red gummy solid (0.530 g, 70%). 1H 
NMR (250 MHz, CDCl3,): δ = 2.46 – 2.63 (m, 2 H, 
NCHCH2, isomer 1, isomer 2), 3.65 (s, 3 H, COOCH3, isomer 1), 3.67 (s, 3 H, COOCH3, 
isomer 2), 5.66 (m, 1 H, NCH, isomer 1, isomer 2), 5.78 – 5.79 (m, 1 H, COCH, isomer 1, 
isomer 2), 5.85 – 5.90 (m, 1 H, CH, isomer 1, isomer 2), 6.74 (d, 3J = 7.6 Hz, 1 H, CH, isomer 
1), 6.91 (m, 1 H, CH, isomer 2), 6.98 – 7.07 (m, 4 H, CHAr), 7.26 (d, 3J = 7.8 Hz, 2 H, CHAr), 
7.61 (d, 3J = 7.9 Hz, 2 H, CHAr), 15.90 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 
43.7/43.9 (NCHCH2), 53.1 (NCH), 53.3/53.9 (COOCH3), 97.4/97.5, 108.7/109.0, 124.1 (CH), 
124.7/124.8, 125.9/126.1, 127.0, 128.0/128.1 (CHAr), 128.3 (2CH), 128.7/128.8 (2CHAr), 
129.8/130.0, 131.0/131.1, 133.2, 138.4/138.7 (CAr), 153.0/153.6 (COH), 182.8/183.7, 
190.5/191.1 (CO); IR (neat): v = 3106 (w), 3066 (w), 2997 (w), 2950 (s), 1704 (s), 1590 (s), 
1079 (s), 775 (m), 750 (s), 671 (w) cm–1; MS (EI, 70 eV): m/z (%) = 383 (M+, 2), 292 (5), 201 
(3), 188 (100), 144 (33), 129 (12), 103 (6), 77 (3); HRMS (EI): Calcd. for C21H18ClNO4 : 
383.09189; found: 383.09167. 
 
1-[(Z)-2-Hydroxy-4-(2-methylphenyl)-4-oxo-2-butenyl]-2(1H)-isoquinoline carboxylic 
acid  methyl ester (36c): Starting with isoquinoline (0.258 
g, 2.00 mmol), 32d (0.961 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36c was prepared as a 
yellow solid (0.300 g, 43%). 1H NMR (250 MHz, CDCl3): δ 
= 2.47 (s, 3 H, CH3, isomer 1, isomer 2), 2.51 – 2.83 (m, 2 
H, NCHCH2, isomer 1, isomer 2), 3.82 (s, 3 H, COOCH3, isomer 1, isomer 2), 5.68 (s, 1 H, 
COCH, isomer 1, isomer 2), 5.77 – 5.92 (m, 1 H, NCH, isomer 1, isomer 2), 6.02 (d, 3J = 7.5 
Hz, 1 H, CH, isomer 1, isomer 2), 6.86 (d, 3J = 7.5 Hz, 1 H, CH, isomer 1), 7.05 (d, 3J = 7.5 
Hz, 1 H, CH, isomer 2), 7.09 – 7.40 (m, 8 H, CHAr), 15.98 (s(br), 1 H, OH); 13C NMR 
(CDCl3, 62 MHz): δC = 21.9 (CH3), 44.8/45.0 (NCHCH2), 54.6/54.7 (COOCH3), 54.9/55.5 
(NCH), 103.1 (CH), 110.1/110.5 (CH), 125.6 (CH), 126.2/126.3, 127.0/127.2, 127.4/127.6, 
128.5, 129.4/129.5, 129.6/129.7 (CHAr), 131.3/131.5 (CAr), 132.1/132.2, 132.5/132.6 (CHAr), 









(EI, 70 eV): m/z (%) = 363 (M+, 1), 272 (1), 188 (100), 144 (21), 129 (8), 103 (6), 91 (5), 59 
(4); HRMS (EI): Calcd. for C22H21NO4: 363.14610; found: 363.14600. 
 
1-[(Z)-2-hydroxy-4-(2-methoxyphenyl)-4-oxo-2-butenyl]-2(1H)-isoquinoline-carboxylic 
acid methyl ester (36d): Starting with isoquinoline (0.258 
g, 2.00 mmol), 32e (1.009 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36d was prepared as 
a reddish highly viscous oil (0.450 g, 68%). 1H NMR (250 
MHz, CDCl3,): δ = 2.65 –2.83 (m, 2 H, NCHCH2, isomer 
1, isomer 2), 3.75 (s, 3 H, OCH3, isomer 1, isomer 2), 3.84 (s, 3 H, COOCH3, isomer 1, 
isomer 2), 5.73 – 5.86 (m, 1 H, NCH, isomer 1, isomer 2), 5.89 – 5.99 (m, 1 H, COCH, 
isomer 1, isomer 2), 6.24 – 6.29 (m, 1 H, CH, isomer 1&2), 6.81 – 6.89 (m, 1 H, CH, Isomer 
1&2), 6.93 – 7.18 (m, 6 H, CHAr) 7.31 – 7.43 (m, 1 H, CHAr), 7.79 (m, 1 H, CHAr), 16.15 
(s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 44.1/44.4 (NCHCH2), 53.1/53.4 (OCH3), 
53.4 (NCH), 54.1/55.5 (COOCH3), 102.7, 108.8/109.0, 111.6 (CH), 120.6, 124.2/124.8 
(CHAr), 125.2 (CAr), 126.1/126.3, 127.1, 127.9/128.0, 129.9/130.1, 130.7 (CHAr), 131.4/131.6 
(CAr), 133.0/133.2 (CHAr), 134.5 (CAr), 153.1/153.8 (COCH3), 158.4 (COH), 182.4/183.5, 
190.8/191.5 (CO); GC-MS (EI, 70 eV): m/z (%) = 379 (M+, 1), 201 (1), 188 (100), 144 (23), 




acid methyl ester (36e):  Starting with isoquinoline (0.258 g, 
2.00 mmol), 32g (1.023 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36e was prepared as a 
yellow oil (0.450 g, 58%). 1H NMR (250 MHz, CDCl3,): δ = 
2.45 – 2.77 (m, 2 H, NCHCH2, isomer 1, isomer 2), 3.78 (s, 3 
H, COOCH3, isomer 1, isomer 2), 5.72 – 5.77 (m, 1 H, NCH, isomer 1, isomer 2), 5.82 (s, 1 
H, COCH, isomer 1), 5.88 (s, 1 H, COCH, isomer 2), 5.97 (d, 3J = 7.5 Hz, 1 H, CH, isomer 1, 
isomer 2), 6.80 (d, 3J = 7.5 Hz, 1 H, CH, isomer 1), 6.99 (d, 3J = 7.5 Hz, 1 H, CH, isomer 2), 
7.04 – 7.20 (m, 4 H, CHAr), 7.29 – 7.48 (m, 4 H, CHAr), 15.52 (s(br), 1 H, OH); 13C NMR 








103.2/103.3, 109.4/109.6, 124.7/125.2 (CH), 125.3/125.4, 125.5, 126.7, 127.4, 127.7, 
128.6/128.7, 130.4 (CHAr), 130.6 (CAr), 131.1/131.2, 131.6/131.7 (CAr), 132.1/132.3 (CHAr), 
136.2 (CAr), 153.6/154.2 (COH), 186.2/187.4, 189.5/190.0 (CO); MS (EI, 70 eV): m/z (%) = 
383 (M+, 1), 292 (2), 201 (2), 188 (100), 144 (23), 129 (10), 103 (6), 77 (3); HRMS (EI): 
Calcd. for C21H18ClNO4: 383.09189; found: 383.09167. 
 
1-[(Z)-4-(2-Fluorophenyl)-2-hydroxy-4-oxo-2-butenyl]-2(1H)isoquinolinecarboxylic acid 
methyl ester (36f): Starting with isoquinoline (0.258 g, 2.00 
mmol), 32h (0.973 g, 3.00 mmol) and methyl chloroformate 
(0.226 g, 2.40 mmol), 36f was prepared as a deep reddish 
viscous oil (0.561 g, 76%, mp. = 165-168 oC). 1H NMR (250 
MHz, CDCl3,): δ = 2.41 – 2.74 (m, 2 H, NCHCH2, isomer 1, 
isomer 2), 3.36 (s, 3 H, COOCH3, isomer 1, isomer 2), 5.64− 5.69 (m, 1 H, NCH, isomer 1), 
5.77 − 5.80 (m, 1 H, NCH, isomer 2), 5.86 − 5.89 (m, 1 H, COCH, isomer 1, isomer 2), 6.00 – 
6.02 (m, 1 H, CH, isomer 1, isomer 2), 6.73 (d, 3J = 7.5 Hz, 1 H, CH, isomer 1), 6.92 (d, 3J = 
7.5 Hz, 1 H, CH, isomer 2), 6.98 – 7.11 (m, 6 H, CHAr), 7.31 – 7.33 (m, 1 H, CHAr), 7.77 6.73 
(ddd, 3J = 7.7 Hz, 3J = 7.7 Hz, 4J = 1.8 Hz,1 H, CHAr), 15.91 (s(br), 1 H, OH); 13C NMR 
(CDCl3, 62 MHz): δC = 44.9/45.3 (NCHCH2), 54.1/54.3 (NCH), 54.5/55.0 (COOCH3), 
103.1/103.5, 109.9/110.1 (CH), 117.4 (d, 2J = 16.2 Hz, CHAr), 124.0/124.2 (CH), 125.2/125.4 
(CHAr), 125.9 (d, 3J = 6.1 Hz, CHAr),127.0/127.2, 128.1 (CHAr), 129.1 (d, 3J = 7.2 Hz, CHAr), 
129.6 (d, 4J = 1.8 Hz, CHAr),131.0 (CHAr), 132.2/132.3, 134.5, 134.6/134.8 (CAr), 154.1/154.6 
(COH), 162.0 (d, 1J = 253.8 Hz, CFAr), 180.6/181.3, 193.0/193.3 (CO); IR (neat): v = 3108 
(w), 3078 (w), 2996 (w), 2969 (w), 1519 (s), 1434 (s), 1110 (s), 643 (m), 776 (s) cm–1; GCMS 
(EI, 70 eV): m/z (%) = 367 (M+, 5), 188 (100), 144 (28), 129 (22), 103 (12), 59 (8). HRMS 











methyl ester (36g):  Starting with isoquinoline (0.258 
g, 2.00 mmol), 32i (1.054 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36g was 
prepared as a yellow solid (0.300 g, 43%). 1H NMR 
(250 MHz, CDCl3,): δ = 2.47 – 2.65 (m, 2 H, 
NCHCH2, isomer 1, isomer 2), 3.62 (s, 3 H, OCH3, isomer 1), 3.66 (s, 3 H, OCH3, isomer 2), 
5.63 (t(br), 3J = 7.6 Hz, 1 H, NCH, isomer 1, isomer 2), 5.70 – 5.85 (m, 1 H, NCH, isomer 1, 
isomer 2), 5.90 (s(br), 1 H, COCH, isomer 1, isomer 2), 6.69 (d, 3J = 7.5 Hz, 1 H, CH, isomer 
1), 6.87 (d, 3J = 7.5 Hz, 1 H, CH, isomer 2), 6.96 – 7.12 (m, 4 H, CHAr), 7.79 (d, 3J = 7.8 Hz , 
2 H, CHAr), 8.12 (d, 3J = 7.8 Hz , 2 H, CHAr), 15.58 – 15.71 (m(br), 1 H, OH); 13C NMR 
(CDCl3, 62 MHz): δC = 44.5 (NCHCH2), 53.3/53.5 (NCH), 53.9 (OCH3), 98.7, 108.9/109.2, 
123.7 (CH), 124.2 (2CHAr), 124.9/125.0, 126.0/126.2 (CHAr), 127.2 (CAr), 127.8 (2CHAr), 
127.9/128.2, 128.3/129.9 (CHAr), 130.5/130.9, 140.3, 149.8 (CAr), 153.2/153.6 (COH), 
179.8/180.9, 193.1/193.9 (CO); IR (neat): v = 3108 (w), 3078 (w), 2994 (w), 2969 (w), 
1519 (s), 1434 (s), 1110 (s), 645 (m), 777 (s), 751 (w) cm–1; MS (EI, 70 eV): m/z (%) = 394 
(M+, 2), 365 (2), 319 (3), 188 (100), 144 (75), 129 (49), 103 (16); HRMS (EI): Calcd. for 
C21H18N2O6: 394.11594; found: 394.11602. 
 
1-[(Z)-2-Hydroxy-4-oxo-4-(3,4,5-trimethoxyphenyl)-2-butenyl]-2(1H)-isoquinoline-
carboxylic acid  methyl ester (36h): Starting with 
isoquinoline (0.258 g, 2.00 mmol), 32j (1.185 g, 
3.00 mmol) and methyl chloroformate (0.226 g, 2.40 
mmol), 36h was prepared as a yellow highly viscous 
oil (0.300 g, 34%). 1H NMR (250 MHz, CDCl3,): δ 
= 2.46 – 2.69 (m, 2 H, NCHCH2, isomer 1, isomer 2), 3.68 (s, 3 H, COOCH3, isomer 1), 3.70 
(s, 3 H, COOCH3, isomer 2), 3.70 (m, 9 H, OCH3 isomer 1&2), 5.68 (m, 1 H, NCH, isomer 
1, isomer 2), 5.76 – 5.85 (m, 1 H, COCH, isomer 1, isomer 2), 5.92 (d, 3J = 7.5 Hz, 1 H, CH, 
isomer 1, isomer 2), 6.75 (d, 3J = 7.6 Hz, 1 H, CH, isomer 1) 6.92 (m, 1 H, CH, isomer 2), 
6.97 – 7.22 (m, 6 H, CHAr), 16.01 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 
41.3/41.7 (NCHCH2), 51.3/51.5 (NCH), 54.3 (3OCH3), 58.9 (COOCH3), 95.3/95.5, 102.6, 
106.9/107.107.1 (CH), 122.3, 122.8/122.9, 124.1/124.3 (CHAr), 125.0 (CAr), 126.0/126.1, 











151.8 (COH), 183.0/183.8, 186.6/187.1 (CO); IR (neat): v = 2997 (w), 2951 (w), 2939 (w), 
2836 (w), 1709 (s), 1570 (s), 1119 (s), 999 (s), 773 (s) cm–1; HRMS (EI): Calcd. for 
C24H25O7N: 439.16255; found: 439.16281. 
 
1-[(Z)-2-Hydroxy-4-(2-naphthyl)-4-oxo-2-butenyl]-2(1H)-isoquinoline-carboxylic acid 
methyl ester (36i): Starting with isoquinoline (0.258 g, 
2.00 mmol), 32k (1.05 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36i was prepared as 
a reddish highly viscous oil (0.325 g, 41% mp. = 86-88 
oC). 1H NMR (250 MHz, CDCl3,): δ = 2.35 – 2.69 (m, 2 
H, NCHCH2, isomer 1, isomer 2), 3.65 (s, 3 H, COOCH3, isomer 1), 3.67 (s, 3 H, COOCH3, 
isomer 2), 5.66 (s, 1 H, COCH, isomer 1, isomer 2), 5.73 – 5.78 (m, 1 H, NCH, isomer 1, 
isomer 2), 5.86 (d, 3J = 7.7 Hz, 1 H, CH, isomer 1, isomer 2), 6.70 (d, 3J = 7.7 Hz, 1 H, CH, 
isomer 1), 6.87 (d, 3J = 7.5 Hz, 1 H, CH, isomer 2), 6.94 – 7.10 (m, 4 H, CHAr), 7.30 – 7.46 
(m, 4 H, CHAr), 7.69 – 7.78 (m, 2 H, CHAr), 8.16 – 7.20 (m, 1 H, CHAr), 15.98 (s(br), 1 H, 
OH); 13C NMR (CDCl3, 62 MHz): δC = 43.2/43.4 (NCHCH2), 53.3/53.4 (COOCH3), 
53.6/54.2 (NCH), 102.7/102.8, 124.2, 1024.7 (CH), 124.8/124.9, 125.4/125.5, 126.1, 126.3, 
127.0 (CHAr), 127.1 (2CHAr), 127.3, 128.1/128.2, 128.4, 130.0 (CHAr), 130.2, 131.1/131.2, 
131.7/131.9, 133.7, 134.3/134.4 (CAr), 153.2/153.1 (COH), 188.5/189.0, 189.5/190.4 (CO); IR 
(neat): v = 3054 (w), 2952 (w), 2926 (w), 2849 (w), 1710 (s), 1593 (s), 1118 (s), 972 (m), 
772 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 399 (M+, 1), 308 (1), 212 (1), 188 (100), 155 (4), 




methyl ester (36j): Starting with isoquinoline (0.258 
g, 2.00 mmol), 32l (1.05 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36ju was 
prepared as a reddish solid (0.561 g, 76% mp. = 122-
125 oC). 1H NMR (250 MHz, CDCl3,): δ = 2.43 – 2.73 
(m, 2 H, NCHCH2, isomer 1, isomer 2), 3.64 (s, 3 H, COOCH3, isomer 1, isomer 2), 5.63 – 








isomer 2), 5.93 – 6.01 (m, 1 H, CH, isomer 1, isomer 2), 6.61 (d, 3J = 7.5 Hz, 1 H, CHAr, 
isomer 1), 6.91 (d, 3J = 7.5 Hz, 1 H, CHAr, isomer 2), 6.95 – 7.11 (m, 4 H, CHAr), 7.39 – 7.44 
(m, 2 H, CHAr), 7.69 – 7.81 (m, 4 H, CHAr), 8.21 (m, 1 H, CHAr), 15.95 (s(br), 1 H, OH); 13C 
NMR (CDCl3, 62 MHz): δC = 43.9/44.2 (NCHCH2), 53.3/53.4 (NCH), 53.6/54.0 (COOCH3), 
97.9, 108.9/109.1, 123.1 (CH), 124.2, 124.8, 126.1/126.3, 126.7, 127.1, 127.7, 128.1, 128.3, 
128.4 (CHAr), 129.3 (2CHAr), 130.0/130.1, 131.2/131.3, 132.1/132.2, 132.6, 135.3 (CAr), 
153.2/153.1 (COH), 184.1/184.8, 190.6/190.9 (CO); IR (neat): v = 3052 (w), 3027 (w), 
2955 (w), 2918 (w), 1714 (s), 1633 (m), 1116 (s), 972 (w), 783 (s) cm–1; GC-MS (EI, 70 eV): 
m/z (%) = 399 (M+, 1), 308 (1), 188 (100), 144 (20), 127 (6), 103 (5), 59 (3); HRMS (EI): 
Calcd. for C25H21NO4: 399.14651; found: 399.14696. 
 
1-[(Z)-2-Hydroxy-4-oxo-4-(2-pyridyl)-2-butenyl]-2(1H)-isoquinoline-carboxylic acid 
methyl ester (36k): Starting with isoquinoline (0.258 g, 2.00 
mmol), 32r (1.009 g, 3.00 mmol) and methyl chloroformate 
(0.226 g, 2.40 mmol), 36k was prepared as a reddish highly 
viscous oil (0.450 g, 68%). 1H NMR (250 MHz, CDCl3,): δ = 
2.46 – 2.77(m, 2 H, NCHCH2, isomer 1, isomer 2), 3.64 (s, 3 
H, COOCH3, isomer 1, isomer 2), 5.65 – 5.71 (m, 1 H, NCH, isomer 1, isomer 2), 5.80 – 5.90 
(m, 1 H, CH, isomer 1, isomer 2), 6.62 (s, 1 H, COCH, isomer 1, isomer 2), 6.73 (d, 3J = 7.2 
Hz, 1 H, CH, isomer 1), 6.89 (d, 3J = 7.2 Hz, 1 H, CH, isomer 2), 6.91 – 7.08 (m, 4 H, CHAr), 
7.26 – 7.29 (m, 1 H, CHAr), 7.65 – 7.70 (m, 1 H, CHAr), 7.92 – 7.96 (m, 1 H, CHAr), 8.51 – 
7.70  (m, 1 H, CHAr), 15.56 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 43.8/44.2 
(NCHCH2), 53.1/53.2 (OCH3), 53.5/53.8 (NCH), 98.0, 108.8/109.1, 122.1 (CH), 124.2, 
124.8/124.9, 126.1/126.2 (CHAr), 126.4, 127.0/127.1 (CAr), 128.0, 129.9/130.1 (CHAr), 131.3 
(CAr), 137.1 (CHAr), 148.8/149.1 (CAr), 151.9 (CHAr), 153.1/153.6 (COH), 182.0/182.5, 
192.0/192.2 (CO); IR (neat): v = 3106 (w), 3055 (w), 2952 (w), 2851 (w), 1709 (s), 1564 
(s), 1119 (s), 772 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 350 (M+, 5), 274 (3), 188 (100), 










methyl ester (36l): Starting with isoquinoline (0.258 g, 2.00 
mmol), 32s (0.937 g, 3.00 mmol) and methyl chloroformate 
(0.226 g, 2.40 mmol), 36l was prepared as a reddish highly 
viscous oil (0.150 g, 22%, mp. = 70- 72 oC). 1H NMR 
(250 MHz, CDCl3,): δ = 2.07 – 2.42 (m, 2 H, NCHCH2, 
isomer 1, isomer 2), 3.42 (s, 3 H, COOCH3, isomer 1, isomer 2), 5.36– 5.41 (m, 1 H, NCH, 
isomer 1, isomer 2), 5.47 (s, 1 H, COCH, isomer 1, isomer 2), 5.54 (d, 3J = 7.5 Hz, 1 H, CH, 
isomer 1), 5.65 (d, 3J = 7.5 Hz, 1 H, CH, isomer 2), 6.48 (d, 3J = 7.5 Hz, 1 H, CH, isomer 1), 
6.66 (d, 3J = 7.5 Hz, 1 H, CH, isomer 2), 6.71 – 6.91 (m, 5 H, CHAr), 7.24 (m, 2 H, CHAr), 
16.01 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 42.4/42.9 (NCHCH2), 53.6/53.7 
(NCH), 53.9/54.4 (OCH3), 98.0, 109.2/109.4, 124.5 (CH), 125.1/125.2, 126.4/126.6, 
127.4/127.5, 128.4/128.5, 128.6/128.7 (CHAr), 130.2/130.4 (CAr), 130.7/131.1 (CHAr), 
131.4/131.5 (CAr), 132.9/133.2 (CHAr), 142.0/142.2 (CAr), 153.6/154.1 (COH), 182.6/183.0, 
184.4/184.9 (CO); IR (neat): v = 3112 (w), 3034 (w), 2972 (w), 2826 (w), 1698 (s), 1598 
(s), 1158 (s), 954 (s), 774 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 355 (M+, 36), 337 (18), 
264 (92), 188 (100), 170 (15), 170 (15), 144 (18), 11 (86), 83 (8),  59 (14); HRMS (EI): 




isoquinoline (36m): Starting with 5-nitroisoquinoline 
(0.348 g, 2.00 mmol), 32c (1.023 g, 3.00 mmol) and 
methyl chloroformate (0.226 g, 2.40 mmol), 36m was 
prepared as a red gummy solid (0.486 g, 54%, mp. = 
166-170 oC). 1H NMR (250 MHz, CDCl3,): δ = 2.71 – 
2.73 (m, 2 H, NCHCH2, isomer 1, isomer 2), 3.76 (s, 3 
H, COOCH3, isomer 1&2), 5.78 (m, 1 H, NCH, isomer 1, isomer 2), 5.84 (m, 1 H, COCH, 
isomer 1, isomer 2), 6.56 – 6.68 (m, 1 H, CH, isomer 1&2), 6.99 − 7.02 (m, 1 H, CH isomer 
1&2), 7.14 − 7.20 (m, 2 H, CHAr), 7.29 – 7.35 (m, 2 H, CHAr), 7.65 − 7.69 (m, 2 H, CHAr), 
7.79 − 7.83(m, 1 H, CHAr), 15.87 (s, 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 43.9 











(2CHAr), 129.9 (2CHAr). 131.4 (CHAr), 132.2 (CAr), 133.133.9 (CHAr), 134.1 (2CAr), 139.9, 
145.4 (CAr), 153.5 (COH), 184.1/184.8, 190.5/191.0 (CO); IR (neat): v = 3035 (w), 3011 
(w), 2957 (w), 2855 (w), 1711 (s), 1590 (s), 1223 (s), 1098 (s), 762 (s) cm–1; MS (EI, 70 eV): 
m/z (%) = 430 ([M+], 37Cl, 2), 428 ([M+], 35Cl, 6), 246 (2), 233 (100), 187 (15), 158 (25), 143 
(80), 128 (15), 59 (34); HRMS (EI): Calcd. for C21H17ClNO6 ([M+], 35Cl): 428.07697; found: 
428.07756. 
 
1-[4-(4-Fluorophenyl)-2,4-dioxobutyl]-2(1H)-isoquinolinecarboxylic acid methyl ester  
(36n): Starting with nitroisoquinoline (0.348 g, 2.00 
mmol), 32b (0.973 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36n was prepared as 
an orange red solid (0.590 g, 72%, mp. = 150-153 oC). 1H 
NMR (300 MHz, CDCl3): δ = 2.51 – 2.61 (m, 2 H, 
NCHCH2, isomer 1, isomer 2), 3.69 (s, 3 H, COOCH3, 
isomer 1, isomer 2), 5.77 (m, 1 H, NCH, isomer 1, isomer 2), 5.82 (s, 1 H, COCH, isomer 1, 
isomer 2), 6.55 – 6.62 (m, 1 H, CH, isomer 1, isomer 2), 6.95 (m, 1 H, CH, isomer 1, isomer 
2), 6.97 – 7.00 (m, 2 H, CHAr), 7.08 – 7.14 (m, 1 H, CHAr), 7.24 – 7.26 (m, 1 H, CHAr), 7.67 – 
7.77 (m, 3 H, CHAr), 15.52 (s(br), 1 H, OH); 13C NMR (CDCl3, 75 MHz): δC = 43.9/44.2 
(NCHCH2), 54.2 (NCH), 55.0 (COOCH3), 98.5, 104.0 (CH), 117.0 (d, 2J = 17.9 Hz, 2CHAr), 
125.9 (CH), 127.9, 130.1 (CHAr), 130.8 (d, 4J = 2.2 Hz, 2CHAr), 132.1/132.2 (CHAr), 132.7, 
134.4, 145.7 (CAr), 153.8/154.3 (COH), 166.5 (d, 1J = 209.6 Hz, CFAr), 185.1/185.7, 
189.9/190.4 (CO); IR (neat): v = 3110 (w), 3030 (w), 2971 (w), 2836 (w), 1695 (s), 1597 (s), 
1155 (s), 951 (s), 771 (s) cm–1; MS (EI, 70 eV): m/z (%) = 414 (M+, 50), 343 (25), 281 (10), 














isoquinolinecarboxylic acid methyl ester (36o): Starting 
with 6-nitroisoquinoline (0.348 g, 2.00 mmol), 32d (0.961 g, 
3.00 mmol) and methyl chloroformate (0.226 g, 2.40 mmol), 
36o was prepared as a yellow gummy solid (0.580 g, 71%). 1H 
NMR (300 MHz, CDCl3,): δ = 2.48 (s, 3 H, CH3, isomer 1, 
isomer 2), 2.65 – 2.81 (m, 2 H, NCHCH2, isomer 1, isomer 2), 
3.89 (s, 3 H, COOCH3, isomer 1, isomer 2), 5.72 (s, 1 H, COCH, isomer 1, isomer 2), 5.90 – 
6.00 (m, 1 H, NCH, isomer 1, isomer 2), 6.70 – 6.76 (m, 1 H, CH, isomer 1, isomer 2), 7.10 – 
7.13 (m, 1 H, CH, isomer 1, isomer 2), 7.23 – 7.45 (m, 6 H, CHAr), 7.92 (d, 3J = 6.7 Hz , 1 H, 
CHAr), 15.89 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 22.0 (CH3), 44.2/44.3 
(NCHCH2), 54.5 (NCH), 54.2 (COOCH3), 103.1, 104.0, 126.0 (CH), 126.5 (CAr), 127.2, 
128.1, 129.7, 130.3, 130.8, 132.4, 132.9 (CHAr), 134.7, 137.0, 138.6, 145.8, (CAr), 
153.9/154.5 (COH), 189.8/190.4, 190.7/191.5 (CO); IR (neat): v = 3065 (w), 3015 (w), 2954 
(w), 2928 (w), 1716 (s), 1519 (s), 1265 (s), 966 (s), 759 (s) cm–1. MS (EI, 70 eV): m/z (%) = 
408 (M+, 35), 393 (14), 340 (15), 271 (28), 210 (33), 195 (53), 177 (30), 135 (12), 123 (100), 
111 (18), 69 (63), 57 (86), 43 (58). 
 
1-[(Z)-4-(2-Fluorophenyl)-2-hydroxy-4-oxo-2-butenyl]-2-(methoxycarbonyl)-5-nitro-
isoquinoline (36p): Starting with 5-nitroisoquinoline (0.348 
g, 2.00 mmol), 32h (0.973 g, 3.00 mmol) and methyl 
chloroformate (0.226 g, 2.40 mmol), 36p was prepared as a 
yellow solid (0.345 g, 41%). 1H NMR (250 MHz, CDCl3,): δ 
= 2.70 – 2.73 (m, 2 H, NCHCH2, isomer 1, isomer 2), 3.76 
(s, 3 H, COOCH3, isomer 1, isomer 2), 5.79− 5.89 (m, 1 H, 
NCH, isomer 1,isomer 2), 6.01 (m, 1 H, COCH, isomer 1, isomer 2), 6.58 – 6.71 (m, 1 H, CH, 
isomer 1&2), 6.99 – 7.02 (m, 1 H, CH, isomer 1, isomer 2), 7.07 − 7.21 (m, 3 H, CH, CHAr), 
7.32 – 7.42 (m, 2 H, CHAr), 7.81 − 7.85 (m, 2 H, CHAr), 15.83 (s(br), 1 H, OH); 13C NMR 
(CDCl3, 62 MHz): δC = 43.2/43.4 (NCHCH2), 52.9/53.4 (NCH), 53.6/53.8 (COOCH3), 102.1 
(CH), 102.3 (d, 3J = 12.0 Hz, CHAr), 102.5 (CH), 116.6 (d, 2J = 21.0 Hz, CHAr), 124.5 (d, 4J = 
3.0 Hz, CHAr), 124.7 (CH), 126.7, 127.1, 127.3/128.8, 130.0 (CHAr), 131.3/131.5, 133.3, 
133.9, 144.5 (CHAr), 153.0 (COH), 161.5 (d, 1J = 247.4 Hz, CFAr), 180.0, 191.3 (CO); GC-











carboxylic acid methyl ester (36q):  Starting with 6-
nitroisoquinoline (0.348 g, 2.00 mmol), 32g (0.961 g, 3.00 
mmol) and methyl chloroformate (0.226 g, 2.40 mmol), 36q 
was prepared as a orange solid (0.520 g, 56%). 1H NMR 
(250 MHz, CDCl3,): δ = 2.45 – 2.61 (m, 2 H, NCHCH2, 
isomer 1, isomer 2), 3.69 (s, 3 H, COOCH3, isomer 1, isomer 
2), 5.69 (s, 1 H, COCH, isomer 1, isomer 2), 5.75 – 5.80 (m, 1 H, NCH, isomer 1, isomer 2), 
6.49 – 6.60 (m, 1 H, CH, isomer 1, isomer 2), 6.80 – 6.92 (m, 1 H, CH, isomer 1, isomer 2), 
7.05 – 7.26 (m, 5 H, CHAr),  7.32 – 7.35 (m, 1 H, CHAr), 7.74 (dd, 3J = 7.5 Hz, 4J = 1.0 Hz, 1 
H, CHAr), 15.30 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 43.2/43.5 (NCHCH2), 
53.7 (NCH), 54.4 (COOCH3), 103.4, 125.3 (CH), 125.7 (CAr), 127.4 (CH), 127.5, 129.3, 
130.0, 130.4, 131.3, 131.8, 132.2 (CHAr), 132.5, 133.8, 136.0, 145.1 (CAr), 153.2/153.6 
(COH), 186.7/187.4, 188.6/188.9 (CO); IR (neat): v = 3067 (w), 3002 (w), 2954 (w), 2851 
(w), 1719 (s), 1604 (s), 1519 (s), 1115 (m), 967 (s), 759 (s) cm–1; MS (EI, 70 eV): m/z (%) = 
430 ([M+], 37Cl, 1), 428 ([M+], 35Cl, 3), 246 (2), 233 (100), 187 (15), 158 (25), 143 (80), 128 




carboxylic acid methyl ester (36r): Starting with 
nitroisoquinoline (0.348 g, 2.00 mmol), 32l (0.973 g, 
3.00 mmol) and methyl chloroformate (0.226 g, 2.40 
mmol), 36r was prepared as an yellow solid (0.500 g, 
56%). 1H NMR (250 MHz, CDCl3,): δ = 2.73 – 2.76 
(m, 2 H, NCHCH2, isomer 1, isomer 2), 3.75 (s, 3 H, 
COOCH3, isomer 1, isomer 2), 5.82 – 5.91 (m, 1 H, CH, isomer 1, isomer 2), 6.01 – 6.06 (m, 
1 H, NCH, isomer 1, isomer 2), 6.59 – 6.70 (m, 1 H, COCH, isomer1&2), 7.15 (m, 1 H, CH, 
isomer 1, isomer 2), 7.33 (d, 3J = 7.7 Hz, 1 H, CHAr), 7.45 – 7.51 (m, 2 H, CHAr), 7.76 – 7.86 
(m, 6 H, CHAr), 8.27 (m, 1 H, CHAr), 16.05 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC 
= 43.0 (NCHCH2), 53.1/53.4 (NCH), 53.8 (COOCH3), 97.9, 102.8, 122.9 (CH), 124.7 
(CHAr), 125.1 (CAr), 126.7, 126.8, 127.7 (CHAr), 128.3 (2CHAr), 128.5 (CHAr), 128.7 (CAr), 










184.4/184.6, 189.6/189.8 (CO); IR (neat): v = 1704 (w), 1615 (m), 1521 (w), 1185 (w), 977 
(w), 761 (w) cm–1; GC-MS (EI, 70 eV): m/z (%) = 444 (M+, 2), 410 (2), 233 (100), 203 (36), 
155 (11), 143 (35), 127 (14), 69 (18); HRMS (EI): Calcd. for C25H20N2O4 : 444.13159; found: 
444.13132. 
Benzyl 1-(4-(4-chlorophenyl)-2-hydroxy-4-oxobut-2-enyl)isoquinoline-2(1H)-carboxylate 
(38f).Starting with Isoquinoline (0.258 g, 2.00 mmol), 
32c (1.023 g, 3.00 mmol) and benzyl chloroformate 
(0.409 g, 2.40 mmol), 38f was isolated as a reddish 
viscous oil (0.563 g, 61%). 1H NMR (250 MHz, 
CDCl3,): δ = 2.34 – 2.67 (m, 2 H, NCHCH2, isomer 1, 
isomer 2), 5.03 – 5.06 (m, 2 H, COOCH2, isomer 1, 
isomer 2), 5.61 – 5.63 (m, 1 H, COCH, isomer 1, isomer 
2), 5.66 – 5.75 (m, 1 H, NCH, isomer 1, isomer 2), 5.85 
– 5.88 (m, 1 H, CH, isomer 1, isomer 2), 6.70 – 6.73 (m, 1 H, CH, isomer 1, isomer 2), 6.94 – 
6.99 (m, 4 H, CHAr), 7.07 – 7.25 (m, 7 H, CHAr), 7.52 – 7.59 (m, 2 H, CHAr), 15.83 (s(br), 1 
H, OH); 13C NMR (CDCl3, 62 MHz): δC = 43.7/44.0 (NCHCH2), 53.5/54.0 (NCH), 68.2 
(COOCH2), 97.4/97.5, 109.0/109.1, 124.1 (CH), 124.7/124.8, 125.0, 126.1, 126.2, 127.1, 
127.2 (CHAr), 128.1/128.2 (2CHAr), 128.2/128.3,(CHAr), 128.5 (2CHAr), 128.8/128.9, 129.9 
(CHAr), 130.1, 131.1/131.2, 133.3/133.4, 135.4/135.7, 138.7/138.8 (CAr), 152.6/153.1 (COH), 
183.2/183.9, 190.3/190.9 (CO); IR (neat): v = 3103 (w), 3060 (w), 2990 (w), 2900 (s), 1702 
(s), 1595 (s), 1070 (s), 770 (m), 752 (s), 675 (w) cm–1; Anal. Calcd for C27H22ClNO4 
(459.96): C 70.50, H 4.82,. Found: C 70.469, H 4.919. 
 
Benzyl 1-(4-(2-chlorophenyl)-2-hydroxy-4-oxobut-2-enyl)isoquinoline-2(1H)-carboxylate 
(38g).Starting with Isoquinoline (0.258 g, 2.00 mmol), 32g 
(1.023 g, 3.00 mmol) and benzyl chloroformate (0.409 g, 
2.40 mmol), 38g was isolated as a reddish viscous oil (0.624 
g, 67%).. 1H NMR (250 MHz, CDCl3,): δ = 2.61 – 2.84 (m, 2 
H, NCHCH2, isomer 1, isomer 2), 5.00 – 5.018 (m, 2 H, 
COOCH2, isomer 1, isomer 2), 5.65 (s, 1 H, COCH, isomer 
1, isomer 2), 5.71 – 5.73 (m, 1 H, NCH, isomer 1, isomer 2), 












(m, 1 H, CH, isomer 1, isomer 2), 6.90 – 7.08 (m, 3 H, CHAr), 7.13 – 7.32 (m, 10 H, CHAr), 
15.840 (s(br), 1 H, OH); 13C NMR (CDCl3, 62 MHz): δC = 43.8/44.2 (NCHCH2), 54.1/54.6 
(NCH), 68.7 (COOCH2), 103.2/103.3, 109.5/109.9, 124.6 (CH), 125.2, 125.4, 125.5, 126.5, 
126.7, 127.4, 127.7, 127.8, 128.7, 128.8, 129.1, 130.4, 130.6 (CHAr), 131.1/131.2, 131.6, 
131.7, 132.1/132.3, 136.0/136.3 (CAr), 153.0/153.7 (COH), 186.6/186.7, 189.1/189.9 (CO); IR 
(neat): v = 3108 (w), 3062 (w), 2995 (w), 2900 (s), 1706 (s), 1593 (s), 1077 (s), 779 (m), 750 
(s), 671 (w) cm–1; Anal. Calcd for C27H22ClNO4 (459.96): C 70.50, H 4.82, N 3.05. Found: C 
70.20, H 4.85, 2.80. 
 
General procedure for the synthesis of 37a-r and 39a-g:To a CH2Cl2 solution (6 mL) of 3 
(1.5 mmol) was added TFA (3.0 mmol) and the solution was stirred for 12 h at 20 °C. For 4a-
ad: a saturated aqueous solution of sodium bicarbonate (2 mL) was added and the organic and 
the aqueous layers were separated. The latter was extracted with CH2Cl2 (3 x 30 mL). The 
combined organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in 
vacuo. For 4a-ad and 6a-e: The residue was purified by chromatography (silica gel, hexane 
→ hexane/EtOAc = 2:1). The product was dried for 16 h at 50 °C and 0.01 mbar to remove 
hydrolyzed 2. Due to the amide resonance and formation of E/Z-isomers, doubling of some 
signals was observed. In all products, the 1,3-dicarbonyl moiety resides in the enolic form.  
 
Methyl 10-(4-fluorobenzoyl)-11-hydroxy-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37a): Starting with 36a 
(0.164 g, 0.43 mmol) and TFA (0.87 g, 0.09 mmol), 37a 
was isolated as a colourless solid (0.110 g, 67%). 1H 
NMR (CDCl3, 250 MHz): δ = 2.23 (d, 2J = 16.5 Hz, 1 H, 
CHCH2), 2.48 (d, 2J = 18.0 Hz, 1 H, CHCH2), 2.89 – 3.12 (m, 2 H, CHCH2), 3.69 (s, 3 H, 
CO2CH3, isomer 1&2), 5.31 − 5.45 (m, 1 H, NCH), 5.50 – 5.72 (m, 1 H, NCH), 6.88 (m, 1 H, 
CHAr), 7.03 − 7.15 (m, 5 H, CHAr), 7.44 – 7.52 (m, 2 H, CHAr), 16.28(s, 1 H, OH). 13C NMR 
(CDCl3, 62 MHz): δC = 34.7/35.1, 40.7/41.1 (CHCH2), 45.2/45.8, 48.2/49.0 (NCH), 53.0/53.1 
(CO2CH3), 109.2 (C), 116.1 (d, 2J = 25.0 Hz, 2CHAr), 126.4/126.7, 127.5/127.6, 129.1/129.2 
(CHAr), 129.5 (d, 3J = 9.5 Hz, 2CHAr), 130.7/131.2 (CHAr), 131.6/131.7, 132.7/132.8, 
135.9/136.0 (CAr), 154.7 (C-OH), 163.9 (d, 1J = 248.0 Hz, CFAr), 187.1/187.9, 188.7/188.9 








1022 (s), 758 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 376 ([M+], 22), 349 (17), 276 (100), 
188 (39), 144 (15), 123 (50), 115 (12), 95 (16), 77 (5), 59(10). HRMS (EI): Calcd. for 
C21H18O4NF: 367.12144; found: 367.12113. 
 
Methyl 10-(4-chlorobenzoyl)-11-hydroxy-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37b): Starting with 36b 
(0.420 g, 1.09 mmol) and TFA (0.249 g, 2.10 mmol), 
37b was isolated as a colourless solid (0.290 g, 69%). 1H 
NMR (CDCl3, 250 MHz): δ = 2.15 (d, 2J = 17.0 Hz, 1 H, 
CHCH2), 2.42 (d, 2J= 19.5, Hz, 1 H, CHCH2), 2.82 – 3.06 (m, 2 H, CHCH2), 3.63 (s(br), 3 H, 
CO2CH3, isomer 1&2), 5.25 − 5.39 (m, 1 H, NCH), 5.41 – 5.62 (m, 1 H, NCH), 6.82 − 6.85 
(m, 1 H, CHAr), 6.93 − 7.06 (m, 3 H, CHAr), 7.31 − 7.43 (m, 4 H, CHAr), 16.17 (s, 1 H, OH). 
13C NMR (CDCl3, 62 MHz): δC = 34.8/35.2, 40.9/41.2 (CHCH2), 45.1/45.7, 48.4/49.0 (NCH), 
53.0/53.4 (CO2CH3), 109.3 (C), 126.4, 126.7/126.8, 127.6/127.7, 128.3, 128.6, 129.2, 
129.7/129.9, 130.7 (CHAr), 131.1, 134.9, 135.8, 136.8 (CAr), 154.3/154.6 (C-OH), 
187.4/188.1, 188.6/188.9 (C=O); IR (neat): v = 3034 (w), 3000 (w), 2990 (w), 2838 (w), 
1691 (s), 1447 (s), 1313 (s), 1023 (s), 759 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 385 ([M+], 
37Cl, 8), 383 ([M+], 35Cl, 21), 294 (37Cl, 33), 383 (35Cl, 100), 188 (68), 139 (51), 111 (25), 91 
(6), 59 (11); HRMS (EI): Calcd. for C21H18O4ClN, ([M+], 35Cl): 383.09189; found: 
383.09192.  
Methyl 11-hydroxy-10-(2-methylbenzoyl)-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37c): Starting with 36c (0.277 g, 
0.76 mmol) and TFA (0.173 g, 1.50 mmol), 37c was isolated 
as a colourless solid (0.201 g, 72%). 1H NMR (CDCl3, 250 
MHz): δ = 2.21 − 2.23 (m, 1 H, CHCH2), 2.25 (s, 3H, CH3), 
2.49 (d, 2J = 17.5, 1 H, CHCH2), 2.78 – 2.86 (m, 1 H, 
CHCH2), 2.98 – 3.13 (m, 1 H, CHCH2), 3.65 (s, 3 H, CO2CH3, isomer 1&2), 5.08 – 5.28 (m, 
1 H, NCH), 5.32 – 5.47 (m, 1 H, NCH), 6.89 – 6.91 (m, 1 H, CHAr), 7.01 – 7.10 (m, 3 H, 
CHAr), 7.14 – 7.29 (m, 4 H, CHAr), 16.20 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 
17.0/17.1 (CH3), 32.5/32.9, 39.1/39.5 (CHCH2), 43.5/44.2, 46.6/47.1 (NCH), 50.9 (CO2CH3), 
108.0 (C), 124.0, 124.2 (CAr), 124.4, 124.7, 125.7, 127.5, 127.7, 128.9, 129.2, 129.7 (CHAr), 














eV): m/z (%) = 363 ([M+], 24), 345 (11), 272 (100), 218 (14), 188 (13), 180 (26), 119 (26), 
77(5), 65 (9); HRMS (EI): Calcd. for C22H21O4N: 363.14651; found: 363.14570. 
 
Methyl 11-hydroxy-10-(2-methoxybenzoyl)-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37d):  Starting with 36d 
(0.210 g, 0.553 mmol) and TFA (0.126 g, 1.107 mmol), 
37d was isolated as a colourless solid (0.190 g, 69%). 1H 
NMR (CDCl3, 250 MHz): δ = 2.23 (d, 2J= 17.5 Hz. 1 H, 
CHCH2), 2.46 (d, 2J= 17.5 Hz, 1 H, CHCH2), 2.77 – 2.88 
(m, 1 H, CHCH2), 2.99 − 3.12 (m,1 H, CHCH2), 3.64 (s, 3H, OCH3), 3.83 (s, 3 H, CO2CH3, 
isomer 1&2), 5.19 – 5.31 (m, 1 H, NCH), 5.34 – 5.43 (m, 1 H, NCH), 6.86 – 7.18 (m, 7 H, 
CHAr), 7.33 – 7.39 (m, 1 H, CHAr), 16.03 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 
34.4/34.9, 40.3/40.7 (CHCH2), 45.3/45.9, 48.3/48.9 (NCH), 52.4 (OCH3), 55.4/55.6 
(CO2CH3), 110.8 (C), 111.3/111.5, 120.9/121.0, 126.5/126.6, 127.4/127.5, 128.1, 129.5/129.8 
(CHAr), 131.5/131.6 (2CHAr), 132.1, 136.2, 136.3, 154.2/154.4 (CAr), 155.0/155.3 (C-OH), 
184.5/185.0, 190.9/191.3 (C=O); IR (neat): v = 2956 (w), 2925 (w), 2910 (w), 2841 (w), 1693 
(s), 1442 (s), 1225 (s), 1012 (s), 750 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 379 ([M+], 27), 
361 (13), 330 (7), 288 (100), 258 (6), 212 (8), 188 (30), 135 (59), 115 (14), 77(21), 59 (7); 
HRMS (EI): Calcd. for C22H21O5N: 379.14142; found: 379.14091.  
 
Methyl 10-(2-chlorobenzoyl)-11-hydroxy-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37e):  Starting with 36e (0.350 g, 
0.911 mmol) and TFA (0.2079 g, 1.823 mmol), 37e was 
isolated as a colourless solid (0.274 g, 78%). 1H NMR 
(CDCl3, 250 MHz): δ = 2.37 (d, 2J = 16.1 Hz. 1 H, CHCH2), 
2.51 (d, 2J = 18.9 Hz, 1 H, CHCH2), 2.84− 2.90 (m,1 H, 
CHCH2), 3.01 – 3.15 (m, 1 H, CHCH2), 3.67 (s, 3 H, CO2CH3, isomer 1&2), 5.11 – 5.25 (m, 
1 H, NCH), 5.35 – 5.46 (m, 1 H, NCH), 6.96 (m, 1 H, CHAr), 7.04 – 7.19 (m, 3 H, CHAr), 7.34 
– 7.47 (m, 4 H, CHAr), 15.88 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 34.2/34.8, 
40.6/41.1 (CHCH2), 45.5/46.2, 48.3/49.0 (NCH), 50.9 (CO2CH3), 110.1 (C), 126.3 (CAr), 
126.6/126.7, 127.7 (CHAr), 127.6/127.7 (CAr), 127.9, 128.8, 129.6/129.9, 130.4/130.7, 130.9, 














(EI, 70 eV): m/z (%) = 385 ([M+], Cl37 7), 383 ([M+], Cl35 20), 365 (11), 348 (10), 330 (12), 
292 (100), 212 (10), 188 (20), 139 (30), 115 (12), 77(5); HRMS (EI): Calcd. for 
C21H18O4NCl: 383.09189 ([M+], Cl35); found: 383.09184 
 
Methyl 10-(2-fluorobenzoyl)-11-hydroxy-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37f): Starting with 36f (0.430 g, 
1.17 mmol) and TFA (0.226 g, 2.34 mmol), 37f was isolated as 
a light yellow solid (0.350 g, 81%). 1H NMR (CDCl3, 250 
MHz): δ = 2.24 (d, 2J = 19.5 Hz, 1 H, CHCH2), 2.49 (d, 2J = 
18.0, 1 H, CHCH2), 2.87 – 2.98 (m, 1 H, CHCH2), 3.06 – 3.12 
(m, 1 H, CHCH2), 3.66 (s, 3 H, CO2CH3, isomer 1&2), 5.18 – 5.30 (m, 1 H, NCH), 5.37 – 
5.44 (m, 1 H, NCH), 6.90 – 7.23 (m, 8 H, CHAr), 15.93 (s, 1 H, OH). 13C NMR (CDCl3, 62 
MHz): δC = 34.6/35.1, 40.6/41.1 (CHCH2), 45.2/45.8, 48.3/48.9 (NCH), 52.9 (CO2CH3), 
110.7 (C), 116.4/116.7 (2CHAr), 124.7 (d, 4J = 3.1 Hz, CHAr), 126.3 (CAr), 126.6/126.7, 
(CHAr), 127.5 (d, 3J = 7.2 Hz, CHAr), 128.6, 129.6/129.9 (CHAr), 131.0/131.4 (CAr), 132.1 (d, 
3J =7.9 Hz, CHAr), 135.9/136.0 (CAr), 154.4/154.5 (C-OH), 158.0/158.2 (d, 1J = 245.0 Hz, 
CFAr), 186.4/186.8, 186.9/187.3 (C=O); IR (neat): v = 2957 (w), 2930 (w), 2915 (w), 2848 
(w), 1693 (s), 1448 (s), 1210 (s), 1022 (s), 754 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 367 
([M+], 70), 349 (45), 276 (100), 258 (20), 188 (73), 123 (83), 95 (37), 57(32).; HRMS (EI): 
Calcd. for C21H18O4NF: 367.12144; found: 367.12106  
Methyl 11-hydroxy-10-(4-nitrobenzoyl)-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37g): Starting with 36g 
(0.169 g, 0.43 mmol) and TFA (0.097 g, 085 mmol), 
37g was isolated as a colourless solid (0.100 g, 60%). 
1H NMR (CDCl3, 250 MHz): δ = 2.19 (d, 2J = 16.1 
Hz, 1 H, CHCH2), 2.53 (d, 2J = 19.0, Hz, 1 H, 
CHCH2), 2.91 – 3.17 (m, 2 H, CHCH2), 3.71 (s, 3 H, CO2CH3, isomer 1&2), 5.22 − 5.41 (m, 
1 H, NCH), 5.46 – 5.59 (m, 1 H, NCH), 6.90 − 6.93 (s, 1 H, CHAr), 7.05 − 7.15 (s, 3 H, 
CHAr), 7.61 − 7.71 (m, 2 H, CHAr), 8.30 − 8.33 (m, 2 H, CHAr),16.05 (s, 1 H, OH). 13C NMR 
(CDCl3, 62 MHz): δC = 34.9/35.3, 40.8/41.3 (CHCH2), 45.0/45.7, 48.3/49.0 (NCH), 53.1/53.4 
(CO2CH3), 109.5 (C), 124.2 (2CHAr), 124.4, 126.7/126.9, 127.8/127.9, 128.2, 129.6/129.9, 














(C=O); MS (EI, 70 eV): m/z (%) = 394 ([M+], 19), 376 (23), 346 (6), 303 (100), 273 (30), 188 
(92), 180 (19), 120 (71), 92 (12), 73 (11), 57 (20).; HRMS (EI): Calcd. for C21H18O6N2: 




Starting with 36h (0.180 g, 0.41 mmol) and TFA 
(0.093 g, 0.82 mmol), 37h was isolated as a 
colourless solid (0.100 g, 55%). 1H NMR (CDCl3, 
250 MHz): δ = 2.29 (d, 2J = 15.7 Hz, 1 H, 
CHCH2), 2.46 (d, 2J = 15.5, Hz, 1 H, CHCH2), 
2.73 – 2.99 (m, 1 H, CHCH2), 3.09 – 3.18 (m, 1 H, CHCH2), 3.70 (s, 3 H, CO2CH3, isomer 1), 
3.73 (s, 3 H, CO2CH3, isomer 2) 3.83 − 3.87 (m(br), 9 H, OCH3, isomer 1&2), 5.14 − 5.45 (m, 
1 H, NCH), 5.60 – 5.90 (m, 1 H, NCH), 6.70 (s, 1 H, CHAr), 6.78 (s, 1 H, CHAr), 7.00 − 7.19 
(m, 4 H, CHAr), 16.21 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 34.9/35.3, 40.5/40.9 
(CHCH2), 45.1/45.8, 48.4/49.0 (NCH), 53.0 (OCH3), 56.2/56.3 (CO2CH3), 61.0, 64.2/64.4 
(OCH3), 108.9/109.1 (C), 126.4/126.6, 127.2/127.3, 127.5/127.6, 129.5/129.7, 129.9/130.0, 
130.4/130.5 (CHAr), 131.7/131.8, 135.5/135.9, 139.9, 153.0, 153.5, 154.4 (CAr), 154.7 (C-
OH), 186.9/187.0, 190.4/190.5 (C=O); MS (EI, 70 eV): m/z (%) = 439 ([M+], 80), 348 (100), 
294 (25), 212(7), 188 (61), 85 (8), 71 (12), 57 (22); HRMS (EI): Calcd. for C24H25O7N: 
439.16255; found: 439.16281 
Methyl 11-hydroxy-10-(1-naphthoyl)-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37i): Starting with 36i (0.115 g, 
0.28 mmol) and TFA (0.067 g, 0.57 mmol), 37i was 
isolated as a colourless solid (0.080 g, 70%, mp. = 154-156 
oC). 1H NMR (CDCl3, 250 MHz): δ = 2.00 − 2.07 (m, 1 H, 
CHCH2), 2.53 (d, 2J = 15.0 Hz, 1 H, CHCH2), 2.59 – 2.69 
(m, 1 H, CHCH2), 3.04 − 3.19 (m,1 H, CHCH2), 3.56 (s, 3 H, CO2CH3, isomer 1), 3.63 (s, 3 
H, CO2CH3, isomer 2), 5.18 (m, 1 H, NCH), 5.31 – 5.43 (m, 1 H, NCH), 6.75 (m, 1 H, CHAr), 
7.01 – 7.15 (m, 3 H, CHAr), 7.38 – 7.50 (m, 4 H, CHAr), 7.67 (m, 1 H, CHAr), 7.83− 7.91 (m, 2 
H, CHAr), 16.08 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 34.8/35.2, 41.1/41.6 


















125.1, 126.4 (CHAr), 126.9 (2CHAr), 127.1/127.3, 127.5/127.6, 128.5, 129.5, 129.8 (CHAr), 
130.2, 131.1, 131.7, 133.3/133.6, 135.9/136.0 (CAr), 154.5 (C-OH), 188.6, 190.1/190.5 
(C=O); GC-MS (EI, 70 eV): m/z (%) = 399 ([M+], 50), 382 (10), 356 (15), 308 (100), 280 
(41), 253 (19), 212 (20), 188 (12), 155 (44), 127 (4); HRMS (EI): Calcd. for C25H21O4N: 
399.14651; found: 399.14617.  
 
Methyl 11-hydroxy-10-(2-naphthoyl)-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37j): Starting with 36j 
(0.399 g, 1.00 mmol) and TFA (0.228 g, 2.00 mmol), 
37j was isolated as a slightly yellow solid (0.307 g, 
77%, mp. = 166-168 oC). 1H NMR (CDCl3, 250 MHz): 
δ = 2.33 (d, 2J = 15.5 Hz, 1 H, CHCH2), 2.60 (d, 2J = 
18.5 Hz, 1 H, CHCH2), 3.01 – 3.34 (m, 1 H, CHCH2), 3.35 − 3.51 (m,1 H, CHCH2), 3.72 (s, 3 
H, CO2CH3, isomer 1), 3.83 (s, 3 H, CO2CH3, isomer 2), 5.25 − 5.44 (m, 1 H, NCH), 5.79 – 
5.96 (m, 1 H, NCH), 6.94 − 7.24 (m, 4 H, CHAr), 7.56 – 7.71 (m, 2 H, CHAr), 7.85 – 8.13 (m, 
4 H, CHAr), 8.20 (s, 1 H, CHAr), 16.18 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 
34.8/35.3, 40.8/41.2 (CHCH2), 45.2/45.8, 48.4/49.1 (NCH), 53.0/53.1 (CO2CH3), 109.1 (C), 
123.7/123.8, 126.3/126.4, 126.6, 126.9, 127.0, 127.2, 127.4, 127.6/127.7, 127.8/127.9, 
128.8/128.9, 129.7/129.9 (CHAr), 130.9, 131.4, 132.6, 133.9/134.1, 135.9/136.1 (CAr), 154.7 
(C-OH), 187.1/187.1, 189.8/190.3 (C=O IR (neat): v = 3061 (w), 3042 (w), 2956 (w), 2849 
(w), 1699 (s), 1443 (s), 1219 (s), 1006 (s), 750 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 399 
([M+], 63), 382 (12), 356 (5), 308 (100), 280 (11), 253 (19), 212 (23), 188 (15), 155 (44), 127 




pentaene-13-carboxylate (37k): Starting with 36k (0.300 g, 
0.85 mmol) and TFA (0.195 g, 1.71 mmol), 37k was isolated 
as a yellow oil (0.080g, 27%). 1H NMR (CDCl3, 250 MHz): 
δ = 2.49 (d, 2J = 17.9 Hz, 1H, CHCH2), 2.78 − 2.85 (m, 1H, 
CHCH2), 3.01 – 3.16 (m, 1 H, CHCH2), 3.18 − 3.29 (m,1 H, 















H, NCH), 6.94 − 7.07 (m, 4 H, CHAr), 7.43 – 7.47 (m, 1 H, CHAr), 7.86 – 7.95 (m, 1 H, CHAr), 
8.08 − 8.14 (s, 1 H, CHAr), 8.54 (m, 1 H, CHAr), 15.59 (s, 1 H, OH). 13C NMR (CDCl3, 62 
MHz): δC = 35.0, 40.9/41.4 (CHCH2), 45.8/46.3, 48.6/49.1 (NCH), 52.8 (CO2CH3), 111.1 (C), 
124.7, 125.3, 126.2/126.5, 127.2/127.4, 129.6, 130.0, 133.0, 133.4 (CHAr), 136.3/136.4, 
138.2, 138.6 (CAr), 154.4/154.8 (C-OH), 183.2, 192.2 (C=O); GC-MS (EI, 70 eV): m/z (%) = 
350 ([M+], 34), 275 (4), 259 (100), 188 (66), 162 (7), 144 (9), 106 (11), 78 (28), 59 (4); 
HRMS (EI): Calcd. for C20H18O4N2: 350.12611; found: 350.12604. 
 
Methyl 11-hydroxy-10-(2-thienylcarbonyl)-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37l):  Starting with 36l (0.120 g, 
0.35 mmol) and TFA (0.045 g, 0.40 mmol), 37l was isolated 
as a reddish viscous oil (0.041g, 34%, mp. = 37-40 oC). 1H 
NMR (CDCl3, 250 MHz): δ = 2.45− 2.47 (m, 1 H, CHCH2 
isomer 1), 2.51 − 2.54 (m, 1 H, CHCH2 isomer 2), 2.76 (d, 
2J= 15.0 Hz, 1 H, CHCH2 isomer 1), 2.83 (d, 2J= 15.0 Hz, 1 H, CHCH2 isomer 2), 3.01− 3.21 
(m, 1 H, CHCH2 isomer 1&2), 3.32− 3.40 (m, 1 H, CHCH2 isomer 1&2), 3.69 (s, 3 H, 
CO2CH3, isomer 1), 3.74 (s, 3 H, CO2CH3, isomer 2), 5.36 − 5.40 (m, 1 H, NCH isomer 1&2), 
5.87 – 6.03 (m, 1 H, NCH isomer 1&2), 6.97 − 7.18 (m, 5 H, CHAr), 7.61 – 7.77 (m, 2 H, 
CHAr). 13C NMR (CDCl3, 62 MHz): δC = 34.8/35.4, 40.9/41.3 (CHCH2), 45.0/45.7, 48.2/48.7 
(NCH), 53.0 (CO2CH3), 108.1 (C), 126.3/126.7, 127.3/127.6, 128.5, 129.7/130.0, 
131.7/131.9, 133.0, 133.8 (CHAr), 135.4, 136.4, 140.3 (CAr), 154.6/155.1 (C-OH), 
178.8/179.4, 187.2/188.1 (C=O); IR (neat): v = 3097 (w), 2990 (w), 2948 (w), 2851 (w), 
1690 (s), 1448 (s), 1249 (s), 1022 (s), 749 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 355 ([M+], 
36), 337 (15), 264 (86), 188 (100), 180 (37), 170 (10), 144 (15), 111 (68), 97 (19), 83 (21), 69 
(25), 57 (29); HRMS (EI): Calcd. for C19H17NO4S: 355.08728; found: 355.08729. 
 
Methyl 10-(4-chlorobenzoyl)-11-hydroxy-6-nitro-13-azatricyclo[7.3.1.02,7]trideca-
2,4,6,8,10-pentaene-13-carboxylate (37m):  Starting 
with 36m (0.399 g, 1.00 mmol) and TFA (0.229 g, 2.01 
mmol), 37m was isolated as a light yellow solid (0.300g, 
















19.0 Hz, 1 H, CHCH2), 2.58 (d, 2J = 18.0 Hz, 1 H, CHCH2), 3.05 – 3.27 (m, 2 H, CHCH2), 
3.67 (s, 3 H, CO2CH3, isomer 1), 3.74 (s, 3 H, CO2CH3, isomer 2), 5.17 − 5.44 (m, 1 H, 
NCH), 5.54 – 5.81 (m, 1 H, NCH), 7.29 − 7.45 (m, 5 H, CHAr), 7.79 – 7.89 (m, 2 H, CHAr), 
16.13 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 32.6/33.0, 40.4/40.8 (CHCH2), 
44.3/45.0, 48.4/49.1 (NCH), 53.3/53.4 (CO2CH3), 108.9 (C), 124.3, 127.3/127.4, 128.2/128.3, 
128.5, (CHAr), 129.3 (2CHAr), 130.2 (CHAr), 131.1/131.8, 134.4, 137.3, 138.8, 149.9 (CAr), 
154.3 (C-OH), 185.9/186.5, 189.5/189.6 (C=O); IR (neat): v = 3082 (w), 3009 (w), 2954 
(w), 2852 (w), 1699 (s), 1445 (s), 1221 (s), 1013 (s), 768 (s) cm–1; GCMS (EI, 70 eV): m/z 
(%) = 430 ([M++1], 37Cl, 1), 428 ([M++1], 35Cl, 3), 390 (100), 312 (35), 256 (30), 210 (10); 
HRMS (EI): Calcd. for C21H17O6N2: ([M+], 35Cl), 428.07697; found: 428.07755. 
 
Methyl 10-(4-fluorobenzoyl)-11-hydroxy-6-nitro-13-azatricyclo[7.3.1.02,7]trideca-
2,4,6,8,10-pentaene-13-carboxylate (37n): Starting with 
36n (0.396 g, 1.04 mmol) and TFA  (0.237 g, 2.08 mmol), 
37n was isolated as a colourless solid (0.220g, 55%, mp. = 
150-153 oC). 1H NMR (CDCl3, 250 MHz): δ = 2.42 (d, 2J = 
15.0 Hz, 1 H, CHCH2), 2.53 (d, 2J = 15.8 Hz, 1 H, 
CHCH2), 2.99 – 3.23 (m, 2 H, CHCH2), 3.62 (s, 3 H, CO2CH3, isomer 1), 3.68 (s, 3 H, 
CO2CH3, isomer 2), 5.12 − 5.38 (m, 1 H, NCH), 5.49 – 5.74 (m, 1 H, NCH), 7.03 − 7.09 (m, 2 
H, CHAr), 7.26 − 7.50 (m, 3 H, CHAr), 7.74 – 7.88 (m, 2 H, CHAr), 16.09 (m(br), 1 H, OH). 13C 
NMR (CDCl3, 62 MHz): δC = 32.6/33.0, 40.4/40.7 (CHCH2), 44.3/45.0, 48.4/49.1 (NCH), 
53.2/53.4 (CO2CH3), 108.7/108.9 (C),  116.3 (d, 2J = 21.0 Hz, 2CHAr), 124.4/124.7, 
127.2/127.3, 127.9/128.3 (CHAr), 129.2 (d, 3J = 8.4 Hz, CHAr), 129.5 (d, 3J = 10.0 Hz, CHAr), 
131.5/131.7, 132.3, 138.3/138.8, 148.9/149.8 (CAr), 154.4 (C-OH), 162.1 (d, 1J = 241.8 Hz, 
CFAr), 185.6/186.4, 189.5/189.8 (C=O); IR (neat): v = 3079 (w), 3002 (w), 2954 (w), 2815 
(w), 1698 (s), 1444 (s), 1224 (s), 1032 (s), 784 (s) cm–1; MS (EI, 70 eV): m/z (%) = 412 ([M+], 
11), 382 (10), 364 (28), 276 (100), 233 (69), 203 (35), 180 (13), 123 (99), 95 (34); HRMS 












2,4,6,8,10-pentaene-13-carboxylate (37o): Starting with 36o 
(0.410 g, 1.09 mmol) and TFA  (0.248 g, 2.18 mmol), 37o 
was isolated as a colourless solid (0.355g, 69%. 1H NMR 
(CDCl3, 250 MHz): δ = 2.18 (s, 3 H, CH3), 2.49 (d, 2J = 15.0 
Hz, 1 H, CHCH2), 2.52 (d, 2J = 15.1, Hz, 1 H, CHCH2), 2.92 
– 2.98 (m, 2 H, CHCH2), 3.70 (s, 3 H, CO2CH3, isomer 1&2), 5.13 − 5.32 (m, 1 H, NCH), 
5.41 – 5.55 (m, 1 H, NCH), 7.11 − 7.34 (m, 6 H, CHAr), 7.75 − 7.79 (m, 1 H, CHAr), 16.17 (s, 
1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 18.8/19.0 (CH3), 32.0/32.4, 40.7/41.2 (CHCH2), 
44.7/45.3, 48.6/49.3 (NCH), 53.2 (CO2CH3), 109.4/109.6 (C), 124.1 (CHAr), 125.9 (CAr), 
126.2, 127.4, 128.3, 130.2, 131.1, 131.5/131.8 (CHAr), 134.2, 135.2, 138.8/138.9, 149.9/150.1 
(CAr), 154.1/154.3 (C-OH), 186.7/187.3, 191.8/192.2 (C=O); HRMS (EI): Calcd. for 
C22H20O6N2: 408.13159; found: 408.13276. 
 
Methyl 10-(2-fluorobenzoyl)-11-hydroxy-6-nitro-13-azatricyclo[7.3.1.02,7]trideca-
2,4,6,8,10-pentaene-13-carboxylate (37p): Starting with 
36p (0.210 g, 0.55 mmol) and TFA  (0.125 g, 1.10 mmol), 
37p was isolated as a slightly yellow solid (0.180 g, 86%). 
1H NMR (CDCl3, 250 MHz): δ = 2.50 (d, 2J= 15.8 Hz, 1 H, 
CHCH2), 2.60 (d, 2J= 15.8 Hz, 1 H, CHCH2), 3.05 – 3.20 (m, 2 H, CHCH2), 3.72 (s, 3 H, 
CO2CH3, isomer 1&2), 5.30 − 5.43 (m, 1 H, NCH), 5.46 – 5.57 (m, 1 H, NCH), 7.15 − 7.34 
(m, 5 H, CHAr), 7.43 (m, 1 H, CHAr), 7.78 – 7.82 (m, 1 H, CHAr), 15.89 (s(br), 1 H, OH). 13C 
NMR (CDCl3, 62 MHz): δC = 32.2/32.8, 40.2/40.7 (CHCH2), 44.3/45.0, 48.2/49.0 (NCH), 
53.2 (CO2CH3), 110.4 (C), 116.4/116.8, 124.3, 125.1, 127.3 (CHAr), 128.3 (CAr), 128.4 (d, 2J 
= 16.5 Hz, CHAr), 129.1 (CHAr), 131.6 (d, 4J = 2.3 Hz, CHAr), 132.5 (d, 3J = 8.2 Hz, CHAr) 
139.0 (2CAr), 149.6 (CAr), 154.4 (C-OH), 185.5/185.8, 187.5 (C=O); MS (CI, 70 eV): m/z (%) 
= 413 ([M+1], 23), 393 (24), 363 (15), 233 (100), 203 (15); HRMS (CI): Calcd. for 




















2,4,6,8,10-pentaene-13-carboxylate (37q): Starting with 
36q (0.416 g, 1.05 mmol) and TFA  (0.239 g, 2.09 mmol), 
37q was isolated as a light yellow solid (0.205 g, 60%). 1H 
NMR (CDCl3, 250 MHz): δ = 2.45 (d, 2J = 16.7 Hz. 1 H, 
CHCH2), 2.66 (d, 2J = 14.6 Hz, 1 H, CHCH2), 2.94− 3.10 (m, 
2 H, CHCH2), 3.64 (s, 3 H, CO2CH3, isomer 1&2), 5.09 – 5.24 (m, 1 H, NCH), 5.37 – 5.50 
(m, 1 H, NCH), 7.14 (m, 1 H, CHAr), 7.27 – 7.42 (m, 5 H, CHAr), 7.72 – 7.76 (m, 1 H, CHAr), 
15.78 (s, 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 31.9/32.5, 40.2/40.7 (CHCH2), 
44.6/45.2, 48.4/49.1 (NCH), 53.2 (CO2CH3), 109.6 (C), 124.2, 127.4, 127.7, 127.9, 128.3, 
130.5, 131.3 (CHAr), 131.7, 133.1, 135.1, 139.0, 149.9 (CAr), 154.3 (C-OH), 185.8, 189.8 
(C=O); IR (neat): v = 3011 (w), 1990 (w), 2956 (w), 2849 (w), 1698 (s), 1443 (s), 1219 (s), 
1029 (s), 731 (s) cm–1; GC-MS (CI, 70 eV): m/z (%) = 431 ([M++1], 37Cl, 3), 429 ([M++1], 
35Cl, 10), 391 (100), 313 (30), 257 (35), 211 (20); HRMS (EI): Calcd. for C21H17O6N2Cl: 
([M+], 35Cl), 428.07697; found: 428.07755. 
 
Methyl 11-hydroxy-10-(2-naphthoyl)-6-nitro-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (37r): Starting with 36r 
(0.443 g, 1.00 mmol) and TFA (0.228 g, 2.00 mmol), 
37r was isolated as a yellowish solid (0.280 g, 63%). 
1H NMR (CDCl3, 250 MHz): δ = 2.49 (d, 2J = 17.5 
Hz, 1 H, CHCH2), 2.61 (d, 2J = 19.0 Hz, 1 H, CHCH2), 
3.02 – 3.11 (m, 2 H, CHCH2), 3.73 (s, 3 H, CO2CH3, isomer 1&2), 5.41− 5.56 (m, 1 H, 
NCH), 5.70 – 5.91 (m, 1 H, NCH), 7.18 (m, 1 H, CHAr), 7.21 – 7.36 (m, 2 H, CHAr), 7.46 – 
7.53 (m, 3 H, CHAr), 7.75 − 8.03 (m, 4 H, CHAr), 16.22 (s, 1 H, OH). 13C NMR (CDCl3, 62 
MHz): δC = 34.8/35.2, 41.1/41.6 (CHCH2), 45.7/46.2, 48.5/49.1 (NCH), 52.9/53.4 (CO2CH3), 
110.9 (C), 124.5/124.6, 124.7, 125.1, 126.4 (CHAr), 126.9 (2CHAr), 127.1/127.3, 127.5/127.6, 
128.5, 129.5, 129.8 (CHAr), 130.2, 131.1, 131.7, 133.3/133.6, 135.9/136.0 (CAr), 154.5 (C-
OH), 188.6, 190.1/190.5 (C=O); IR (neat): v = 3033 (w), 3014 (w), 2958 (w), 2852 (w), 1702 
(s), 1528 (s), 1340 (s), 1029 (s), 771 (s) cm–1; GC-MS (EI, 70 eV): m/z (%) = 444 ([M+], 10), 
425 (16), 385 (10), 308 (90), 257 (13), 233 (37), 180 (40), 155 (100), 143 (29), 125 (43), 59 














pentaene-13-carboxylate (39f): Starting with 38f 
(0.200 g, 0.43 mmol) and TFA (0.869 g, 0.69 mmol), 
39f was isolated as a yellowish gummy solid (0.163 g, 
81%). 1H NMR (CDCl3, 250 MHz): δ = 2.20 – 2.29 (m, 
1 H, CHCH2), 2.45 – 2.52 (m, 1 H, CHCH2), 2.91 – 3.17 
(m, 2 H, CHCH2), 5.37 – 5.48 (m, 1 H, NCH), 5.22 (s, 2 
H, CO2CH2, isomer 1&2), 5.47− 5.73 (m, 1 H, NCH), 7.15 – 7.50 (m, 13 H, CHAr), 16.05 
(s(br), 1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 34.8/35.3, 40.7/41.2 (CHCH2), 45.1/45.8, 
48.5/49.1 (NCH), 67.3/67.9 (CO2CH2), 109.4 (C), 126.4/136.6, 126.4/126.6, 126.7/126.8 
(CHAr), 127.6/127.7 (2CHAr), 128.1/128.3, 128.4/128.6,128.65/128.7 (CHAr), 129.0/129.1 
(2CHAr), 129.6/129.8, 130.5, 131.1, 132.0/132.1(CHAr), 133.5/133.8, 134.7/134.8, 
135.9/136.1, 136.7, 137.1 (CAr), 153.7/154.1 (C-OH), 187.4/187.9, 188.4/188.9 (C=O); MS 
(EI, 70 eV): 461 ([M++1], 37Cl, 3), 459 ([M++1], 35Cl, 8), 434 (4), 375 (7), 324  (17), 264 (5), 
212 (10), 181 (6), 138 (26), 111 (19), 91 (100), 69 (32), 57 (51), 44 (86); HRMS (EI): Calcd. 
for C27H22O4NCl: ([M+], 35Cl), 459.12313; found: 459.12318. 
 
Benzyl 10-(2-chlorobenzoyl)-11-hydroxy-13-azatricyclo[7.3.1.02,7]trideca-2,4,6,8,10-
pentaene-13-carboxylate (39g). Starting with 38g (0.424 g, 
0.923 mmol) and TFA (0.210 g, 2.10 mmol), 39g was 
isolated as a gummy  solid (0.212 g, 50%). 1H NMR (CDCl3, 
250 MHz): δ = 2.31 – 2.56 (m, 2 H, CHCH2), 2.83 – 3.18 (m, 
2 H, CHCH2), 5.00 – 5.18 (m, 1 H, NCH), 5.22 (s, 2 H, 
CO2CH2, isomer 1&2), 5.27− 5.46 (m, 1 H, NCH), 6.97 – 
7.11 (m, 4 H, CHAr), 7.29 – 7.37 (m, 9 H, CHAr), 15.70 (s(br), 
1 H, OH). 13C NMR (CDCl3, 62 MHz): δC = 34.3/34.8, 40.6/40.9 (CHCH2), 45.5/46.1, 
48.4/49.0 (NCH), 67.7 (CO2CH2), 110.0 (C), 126.3, 126.6, 126.8/126.9, 127.2, 127.6/127.7, 
127.9, 128.1, 128.2/128.3, 128.5, 128.6 , 129.7, 129.9, 130.4 (CHAr), 131.1, 131.6, 135.4, 
135.8, 136.3 (CAr), 154.2 (C-OH), 187.0, 189.4 (C=O); MS (EI, 70 eV): 461 ([M++1], 37Cl, 
8), 459 ([M++1], 35Cl, 23), 444 (8), 414 (2), 368 (18), 324 (65), 288 (114), 212 (21), 198 (21), 
161 (18), 129 (34), 91 (100), 57 (18), 44 (80); HRMS (EI): Calcd. for C27H22O4NCl: ([M+], 
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X-Ray Crystals Data 
Data for compound 19m Chapter 2:  
 
data_  ks      709m  
  
_audit_creation_method            SHELXL-97  
_chemical_name_systematic  
_chemical_name_common             ?  
_chemical_melting_point           ?  
_chemical_formula_moiety          ?  
_chemical_formula_sum '           C16 H15 N O5'  
 
 _chemical_formula_weight          301.29  
 
loop_  
 _atom_type_symbol  
 _atom_type_description  
 _atom_type_scat_dispersion_real  
 _atom_type_scat_dispersion_imag  
 _atom_type_scat_source  
 'C'  'C'   0.0033   0.0016  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'H'  'H'   0.0000   0.0000  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'N'  'N'   0.0061   0.0033  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'O'  'O'   0.0106   0.0060  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
  
_symmetry_cell_setting            monoclinic  
_symmetry_space_group_name_H-M    P2(1)/n  
  
loop_  
 _symmetry_equiv_pos_as_xyz  
 'x, y, z'  
 '-x+1/2, y+1/2, -z+1/2'  
 '-x, -y, -z'  
 'x-1/2, -y-1/2, z-1/2'  
  
 152
_cell_length_a                    13.539(3)  
_cell_length_b                    7.6294(15)  
_cell_length_c                    13.870(3)  
_cell_angle_alpha                 90.00  
_cell_angle_beta                  98.50(3)  
_cell_angle_gamma                 90.00  
_cell_volume                      1417.0(5)  
_cell_formula_units_Z             4  
_cell_measurement_temperature     200(2)  
_cell_measurement_reflns_used     all  
_cell_measurement_theta_min       ?  
_cell_measurement_theta_max       ?  
  
_exptl_crystal_description        prism  
_exptl_crystal_colour             colourless  
_exptl_crystal_size_max           0.50 
_exptl_crystal_size_mid           0.45 
_exptl_crystal_size_min           0.30  
_exptl_crystal_density_meas       ?  
_exptl_crystal_density_diffrn     1.412  
_exptl_crystal_density_method     'not measured'  
_exptl_crystal_F_000              632  
_exptl_absorpt_coefficient_mu     0.106  
_exptl_absorpt_correction_type    none  
_exptl_absorpt_correction_T_min   ?  
_exptl_absorpt_correction_T_max   ?  
_exptl_absorpt_process_details    ?  
 
Data for compound 26a Chapter 3: 
 
Table 1.  Crystal data and structure refinement for  ah137cl. 
Identification code  ah137cl 
Empirical formula  C15H13Cl O3 
Formula weight  276.70 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group (H.-M.) Pnma  
Space group (Hall) -P 2ac 2n  
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Unit cell dimensions a = 14.3783(6) Å α= 90°. 
 b = 6.9445(4) Å β= 90°. 
 c = 13.1845(6) Å γ = 90°. 
Volume 1316.47(11) Å3 
Z 4 
Density (calculated) 1.396 Mg/m3 
Absorption coefficient 0.291 mm-1 
F(000) 576 
Crystal size 0.98 x 0.29 x 0.08 mm3 
θ range for data collection 2.10 to 29.99°. 
Index ranges -20≤h≤19, -9≤k≤8, -18≤l≤16 
Reflections collected 10853 
Independent reflections 1960 [R(int) = 0.0363] 
Completeness to θ = 29.99° 94.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9777 and 0.7639 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1960 / 0 / 113 
Goodness-of-fit on F2 1.054 
Final R indices [I>2σ(I)] R1 = 0.0388, wR2 = 0.1048 
R indices (all data) R1 = 0.0523, wR2 = 0.1171 
Extinction coefficient 0.003(2) 
Largest diff. peak and hole 0.423 and -0.243 e.Å-3 
 
Data for compound 27d Chapter 3: 
 
Table 1.  Crystal data and structure refinement for fo3174. 
Identification code  FO3174 
Empirical formula  C16 H13 Cl O3 
Formula weight  288.71 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 17.9894(10) Å α= 90°. 
 b = 6.8769(3) Å β= 90°. 
 c = 20.6852(13) Å γ = 90°. 
Volume 2559.0(2) Å3 
Z 8 
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Density (calculated) 1.499 Mg/m3 
Absorption coefficient 0.302 mm-1 
F(000) 1200 
Crystal size 0.05 x 0.05 x 0.04 mm3 
Theta range for data collection 2.26 to 27.48°. 
Index ranges -23<=h<=22, -8<=k<=8, -26<=l<=25 
Reflections collected 19690 
Independent reflections 2929 [R(int) = 0.1290] 
Completeness to theta = 27.48° 99.9 %  
Absorption correction NONE 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2929 / 0 / 186 
Goodness-of-fit on F2 1.020 
Final R indices [I>2sigma(I)] R1 = 0.0551, wR2 = 0.1123 
R indices (all data) R1 = 0.1348, wR2 = 0.1418 
Largest diff. peak and hole 0.385 and -0.421 e.Å-3 
 
Data for compound 34f Chapter 4: 
 
Table 1.  Crystal data and structure refinement for 34f (FO3176). 
Identification code  FO3176 
Empirical formula  C20 H12 Br F O4 
Formula weight  415.21 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pbca 
Unit cell dimensions a = 7.5626(2) Å α= 90°. 
 b = 19.2580(5) Å β= 90°. 
 c = 22.4319(4) Å γ = 90°. 
Volume 3266.99(13) Å3 
Z 8 
Density (calculated) 1.688 Mg/m3 
Absorption coefficient 2.551 mm-1 
F(000) 1664 
Crystal size 0.04 x 0.04 x 0.02 mm3 
Theta range for data collection 2.79 to 27.48°. 
Index ranges -9<=h<=9, -25<=k<=24, -28<=l<=29 
Reflections collected 21125 
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Independent reflections 3734 [R(int) = 0.0517] 
Completeness to theta = 27.48° 99.8 %  
Absorption correction NONE 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3734 / 0 / 243 
Goodness-of-fit on F2 1.006 
Final R indices [I>2sigma(I)] R1 = 0.0324, wR2 = 0.0759 
R indices (all data) R1 = 0.0506, wR2 = 0.0841 
Largest diff. peak and hole 0.376 and -0.530 e.Å-3 
 
Data for compound 34m Chapter 4: 
 
Table 1.  Crystal data and structure refinement for 34m (FO3180). 
Identification code  FO3180 
Empirical formula  C20 H12 Br F O4 
Formula weight  415.21 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  Pc 
Unit cell dimensions a = 9.0722(4) Å α= 90°. 
 b = 26.1738(5) Å β= 73.646(2)°. 
 c = 7.3483(3) Å γ = 90°. 
Volume 1674.29(11) Å3 
Z 4 
Density (calculated) 1.647 Mg/m3 
Absorption coefficient 2.489 mm-1 
F(000) 832 
Crystal size 0.04 x 0.04 x 0.04 mm3 
Theta range for data collection 2.34 to 27.56°. 
Index ranges -11<=h<=11, -33<=k<=28, -9<=l<=9 
Reflections collected 10672 
Independent reflections 6004 [R(int) = 0.0948] 
Completeness to theta = 27.56° 97.0 %  
Absorption correction NONE 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6004 / 2 / 469 
Goodness-of-fit on F2 1.070 
Final R indices [I>2sigma(I)] R1 = 0.0756, wR2 = 0.1838 
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R indices (all data) R1 = 0.1035, wR2 = 0.2105 
Absolute structure parameter 0.018(18) 
Largest diff. peak and hole 1.483 and -0.886 e.Å-3 
 
 
Data for compound 37d Chapter 5: 
 
Data for _ks720o   
_audit_creation_method            SHELXL-97  
_chemical_name_systematic  
_chemical_name_common             ?  
_chemical_melting_point           ?  
_chemical_formula_moiety          ?  
_chemical_formula_sum                 'C22 H21 N O5'  
_chemical_formula_weight          379.40  
  
loop_  
 _atom_type_symbol  
 _atom_type_description  
 _atom_type_scat_dispersion_real  
 _atom_type_scat_dispersion_imag  
 _atom_type_scat_source  
 'C'  'C'   0.0033   0.0016  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'H'  'H'   0.0000   0.0000  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'N'  'N'   0.0061   0.0033  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'O'  'O'   0.0106   0.0060  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
  
_symmetry_cell_setting            orthorhombic  
_symmetry_space_group_name_H-M    P2(1)2(1)2(1)  
  
loop_  
 _symmetry_equiv_pos_as_xyz  
 'x, y, z'  
 '-x+1/2, -y, z+1/2'  
 '-x, y+1/2, -z+1/2'  
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 'x+1/2, -y+1/2, -z'  
  
_cell_length_a                    8.7657(2)  
_cell_length_b                    12.8998(4)  
_cell_length_c                    16.4167(4)  
_cell_angle_alpha                 90.00  
_cell_angle_beta                  90.00  
_cell_angle_gamma                 90.00  
_cell_volume                      1856.33(8)  
_cell_formula_units_Z             4  
_cell_measurement_temperature     200(2)  
_cell_measurement_reflns_used     all  
_cell_measurement_theta_min       ?  
_cell_measurement_theta_max       ?  
  
_exptl_crystal_description        prism 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.50  
_exptl_crystal_size_mid           0.43 
_exptl_crystal_size_min           0.35 
_exptl_crystal_density_meas       ?  
_exptl_crystal_density_diffrn     1.358  
_exptl_crystal_density_method     'not measured'  
_exptl_crystal_F_000              800  
_exptl_absorpt_coefficient_mu     0.097  
_exptl_absorpt_correction_type    none  
_exptl_absorpt_correction_T_min   ?  
  
Data for compound 37f Chapter 5: 
 
Data for _ks719 37f  
_audit_creation_method            SHELXL-97  
_chemical_name_systematic  
_chemical_name_common             ?  
_chemical_melting_point           ?  
_chemical_formula_moiety          ?  
_chemical_formula_sum           'C21 H18 F N O4'  




 _atom_type_symbol  
 _atom_type_description  
 _atom_type_scat_dispersion_real  
 _atom_type_scat_dispersion_imag  
 _atom_type_scat_source  
 'C'  'C'   0.0033   0.0016  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'H'  'H'   0.0000   0.0000  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'N'  'N'   0.0061   0.0033  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'O'  'O'   0.0106   0.0060  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
 'F'  'F'   0.0171   0.0103  
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4'  
  
_symmetry_cell_setting            orthorhombic  
_symmetry_space_group_name_H-M    P2(1)2(1)2(1)  
  
loop_  
 _symmetry_equiv_pos_as_xyz  
 'x, y, z'  
 '-x+1/2, -y, z+1/2'  
 '-x, y+1/2, -z+1/2'  
 'x+1/2, -y+1/2, -z'  
  
_cell_length_a                    8.5991(5)  
_cell_length_b                    13.1245(5)  
_cell_length_c                    15.0112(6)  
_cell_angle_alpha                 90.00  
_cell_angle_beta                  90.00  
_cell_angle_gamma                 90.00  
_cell_volume                      1694.15(14)  
_cell_formula_units_Z             4  
_cell_measurement_temperature     200(2)  
_cell_measurement_reflns_used     all  
_cell_measurement_theta_min       ?  
_cell_measurement_theta_max       ?  
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_exptl_crystal_description        prism  
_exptl_crystal_colour             colourless  
_exptl_crystal_size_max           0.60 
_exptl_crystal_size_mid           0.40  
_exptl_crystal_size_min           0.35  
_exptl_crystal_density_meas       ?  
_exptl_crystal_density_diffrn     1.440  
_exptl_crystal_density_method     'not measured'  
_exptl_crystal_F_000              768  
_exptl_absorpt_coefficient_mu     0.107  
_exptl_absorpt_correction_type    numerical  
_exptl_absorpt_correction_T_min   0.8326  
_exptl_absorpt_correction_T_max   0.9377  
_exptl_absorpt_process_details    ?  
  
_exptl_absorpt_correction_T_max   ?  
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